0001493152-17-013098.txt : 20171114 0001493152-17-013098.hdr.sgml : 20171114 20171114131151 ACCESSION NUMBER: 0001493152-17-013098 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171114 DATE AS OF CHANGE: 20171114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bone Biologics Corp CENTRAL INDEX KEY: 0001419554 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 421743430 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53078 FILM NUMBER: 171200083 BUSINESS ADDRESS: STREET 1: 2 BURLINGTON WOODS DRIVE, STREET 2: SUITE 100, CITY: BURLINGTON STATE: MA ZIP: 01803 BUSINESS PHONE: (781) 552-4452 MAIL ADDRESS: STREET 1: 2 BURLINGTON WOODS DRIVE, STREET 2: SUITE 100, CITY: BURLINGTON STATE: MA ZIP: 01803 FORMER COMPANY: FORMER CONFORMED NAME: Bone Biologics, Corp. DATE OF NAME CHANGE: 20140924 FORMER COMPANY: FORMER CONFORMED NAME: AFH ACQUISITION X, INC. DATE OF NAME CHANGE: 20071127 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to _________

Commission File No. 000-53078

Bone Biologics Corporation

(Exact name of registrant as specified in its charter)

Delaware

42-1743430

(State or other jurisdiction of

incorporation or formation)

(I.R.S. employer

identification number)

2 Burlington Woods Drive, Ste 100, Burlington, MA 01803

(Address of principal executive offices and Zip Code)

(781) 552-4452

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

[X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

[X] Yes [ ] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in rule 12b-2 of the Exchange Act.

Large accelerated filer	[ ]	Accelerated filer	[ ]
Non-accelerated filer	[ ]	Smaller reporting company	[X]
Emerging growth company	[X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

[ ] Yes [X] No

As of November 10, 2017, there were 39,077,322 shares of the issuer’s common stock, $0.001 par value, outstanding.

Bone Biologics Corporation

- INDEX -

	Page
PART I – FINANCIAL INFORMATION:

Item 1.	F-1

Unaudited Condensed Consolidated Financial Statements

Unaudited Condensed Consolidated Balance Sheets	F-1

Unaudited Condensed Consolidated Statements of Operations	F-2

Unaudited Condensed Consolidated Statements of Cash Flows	F-3

Notes to Unaudited Condensed Consolidated Financial Statements	F-4

Item 2. Management’s Discussion and Analysis or Plan of Operation	4

Item 3. Quantitative and Qualitative Disclosures about Market Risk	10

Item 4. Controls and Procedures	10

PART II – OTHER INFORMATION:

Item 1. Legal Proceedings	11

Item 1A. Risk Factors	11

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	11

Item 3. Defaults Upon Senior Securities	11

Item 4. Mine Safety Disclosures	11

Item 5. Other Information	11

Item 6. Exhibits	12

Signatures	13

NOTE ON FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (this “Form 10-Q”) contains forward-looking statements. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. For a more detailed listing of some of the risks and uncertainties facing the Company, please see our Current Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2017.

All statements other than historical facts contained in this report, including statements regarding our future financial position, capital expenditures, cash flows, business strategy and plans and objectives of management for future operations are forward-looking statements. The words “anticipated,” “believe,” “expect,” “plan,” “intend,” “seek,” “estimate,” “project,” “could,” “may,” and similar expressions are intended to identify forward-looking statements. These statements include, among others, information regarding future operations, future capital expenditures, and future net cash flow. Such statements reflect our management’s current views with respect to future events and financial performance and involve risks and uncertainties, including, without limitation, our ability to raise additional capital to fund our operations, obtaining Food and Drug Administration (“FDA”) and other regulatory authorization to market our drug and biological products, successful completion of our clinical trials, our ability to achieve regulatory authorization to market our lead product NELL-1, our reliance on third party manufacturers for our drug products, market acceptance of our products, our dependence on licenses for certain of our products, our reliance on the expected growth in demand for our products, exposure to product liability and defect claims, development of a public trading market for our securities, and various other matters, many of which are beyond our control.

Should one or more of these risks or uncertainties occur, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated or otherwise indicated. Consequently, all of the forward-looking statements made in this Annual Report are qualified by these cautionary statements and accordingly there can be no assurances made with respect to the actual results or developments. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

Unless expressly indicated or the context requires otherwise, the terms “Company,” “we,” “us,” and “our” in this document refer to Bone Biologics Corporation, a Delaware corporation, and, its wholly owned subsidiary as defined under the heading “Management’s Discussion and Analysis” in this Form 10-Q.

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

Bone Biologics Corporation

Condensed Consolidated Balance Sheets

	September 30, 2017			December 31, 2016
		(unaudited)
Assets

Current assets
Cash	$	1,621,979		$	620,375
Prepaid expenses		46,406			80,523
Prepaid expenses – Related Party		271,945			271,945

Total current assets		1,940,330			972,843

Property and equipment, net		170			242

Total assets	$	1,940,500		$	973,085

Liabilities and Stockholders’ Deficit

Current liabilities
Accounts payable and accrued expenses	$	740,064		$	260,149
Current notes payable, net of debt discount of $1,012,124 and $-0-, respectively		2,887,876			1,200,000
Deferred compensation		191,667			41,667
Shares to be issued		1,823,077			1,823,077

Total current liabilities		5,642,684			3,324,893

Note payable, net of debt discount of $1,797,709 and $2,717,752, respectively		7,202,291			6,282,248

Total liabilities		12,844,975			9,607,141

Commitments and Contingencies

Stockholders’ deficit
Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at September 30, 2017 and December 31, 2016		-			-
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 39,077,322 and 38,828,607 shares issued and outstanding at September 30, 2017 and December 31, 2016		39,062			38,829
Additional paid-in capital		40,737,523			38,271,173
Accumulated deficit		(51,681,060	)		(46,944,058	)

Total stockholders’ deficit		(10,904,475	)		(8,634,056	)

Total liabilities and stockholders’ deficit	$	1,940,500		$	973,085

See accompanying notes to unaudited condensed consolidated financial statements.

F-1

Bone Biologics Corporation

Condensed Consolidated Statements of Operations

	Three Months Ended September 30, 2017			Three Months Ended September 30, 2016			Nine Months Ended September 30, 2017			Nine Months Ended September 30, 2016
		(unaudited)			(unaudited)			(unaudited)			(unaudited)
Revenues	$	-		$	-		$	-		$	-

Cost of revenues		-			-			-			-

Gross profit		-			-			-			-

Operating expenses
Research and development		248,377			2,473,433			(1,654,074	)		9,470,369
General and administrative		882,399			1,383,982			2,970,060			5,235,736

Total operating expenses		1,130,776			3,857,415			1,315,986			14,706,105

Loss from operations		(1,130,776	)		(3,857,415	)		(1,315,986	)		(14,706,105	)

Other expenses
Other expense		-			-			-			(4,862	)
Interest expense, net		(1,396,643	)		(513,846	)		(3,419,417	)		(1,436,643	)

Total other expenses		(1,396,643	)		(513,846	)		(3,419,417	)		(1,441,505	)

Loss before provision for income taxes		(2,527,419	)		(4,371,261	)		(4,735,403	)		(16,147,610	)

Provision for income taxes		-			1,010			1,600			2,745

Net Loss	$	(2,527,419	)	$	(4,372,271	)	$	(4,737,003	)	$	(16,150,355	)

Weighted average shares outstanding – basic and diluted		38,888,082			38,828,607			38,868,692			37,228,340

Net Loss per share – basic and diluted	$	(0.06	)	$	(0.11	)	$	(0.12	)	$	(0.43	)

See accompanying notes to unaudited condensed consolidated financial statements.

F-2

Bone Biologics Corporation

Condensed Consolidated Statements of Cash Flows

	Nine Months Ended September 30, 2017			Nine Months Ended September 30, 2016
		(unaudited)			(unaudited)
Operating activities
Net loss	$	(4,737,003	)	$	(16,150,355	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		72			660
Amortization of prepaid expenses – related party		-			39,093
Debt discount amortization		2,412,398			657,159
Debt issuance costs amortization		230,521			223,990
Stock-based compensation		1,405,396			2,938,825
Options issued to consultants		(2,338,812	)		4,512,033
Warrants issued to consultants		-			100,930
Interest expense deducted from loan proceeds		-			1,889
Loss on disposal of assets		-			4,862
Shares issued for Sygnal license		-			1,435,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		34,117			27,119
Accounts payable and accrued expenses		479,915			148,808
Deferred issuance costs		(35,000	)
Deferred compensation		150,000			-

Net cash used in operating activities		(2,398,396	)		(6,059,987	)

Financing activities
Proceeds from exercise of warrants		-			1,250,000
Proceeds from issuance of common stock		700,000			2,500,000
Proceeds from issuance of notes payable		2,700,000			1,883,111
Net cash provided by financing activities		3,400,000			5,633,111

Net increase (decrease) in cash		1,001,604			(426,876	)

Cash, beginning of period		620,375			1,115,109
Cash, end of period	$	1,621,979		$	688,233

Supplemental non-cash information
Interest paid	$	516,375		$	555,805
Taxes paid	$	1,600		$	2,745

See accompanying notes to unaudited condensed consolidated financial statements.

F-3

Bone Biologics Corporation

Notes to Unaudited Condensed Consolidated Financial Statements

1. The Company

Bone Biologics Corporation (the “Company”) was incorporated under the laws of the State of Delaware on October 18, 2007 as AFH Acquisition X, Inc. Pursuant to a Merger Agreement, dated September 19, 2014, by and among the Company, its wholly-owned subsidiary, Bone Biologics Acquisition Corp., a Delaware corporation (“Merger Sub”), and Bone Biologics, Inc. Merger Sub merged with and into Bone Biologics Inc., with Bone Biologics Inc. remaining as the surviving corporation in the merger. Upon the consummation of the merger, the separate existence of Merger Sub ceased. On September 22, 2014, the Company officially changed its name to “Bone Biologics Corporation” to more accurately reflect the nature of its business and Bone Biologics, Inc. became a wholly owned subsidiary of the Company. Bone Biologics, Inc. was incorporated in California on June 9, 2004. In connection with the merger, the 5,000,000 outstanding shares of common stock of the Company, par value $0.001 per share (“Common Stock”), prior to the merger were consolidated into 3,853,600 shares of Common Stock and the remaining shares were cancelled.

Additionally, all of the issued and outstanding shares of Bone Biologics Inc.’s $0.0001 par value common stock converted into a combined 19,897,587 shares of the Company’s Common Stock (including 2,151,926 shares issuable upon the exercise of outstanding warrants and 5,648,658 shares issuable upon the conversion of debt).

We are a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX®. The NELL-1/DBX® combination product is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The protein, as part of the UCB-1 technology platform has been licensed exclusively for worldwide applications to us through a technology transfer from UCLA Technology Development Group on behalf of UC Regents (“UCLA TDG”). UCLA TDG and the Company received guidance from the FDA that NELL-1/DBX® will be classified as a combination product with a device lead.

We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, which we refer to as the JOBS Act. We would cease to be an emerging growth company upon the earliest of: (i) the last day of the first fiscal year in which our annual gross revenues are $1.07 billion or more; (ii) the end of any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700.0 million as of the end of the second quarter of that fiscal year; or (iii) the date on which we have, during the previous three-year period, issued more than $1.07 billion in non-convertible debt securities. An emerging growth company may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. We have elected to take advantage of these reduced disclosure obligations, and may elect to take advantage of other reduced reporting obligations in the future.

The JOBS Act permits an emerging growth company like us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We are choosing to irrevocably “opt out” of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted.

The Company is a development stage entity. The production and marketing of the Company’s products and its ongoing research and development activities will be subject to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any combination product developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive regulatory approval process implemented by the FDA under the Food, Drug and Cosmetic Act. There can be no assurance that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay or suspend clinical trials.

The Company’s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and operate without infringing on the proprietary rights of others, both in the United States and other countries. There can be no assurance that patents issued to or licensed by the Company will not be challenged, invalidated, or circumvented, or that the rights granted thereunder will provide proprietary protection or competitive advantages to the Company.

F-4

Going Concern and Liquidity

The Company has no significant operating history and since inception to September 30, 2017 has generated a net loss of approximately $52 million. The Company will continue to incur significant expenses for development activities for their lead product NELL-1. Operating expenditures for the next twelve months are estimated at $6.5 million. The accompanying consolidated financial statements for the nine months ended September 30, 2017 have been prepared assuming the Company will continue as a going concern. The Company intends to raise additional debt and/or equity financing to fund future operations and to provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company’s needs. If cash resources are insufficient to satisfy the Company’s on-going cash requirements, the Company will be required to scale back or discontinue its product development programs, or obtain funds if available (although there can be no certainties) through strategic alliances that may require the Company to relinquish rights to its technology, substantially reduce or discontinue its operations entirely.

Pursuant to the October 2016 and February 2017 Note Purchase Agreements (Note 6), the Company may only use the proceeds from the issuance of the convertible notes to focus on prioritizing operations on essential research and development activities. Also pursuant to the October 2016 Note Purchase Agreement, the Company’s management has agreed to defer 20% of earned compensation and the Board of Directors has authorized a change in director compensation to defer 50% of the directors’ cash compensation until at least $5,000,000 has been received in cumulative funding from non-current stockholders.

The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

2. Summary of Significant Accounting Policies

We have prepared the unaudited interim condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in the annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes for the year ended December 31, 2016. The results of the three and nine month periods ended September 30, 2017 are not necessarily indicative of the results to be expected for the full year ending December 31, 2017.

Basis of Presentation

The accompanying condensed consolidated financial statements and related notes included activities of the Company and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

Use of Estimates

The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant estimates include warrants and income tax valuation allowances. Actual results could differ from those estimates.

F-5

Fair Value of Financial Instruments

The Company’s consolidated financial instruments are accounts payable and notes payable. The recorded values of accounts payable approximate their values based on their short-term nature. Notes payable are recorded at their issue value or if warrants are attached at their issue value less the value of the warrant.

The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from embedded derivatives associated with certain warrants to purchase common stock.

Property and Equipment

Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets, ranging from three to seven years. Expenditures for additions and improvements are capitalized, while repairs and maintenance costs are expensed as incurred. The cost and related accumulated depreciation of property and equipment sold or otherwise disposed of are removed from the accounts and any gain or loss is recorded in the year of disposal.

Impairment of Long-Lived Assets

The long-lived assets held and used by the Company are reviewed for impairment no less frequently than annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. Management has determined that there was no impairment in the value of long-lived assets during the nine months ended September 30, 2017.

Research and Development Costs

Research and development costs include, but are not limited to, patents and license expenses, payroll and other personnel expenses, consultants, expenses incurred under agreements with contract research and manufacturing organizations and animal clinical investigative sites and the cost to manufacture clinical trial materials. Costs related to research, design and development of products are charged to research and development expense as incurred.

Patents and Licenses

In March 2006, the Company entered into an exclusive license agreement (“Exclusive License Agreement”), with UCLA TDG for the worldwide application of the NELL-1 protein through a technology transfer. See Note 5 for commitments related to the Exclusive License Agreement. Patent expenses include costs to acquire the license of NELL-1, which was de minimis, and costs to file patent applications related to NELL-1.

The Company expenses the costs incurred to file patent applications, all costs related to abandoned patent applications and maintenance costs, and these costs are included in research and development expenses. Costs associated with licenses acquired to be able to use products from third parties prior to receipt of regulatory approval to market the related products are also expensed. The Company’s licensed technologies may have alternative future uses in that they are enabling (or platform) technologies that can be the basis for multiple products that would each target a specific indication. Costs of acquisition of licenses are expensed.

F-6

Prepaid expenses – related party

Prepaid expenses – related party represent the fair value of warrants issued to AFH Holding & Advisory, LLC (“AFH”), a shareholder, for services pursuant to certain letter agreement dated May 4, 2014. Prepaid costs will be amortized as the required services are performed. As of September 30, 2017 and December 31, 2016 prepaid expenses – related party totaled $271,945.

Concentration of Credit Risk and Other Risks and Uncertainties

Cash balances are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. Federal insurance coverage is $250,000 per depositor at each financial institution. A substantial majority of the Company’s cash balances exceed federally insured limits.

Debt Issuance Costs

Debt issuance costs represent costs incurred in connection with the issuance of the convertible notes payable and private equity financing. Debt issuance costs related to the issuance of debt are being amortized over the term of the financing instrument using the effective interest method, while debt issuance costs from equity financings are netted against the gross proceeds received from the equity financings.

Stock Based Compensation

ASC 718, Compensation – Stock Compensation, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, Equity – based Payments to Non-Employees. Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

Pursuant to ASU No. 2016-09 – Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, the Company accounts for forfeitures when they occur.

Income Taxes

Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due and deferred taxes resulting from timing differences in recording of transactions for tax purposes and financial reporting purposes.

The deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are received or settled. Valuation allowances are established when necessary to reduce deferred tax assets to amounts expected to be realized.

The accounting provisions related to uncertain income tax positions require the Company to determine whether any tax position in all open years meets a more likely than not threshold of being sustained upon examination by the applicable taxing authority. The Company did not have any changes to its liability for uncertain tax positions as at September 30, 2017 and December 31, 2016.

F-7

The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. No such amounts are accrued as of September 30, 2017 and December 31, 2016.

Loss per Common Share

The Company utilizes FASB ASC Topic No. 260, Earnings per Share. Basic loss per share is computed by dividing loss available to common shareholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible debentures, options and warrants were to be exercised or converted or otherwise resulted in the issuance of common stock that then shared in the earnings of the entity.

Since the effects of outstanding options, warrants, and the conversion of convertible debt are anti-dilutive in during the three months ended September 30, 2016 and the nine months periods ended September 30, 2017 and 2016, shares of common stock underlying these instruments have been excluded from the computation of loss per common share.

The following sets forth the number of shares of common stock underlying outstanding options, warrants, and convertible debt as of September 30, 2017 and 2016:

	September 30,
		2017	2016
Warrants		10,390,820	10,451,740
Stock options		8,397,216	12,656,067
Convertible promissory notes		9,596,203	5,696,203
		28,384,239	28,804,010

New Accounting Standards

The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its consolidated financial statements.

In August 2016, the FASB issued authoritative guidance under ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 is intended to reduce diversity in practice in how certain cash receipts and cash payments are presented and classified in the Consolidated Statement of Cash Flows by providing guidance on eight specific cash flow issues. ASU 2016-15 is effective retrospectively on January 1, 2018, with early adoption permitted. We have not yet determined the effect of the ASU on our Consolidated Financial Statements nor have we selected a transition date.

In January 2017, the FASB issued authoritative guidance under ASU 2017-01, Business Combinations – Clarifying the Definition of a Business, which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The standard introduces a screen for determining when assets acquired are not a business and clarifies that a business must include, at a minimum, an input and a substantive process that contribute to an output to be considered a business. This standard is effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. The Company does not expect this new guidance to have a material impact on its consolidated financial statements.

F-8

3. Property and Equipment

Property and equipment consist of the following at:

	September 30, 2017			December 31, 2016
Furniture and equipment	$	503		$	503
Less accumulated depreciation		(333	)		(261	)
	$	170		$	242

Depreciation expense for the nine months ended September 30, 2017 and 2016 was $72 and $660, respectively. During the nine months ended September 30, 2016, we recorded a loss on disposal of assets of $4,862.

4. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following:

	September 30, 2017		December 31, 2016
Interest expense	$	218,757	$	22,383
Accounts payable		225,082		226,516
Accrued bonus		256,500		-
Deferred Directors’ fees		39,725		11,250
	$	740,064	$	260,149

5. Commitments and Contingencies

UCLA TDG Exclusive License Agreement

Effective August 18, 2017, the Company entered into an Amended and Restated Exclusive License Agreement (the “Restated License Agreement”) with the UCLA Technology Development Group on behalf of UC Regents (“UCLA TDG”). The Restated License Agreement amends and restates the Exclusive License Agreement, effective March 15, 2006, between the Company and UCLA TDG, as amended by ten amendments. Under the terms of the Restated License Agreement, the Regents have continued to grant the Company exclusive rights to develop and commercialize NELL-1 (the “Licensed Product”) for spinal fusion applications. The Licensed Product is a recombinant human protein growth factor that is essential for normal bone development.

Following the completion of several key milestones, Bone Biologics has expanded its Field of Use definition beyond spine fusion within the NELL-1 license agreement with UCLA TDG. Consistent with that expansion, Bone Biologics has entered into an exclusive license agreement with UCLA TDG for the worldwide application of the NELL-1 protein for both osteoporosis and trauma through a technology transfer.

We have agreed to pay an annual maintenance fee to UCLA TDG of $10,000 as well as to pay certain royalties to UCLA TDG under the Restated License Agreement at the rate of 3.0% of net sales of licensed products. We must pay the royalties to UCLA TDG on a quarterly basis. Upon a first commercial sale, we also must pay between $50,000 and $250,000, depending on the calendar year that is after the first commercial sale. If we are required to pay any third party any royalties as a result of us making use of UCLA TDG patents, then we may reduce the royalty owed to UCLA TDG by 0.333% for every percentage point paid to a third party. If we grant sublicense rights to a third party to use the UCLA TDG patent, then we will pay to UCLA TDG 10% to 20% of the sublicensing income we receive from such sublicense.

We are obligated to make the following milestone payments to UCLA TDG for each Licensed Product or Licensed Method:

	●	$100,000 upon enrollment of the first subject in a Feasibility Study;

	●	$250,000 upon enrollment of the first subject in a Pivotal Study:

	●	$500,000 upon Pre-Market Approval of a Licensed Product or Licensed Method; and

	●	$1,000,000 upon the First Commercial Sale of a Licensed Product or Licensed Method.

F-9

We are also obligated to pay UCLA TDG a cash milestone payment within thirty (30) days of a Liquidity Event (including a Change of Control Transaction and a payment election by UCLA TDG exercisable after December 22, 2016, such payment to equal the greater of:

	●	$500,000; or

	●	2% of all proceeds in connection with a Change of Control Transaction.

We are obligated to diligently proceed with developing and commercializing licensed products under UCLA patents set forth in the Restated License Agreement. UCLA TDG has the right to either terminate the license or reduce the license to a non-exclusive license if we do not meet certain diligence milestone deadlines set forth in the Restated License Agreement.

We must reimburse or pre-pay UCLA TDG for patent prosecution and maintenance costs incurred during the term of the Restated License Agreement. We have the right to bring infringement actions against third party infringers of the Restated License Agreement, UCLA TDG may join voluntarily, at its own expense, or, at our expense, be joined involuntarily to the action. We are required to indemnify UCLA TDG against any third party claims arising out of our exercise of the rights under the Restated License Agreement or any sublicense.

Contingencies

The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company’s management does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows.

Indemnification

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.

In accordance with its amended and restated certificate of incorporation and amended and restated bylaws, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. There have been no claims to date and the Company has a director and officer insurance policy that enables it to recover a portion of any amounts paid for future potential claims.

6. Notes Payable

Convertible Notes Payable

The convertible promissory notes are considered hybrid instruments, which consist of a debt host instrument together with a conversion feature, thus giving the holder of a convertible note an option to convert into an equity instrument providing the holder a residual interest in the Company. The holder of a convertible promissory note also has the option to present its convertible promissory note to the Company and demand payment under the terms of the note after the maturity date or upon the occurrence of certain events such as the failure of the Company to make a payment on the note when due, bankruptcy or certain other liquidation events. The Company concluded that the convertible promissory notes would be accounted for as a typical debt instrument with related interest expense recorded in the Company’s statements of operations. The Company’s Third Convertible Secured Term Note and October 2016 and February 2017 Convertible Promissory Notes contain a conversion feature is determined to be “beneficial” and the fair value of the conversion feature is recorded as financing costs Company’s statements of operations.

F-10

First Secured Convertible Note and Warrant

On October 24, 2014, the Company issued a convertible promissory note in the amount of $5,000,000 to Hankey Capital, LLC (“Hankey Capital”). The Convertible Note matures on December 31, 2019 and bears interest at an annual rate of interest of the “prime rate” plus 4.0%, with a minimum rate of 8.5% per annum until maturity, with interest payable monthly in arrears. Prior to the Maturity Date, Hankey Capital has a right, in its sole discretion, to convert the Convertible Note into shares of the Company’s Common Stock, at a conversion rate of $1.58 per share.

The Convertible Note is secured by certain collateral shares of Common Stock issued by the Company in the name of Hankey Capital, in such amount so as to maintain a loan to value ratio of no greater than 50% (the “Collateral”). 6,329,114 shares were issued upon closing the lending. The number of shares in the Collateral shall be adjusted on a yearly basis. The shares representing the Collateral contain a restrictive legend. The Company shall seek to register the Collateral shares initially delivered on the date of the Convertible Note pursuant to the Registration Rights Agreement described below. Upon the effectiveness of such Registration Statement, the Company will remove the restrictive legends from the Collateral shares so long as Hankey Capital agrees in any event not to sell any Collateral shares if Hankey Capital is notified that the Registration Statement is no longer effective. Hankey Capital may hold the Collateral in any brokerage account of its choosing, but shall not transfer, sell or otherwise dispose of any Collateral, except during the existence of an Event of Default, as defined in the Convertible Note. The Convertible Note is further secured by collateral assignments of all the Company’s license agreements. The principal amount of the loan is pre-payable in whole or in part at any time, without premium or penalty. Upon any voluntary partial prepayment of outstanding principal, Hankey Capital will return Collateral shares to the Company in the amount necessary, if any, to maintain the loan to value ratio at no less than 50%. Upon a full payment of the outstanding principal, all Collateral shares shall be returned return and cancelled. Hankey Capital will also return Collateral shares under the same terms in case of partial or full conversion of the Convertible Note. The Company paid a commitment fee in the amount of 3.0% of the original principal amount of the loan ($150,000) to Hankey Capital. On October 24, 2014, the Company also issued a warrant to Hankey Capital for 3,955,697 shares of Common Stock at an exercise price per share of $1.58. The Warrant was amended as of February 10, 2016 to extend the expiration date to October 24, 2019. The Note and Warrant contain provisions limiting the exercise/conversion thereof.

Second Secured Convertible Note and Warrant

On May 4, 2015, the Company issued a convertible promissory note in the amount of $2,000,000 to Hankey Capital. The Second Convertible Note matures on December 31, 2019 and bears interest at an annual rate of interest of the “prime rate” plus 4.0%, with a minimum rate of 8.5% per annum until maturity, with interest payable monthly in arrears. Prior to the Maturity Date, Hankey Capital has a right, in its sole discretion, to convert the Convertible Note into shares of the Company’s Common Stock, at a conversion rate of $1.58 per share. The Convertible Note is secured by certain collateral shares of Common Stock issued by the Company in the name of Hankey Capital, in such amount so as to maintain a loan to value ratio of no greater than 50%. The number of shares in the Collateral shall be adjusted on a yearly basis. The Convertible Note is further secured by collateral assignments of all the Company’s license agreements. The principal amount of the loan is pre-payable in whole or in part at any time, without premium or penalty. Upon any voluntary partial prepayment of outstanding principal, Hankey Capital shall return Collateral shares to the Company in the amount necessary, if any, to maintain the loan to value ratio at no less than 50%. Upon a full payment of the outstanding principal, all the collateral shares shall be returned return and cancelled. Hankey Capital shall also return the collateral shares under the same terms in case of partial or full conversion of the Convertible Note. In connection with the Convertible Note, on May 4, 2015 the Company issued 2,531,646 common shares as collateral. The Company paid a commitment fee in the amount of $60,000 (3% of the original principal amount of the loan) to Hankey Capital. On May 4, 2015, the Company also issued a warrant to Hankey Capital for 1,898,734 shares of Common Stock at an exercise price per share of $1.58. The Warrant was amended as of February 10, 2016 to extend the expiration date to May 4, 2020. The Note and Warrant contain provisions limiting the exercise/conversion thereof.

F-11

Third Convertible Secured Term Note and Warrant

On February 24, 2016, the Company issued a convertible promissory note in the amount of $2,000,000 to Hankey Capital. The Third Convertible Note matures on February 23, 2019 (the “Maturity Date”) and bears interest at an annual rate of interest at the “prime rate” (as quoted in the “Money Rates” section of The Wall Street Journal) plus 4.0%, with a minimum rate of 8.5% per annum until maturity, with interest payable monthly in arrears. Prior to the Maturity Date, Hankey Capital has a right, in its sole discretion, to convert the Convertible Note into shares of the Company’s common stock (the “Conversion Shares”), at a conversion rate equal to $1.58 per share. The Convertible Note is secured by certain collateral shares of Common Stock issued by the Company in the name of Hankey Capital, in such amount so as to maintain a loan to value ratio of no greater than 50%. The number of Collateral Shares will be adjusted on a yearly basis. The Convertible Note is further secured by all of the Company’s personal property, including collateral assignments of all the Company’s license agreements and the Option Agreement. The principal amount of the loan is prepayable in whole or in part at any time, without premium or penalty. Upon any voluntary partial prepayment of outstanding principal, Hankey Capital will return Collateral Shares to the Company in the amount necessary, if any, to maintain the loan to value ratio at no less than 50%. Upon a full payment of the outstanding principal, all Collateral Shares will be returned and cancelled. Hankey Capital will also return Collateral Shares under the same terms in case of partial or full conversion of the Convertible Note. In connection with the Convertible Note, on February 24, 2016 the Company issued 2,531,646 common shares as collateral, paid a commitment fee in the amount of $40,000 (2% of the original principal amount of the Loan) and a warrant to Hankey Capital for 1,463,415 shares of Common Stock at an exercise price per share of $2.05. The Warrant will expire on February 23, 2021. The Note and Warrant contain provisions limiting the exercise/conversion thereof.

In connection with the financing with Hankey Capital, Hankey Capital exercised warrants to purchase an aggregate of 791,139 shares resulting in gross proceeds to the Company of $1,250,000, and the parties agreed to extend the maturity date of the first two convertible secured notes to December 31, 2019 and fix the conversion rate to $1.58. The Company also agreed to extend the term of all outstanding warrants to five years from issuance.

Convertible Promissory Notes

On October 14, 2016, pursuant to a Note Purchase Agreement, the Company issued to each of MTF and Hankey Capital a convertible promissory note in the amount of $600,000 (each a “Convertible Note”). The Convertible Note matures on December 31, 2017 (the “Maturity Date”) and bears interest at an annual rate of interest of 8.5% per annum until maturity. Prior to the Maturity Date, each of MTF and Hankey Capital has a right, in its sole discretion, to convert their Convertible Note into shares of the Company’s common stock (the “Conversion Shares”), at a conversion rate equal to $1.00 per share. In the event of a financing resulting in gross proceeds of at least $5,000,000, the holders of the Convertible Notes will be required to convert their Convertible Notes into the same securities issued in such financing at the same price per share. In addition, if the Convertible Notes are not paid by the Maturity Date, they will be automatically converted in shares of Common Stock at a conversion price of $1.00 per share. Hankey Capital’s Convertible Note is secured by all of the Company’s assets. The Company has granted piggyback registration rights with respect to the Conversion Shares.

Pursuant to the October 2016 and February 2017 Note Purchase Agreements, the Company may only use the proceeds from the issuance of those convertible notes to focus on prioritizing operations on essential research and development activities. Also pursuant to the October 2016 Note Purchase Agreement, the Company’s management has agreed to defer 20% of earned compensation and the Board of Directors has authorized a change in director compensation to defer 50% of the directors’ cash compensation until at least $5,000,000 has been received in cumulative funding from non-current stockholders.

On February 10, 2017 pursuant to a Note Purchase Agreement, the Company issued to each of MTF and Hankey Capital a convertible promissory note in the amount of $1,000,000 (each a “Convertible Note”). The Convertible Note matures on December 31, 2017 (the “Maturity Date”) and bears interest at an annual rate of interest of 8.5% until maturity. Prior to the Maturity Date, each of MTF and Hankey Capital has a right, in its sole discretion, to convert their Convertible Note into shares of the Company’s common stock (the “Conversion Shares”), at a conversion rate equal to $1.00 per share. In the event of a financing resulting in gross proceeds of at least $5,000,000, the holders of the Convertible Notes will be required to convert their Convertible Notes into the same securities issued in such financing at the same price per share. Also, if the Convertible Notes are not paid by the Maturity Date, they will be automatically converted in shares of Common Stock at a conversion price of $1.00 per share. Hankey Capital’s Convertible Note is secured by all of the Company’s assets. The Company has granted piggyback registration rights with respect to the Conversion Shares.

F-12

On August 18, 2017 pursuant to a Note Purchase Agreement, the Company issued to Hankey Capital a convertible promissory note in the amount of $700,000 (“Convertible Note”). The Convertible Note matures on December 31, 2017 (the “Maturity Date”) and bears interest at an annual rate of interest of 8.5% until maturity. Prior to the Maturity Date, Hankey Capital has a right, in its sole discretion, to convert their Convertible Note into shares of the Company’s common stock (the “Conversion Shares”), at a conversion rate equal to $1.00 per share. In the event of a financing resulting in gross proceeds of at least $5,000,000, the holders of the Convertible Note will be required to convert their Convertible Note into the same securities issued in such financing at the same price per share. Also, if the Convertible Note is not paid by the Maturity Date, it will be automatically converted in shares of Common Stock at a conversion price of $1.00 per share. Hankey Capital’s Convertible Note is secured by all of the Company’s assets. The Company has granted piggyback registration rights with respect to the Conversion Shares.

The total debt discount costs related to our outstanding debt for the nine months ended September 30, 2017 and 2016, was $2,412,398 and $657,159, respectively was amortized to interest expense. The unamortized debt discount at September 30, 2017 was $2,655,310. The cost is expected to be recognized over a period of 1.27 years. The unamortized debt discount at December 31, 2016 was $2,367,708.

The total debt issuance costs related to our outstanding debt for the nine months ended September 30, 2017 and 2016, was $230,521 and $223,990, respectively was amortized to interest expense. The unamortized debt issuance costs at September 30, 2017 was $154,523. The cost is expected to be recognized over a period of 1.27 years. The unamortized debt issuance costs at December 31, 2016 was $350,044.

Note Type	Issue Date	Maturity Date	Interest Rate			September 30, 2017		December 31, 2016

First Secured Convertible Note	10/24/14	12/31/19		8.5	%		5,000,000		5,000,000

Second Secured Convertible Note	5/4/15	12/31/19		8.5	%		2,000,000		2,000,000

Third Secured Convertible Note	2/24/16	2/23/19		8.5	%		2,000,000		2,000,000

Convertible Promissory Notes	10/14/16	12/31/17		8.5	%		1,200,000		1,200,000

Convertible Promissory Notes	2/10/17	12/31/17		8.5	%		2,000,000		-

Convertible Promissory Notes	8/18/17	12/31/17		8.5	%		700,000		-
							12,900,000		10,200,000
Less: Current notes payable, net							2,887,876		1,200,000
Less: Debt discount							2,655,310		2,367,708
Less: Debt issuance costs							154,523		350,044
Net Notes payable						$	7,202,291	$	6,282,248

F-13

7. Stockholders’ Equity

Preferred Stock

The Company’s amended and restated certificate of incorporation authorizes the Company to issue a total of 20,000,000 shares of preferred stock. No shares have been issued.

Common Stock

The Company’s amended and restated certificate of incorporation authorizes the Company to issue a total of 100,000,000 shares of common stock. As of September 30, 2017 and December 31, 2016, the Company had an aggregate of 39,077,322 and 38,828,607 shares of common stock outstanding, respectively.

On August 18, 2017, the Company sold to MTF an aggregate of 233,333 shares of common stock of the Company at a price per share equal to $3.00.

On August 18, 2017, 15,382 shares of common stock of the Company were issued from the exercise of options.

In connection with the Secured Convertible Notes to Hankey Capital, the Company issued 11,392,406 common shares as collateral. (See Note 6)

Each share of common stock has the right to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared by the Board.

Common Stock Warrants

As of September 30, 2017, the Company had outstanding unexercised Common Stock Warrants as follows:

Date Issued	Exercise Price		Number of Shares		Expiration date
2009	$	0.44		118,383	March 16, 2019
2010	$	0.44		254,997	February 4, 2020
April 2013	$	1.00		50,000	April 28, 2020
September 2013	$	1.00		50,000	September 4, 2020
September 2013	$	1.00		25,000	September 20, 2020
November 2013	$	1.00		75,000	November 14, 2020
July 2014	$	1.50		166,667	May 30, 2018
July 2014	$	1.50		166,667	September 30, 2018
July 2014	$	1.00		500,000	September 30, 2018
July 2014	$	1.00		46,667	July 2, 2018
July 2014	$	0.00		12,625	July 10, 2018
September 2014	$	1.62		625,000	August 31, 2021
September 2014	$	1.00		699,671	September 18, 2021
September 2014	$	1.00		89,588	September 29, 2021
October 2014	$	1.00		126,582	October 23, 2017
October 2014	$	1.58		3,164,558	October 23, 2019
February 2015	$	1.58		699,037	February 14, 2018
May 2015	$	1.58		1,898,734	May 4, 2020
October 2015	$	1.58		158,229	October 27, 2018
February 2016	$	2.05		1,463,415	February 23, 2021

Total warrants at September 30, 2017				10,390,820	2.45 years

F-14

No common stock warrants were exercised or expired during the nine months ended September 30, 2017. An aggregate of 791,139 common stock warrants were exercised during the nine months ended September 30, 2016. No common stock warrants expired during the nine months ended September 30, 2016.

8. Stock-based Compensation

2015 Equity Incentive Plan

The Company has 14,000,000 shares of Common Stock authorized and reserved for issuance under our 2015 Equity Incentive Plan for option awards. This reserve may be increased by the Board each year by up to the number of shares of stock equal to 5% of the number of shares of stock issued and outstanding on the immediately preceding December 31. Appropriate adjustments will be made in the number of authorized shares and other numerical limits in our 2015 Equity Incentive Plan and in outstanding awards to prevent dilution or enlargement of participants’ rights in the event of a stock split or other change in our capital structure. Shares subject to awards granted under our 2015 Equity Incentive Plan which expire, are repurchased or are cancelled or forfeited will again become available for issuance under our 2015 Equity Incentive Plan. The shares available will not be reduced by awards settled in cash. Shares withheld to satisfy tax withholding obligations will not again become available for grant. The gross number of shares issued upon the exercise of stock appreciation rights or options exercised by means of a net exercise or by tender of previously owned shares will be deducted from the shares available under our 2015 Equity Incentive Plan.

Awards may be granted under our 2015 Equity Incentive Plan to our employees, including officers, director or consultants, and our present or future affiliated entities. While we may grant incentive stock options only to employees, we may grant non-statutory stock options, stock appreciation rights, restricted stock purchase rights or bonuses, restricted stock units, performance shares, performance units and cash-based awards or other stock based awards to any eligible participant.

The 2015 Equity Incentive Plan will be administered by our compensation committee. Subject to the provisions of our 2015 Equity Incentive Plan, the compensation committee determines, in its discretion, the persons to whom, and the times at which, awards are granted, as well as the size, terms and conditions of each award. All awards are evidenced by a written agreement between us and the holder of the award. The compensation committee has the authority to construe and interpret the terms of our 2015 Equity Incentive Plan and awards granted under our 2015 Equity Incentive Plan.

During the nine months ended September 30, 2017 and 2016, the Company had stock-based compensation expenses of $1,405,396 and $2,938,825, respectively, related to issuances to the Company’s employees and directors, included in our reported net loss. During the nine months ended September 30, 2017 and 2016, the Company had stock-based compensation expenses of $(2,338,812) and $4,512,033, respectively, related to issuances to consultants.

A summary of stock option activity for the nine months ended September 30, 2017, is presented below:

	Number			Weighted
	of Shares			Average		Weighted
	Remaining			Exercise		Average		Aggregate
Subject to Exercise	Options			Price		Life (Years)		Value
Outstanding as of January 1, 2016		6,294,226		$	1.59		10.00		-
Granted – 2016		6,361,841			1.66		9.95		-
Forfeited – 2016		-			-		-		-
Exercised – 2016		-			-		-		-
Outstanding as of January 1, 2017		12,656,067		$	1.62		9.21		-
Granted – 2017		80,341			2.05		10.00		-
Forfeited – 2017		(4,270,639	)		1.60		8.54		-
Exercised – 2017		(68,553	)		2.05		8.25		-
Outstanding as of September 30, 2017		8,397,216		$	1.64		7.80		-

F-15

Date Issued	Exercise Price		Number of Shares		Expiration date
September 2014	$	1.59		583,059	December 27, 2025
November 2014	$	1.59		174,918	December 27, 2025
August 2015	$	1.59		3,121,787	December 27, 2025
September 2015	$	1.59		200,000	December 27, 2025
November 2015	$	1.59		1,224,640	December 27, 2025
December 2015	$	1.59		802,716	December 27, 2025
January 2016	$	1.59		1,275,786	January 9, 2026
March 2016	$	2.05		54,000	February 24, 2021
May 2016	$	2.05		807,434	May 26, 2026
June 2016	$	2.05		99,315	May 31, 2026
January 2017	$	2.05		53,561	January 1, 2027

Total options at September 30, 2017				8,397,216

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (i.e., the difference between our closing stock price on the respective date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised their options. There were 68,553 and -0- options exercised during either the nine months ended September 30, 2017 and 2016. There were 4,125,306 options cancelled in conjunction with the termination of the Founders Professional Services Agreement (Note 10). There were 20,085 options forfeited upon the resignation of one of our directors. Our policy is to account for forfeitures when they occur; therefore these forfeitures are recorded as a reversal to expense. Forfeiture reversals for the nine months ended September 30, 2017 and 2016 were $3,650,419 and $-0-, respectively.

There were 80,341 and 6,361,841 options issued during the nine months ended September 30, 2017 and 2016, respectively. Vesting of options differs based on the terms of each option. The Company has valued the options at their date of grant utilizing the Black-Scholes option pricing model. As of the issuance of these consolidated financial statements, there was not an active public market for the Company’s shares. Accordingly, the fair value of the underlying options was determined based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified method. The expected life of the options used was based on the contractual life of the option granted. Stock-based compensation is a non-cash expense because we settle these obligations by issuing shares of our common stock from our authorized shares instead of settling such obligations with cash payments.

The Company utilized the Black-Scholes option pricing model. The assumptions used for the nine months ended September 30, 2017 are as follows:

	September 30, 2017
Risk free interest rate		1.99%-2.306	%
Expected life (in years)		5.5-9.0
Expected Volatility		135.94%-153.79	%
Expected dividend yield		0	%

F-16

A summary of the changes in the Company’s non-vested options during the three months ended September 30, 2017, is as follows:

	Number of Non-vested Options			Weighted Average Fair Value at Grant Date		Intrinsic Value
Non-vested at January 1, 2016		5,156,710		$	1.29		-
Granted in 2016		6,361,841		$	1.93		-
Vested in year ended December 31, 2016		(1,913,491	)	$	1.31		-
Non-vested at January 1, 2017		9,605,060		$	1.74		-
Granted in 2017		80,341		$	1.87		-
Forfeited – 2017		(4,145,391	)	$	1.95		-
Vested in 2017		(2,718,316	)	$	1.69		-
Non-vested at September 30, 2017		2,821,694		$	1.49		-
Exercisable at September 30, 2017		5,575,522		$	1.44		-
Outstanding at September 30, 2017		8,397,216		$	1.46		-

As of September 30, 2017, total unrecognized compensation cost related to unvested stock options was $647,091. The cost is expected to be recognized over a weighted average period of 0.61 years.

9. Income Taxes

The Company’s effective tax rate is 0% for income tax for the nine months ended September 30, 2017 and the Company expects that its effective tax rate for the full year 2017 will be 0%. Based on the weight of available evidence, including cumulative losses since inception and expected future losses, the Company has determined that it is more likely than not that the deferred tax asset amount will not be realized and therefore a valuation allowance has been provided on net deferred tax assets.

The Company files tax returns for U.S. Federal and the states of New Jersey and California. The Company is not currently subject to any income tax examinations. Since the Company’s inception, the Company had incurred losses from operations, which generally allows all tax years to remain open.

Uncertain Tax Positions

The Company recognizes the financial statement effects of a tax position when it becomes more likely than not, based upon the technical merits, that the position will be sustained upon examination.

The Company recognizes interest and/or penalties related to uncertain tax positions. To the extent accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected in the period that such determination is made. The interest and penalties are recognized as other expense and not tax expense. The Company currently has no interest and penalties related to uncertain tax positions.

10. Related Party Transactions

AFH Holding & Advisory LLC

Pursuant to a letter agreement dated February 10, 2016, the Company agreed to issue a total of 1,260,255 shares of common stock of the Company to AFH. The Letter Agreement was entered into in connection with the AFH/MTF Agreement under which AFH and its affiliated entities, individuals or assignees (“AFH Group”) were entitled to 10% of the outstanding shares of common stock of the Company (the “Share Adjustment”) after giving effect to an anticipated private placement of between $8,000,000 and $10,000,000 (the “PIPE”). In the Letter Agreement, the Company recognized that, at the time the AFH/MTF Agreement was entered into, it was not anticipated that certain events in addition to the PIPE would dilute directly or indirectly the interest of AFH Group as stockholders of the Company, including the Ninth Amendment to the UCLA License Agreement and the issuance of the Company’s Common Shares pursuant to the Professional Services Agreement with each of Dr. Chia Soo, Dr. Ben Wu, and Dr. Eric Ting discussed below. Accordingly, the Company agreed to issue the 1,260,255 shares in connection with the Share Adjustment.

F-17

On April 7, 2016, the Company entered into a consulting agreement with AFH pursuant to which the Company engaged AFH for a term of three months to provide certain consulting services to the Company effective April 5, 2016. Under the consulting agreement, AFH received an up-front retainer of $100,000 and $33,333.33 per month for three months.

On June 1, 2016, the Company agreed (i) to issue to AFH 20,186 shares of common stock of the Company as an adjustment to the October 28, 2015 invoice and (ii) to issue 23,173 shares of common stock of the Company as an adjustment to the letter agreement dated February 10, 2016. The fair value of the shares issued for services, $100,930, was recorded as general and administrative expense.

In addition to the shares and warrants issued for services, AFH received cash totaling $-0- and $325,000 for services during the nine months ended September 30, 2017 and 2016, respectively.

Amir Heshmatpour is the controlling party of AFH.

Musculoskeletal Transplant Foundation (MTF)

On February 22, 2016, the Company entered into a share purchase agreement with MTF, pursuant to which MTF purchased from the Company an aggregate of 731,707 shares of common stock of the Company at a price per share equal to $2.05.

On February 24, 2016 the Company entered into an Option Agreement for the Distribution and Supply of Sygnal™ demineralized bone matrix (“Sygnal”) with MTF pursuant to which:

	a.	MTF grants to the Company the exclusive right and option (the “Option”) to distribute Sygnal upon the critical terms as described in the Option Agreement (the “Option Rights”). The Company will exercise the Option, if at all, by providing written notice to MTF of its intent to do so. During the term of the Option, MTF will not enter into any agreements with any third parties which include the transfer by MTF of the Option Rights.

	b.	Upon the exercising of the Option, the Company will grant to MTF 700,000 shares of common stock in the Company.

	c.	Within 30 days of exercising the Option, MTF will provide the Company with a written proposal of a Definitive Agreement that includes, inter alia, the Critical Terms and those other commercially reasonable terms as agreed upon by the parties. The parties will fully negotiate in good faith all of the terms of the Definitive Agreement, and any ancillary agreements thereto consistent with the Critical Terms.

	d.	In the event the Company does not exercise the Option within the Term of the Option Agreement, MTF will be free to enter into any other agreement relating to the Option Rights as it deems appropriate without liability to the Company.

Sygnal is a bone void filler contouring allograft bone that has the inorganic mineral removed, leaving behind the organic “collagen” matrix.

On June 24, 2016, the Company exercised this option. As provided in the Option Agreement, the Company issued 700,000 shares of its restricted common stock in connection with the exercise of the Option. Additionally, within 30 days of exercising the Option, MTF will provide the Company with a written proposal of a Definitive Agreement that includes, inter alia, certain Critical Terms described in the Agreement and those other commercially reasonable terms as agreed upon by the parties. The parties will fully negotiate in good faith all of the terms of the Definitive Agreement and any ancillary agreements thereto consistent with the Critical Terms. The Company expensed the cost of this license, $1,435,000, as research and development during the year ended December 31, 2016.

On October 14, 2016, pursuant to a Note Purchase Agreement, the Company issued to MTF a convertible promissory note in the amount of $600,000 (See Note 6).

F-18

On February 10, 2017, pursuant to a Note Purchase Agreement, the Company issued to MTF a convertible promissory note in the amount of $1,000,000 (See Note 6).

On August 18, 2017, the Company entered into a share purchase agreement with MTF, pursuant to which MTF purchased from the Company an aggregate of 233,333 shares of common stock of the Company at a price per share equal to $3.00.

Bruce Stroever, our Chairman of the Board, is the President and Chief Executive Officer of MTF.

Founders

The Company entered into a Letter Agreement effective October 2, 2015, with each of Dr. Chia Soo, Dr. Eric Kang Ting and Dr. Ben Wu (collectively, the “Founders”). The Founders were three of the original shareholders of the Company. Pursuant to the Letter Agreement, the Founders agrees to deliver to the Company all past work product and past data related to NELL-1 (the “Data”) for use by the Company in its sole discretion, within the applicable licensing rights granted under the UCLA license and in exchange the Company agreed to the future issuance of an aggregate of 1,153,846 shares of the Company’s common stock. The Shares are to be equally distributed between the Founders upon the earlier of (i) the third anniversary of the Agreement and (ii) the occurrence of a Liquidity Event (as defined in the Letter Agreement) and is currently reported as shares to be issued.

Founders Professional Services Agreement

Effective January 8, 2016, the Company entered into separate Professional Services Agreements with each of the Founders. Pursuant to each of the Agreements, each Founder has agreed to provide certain services to the Company, including providing strategic advice and strategic introductions to the Company’s management team as well as specific services set forth on an Exhibit to each Agreement. The Agreements are substantially identical. In consideration for the services to be rendered under the applicable Agreement, each Founder is granted 10-year stock options (the “Options”) to purchase 1,800,364 shares of the Company’s common stock corresponding to 4% of the Company’s outstanding common stock, on a fully diluted basis, at an exercise price of $1.59 per share. The shares subject to the Options will vest 25% on each of the first, second and third anniversary of the effective date and 12.5% on each of the fourth and fifth anniversary of the effective date. The options fully vest on a change of control of the Company, if the Company terminates the Agreement without cause or the Founder terminates the Agreement with cause. Additionally, beginning January 1, 2017, the Company will pay each Founder an annual consulting fee of $200,000 in cash or, at the option of the Company, in shares of its common stock valued as provided in the Agreement.

On June 1, 2016, the Company agreed to issue to each Founder a 10-year stock options to purchase 33,105 shares of the Company’s common stock at an exercise price of $2.05 per share as an adjustment to the Professional Services Agreements with each of the Founders dated January 8, 2016.

On December 13, 2016, the Company provided written notice to each of the Founders that it was terminating the Agreements for cause, indicating that absent cure of the material breach of the Agreements, termination of the Agreements was to be effective on January 12, 2017. Despite lengthy discussions with the Founders, and multiple extensions of the termination date to accommodate such discussions, the Company was unable to resolve the outstanding issues under the Agreements, and the Company provided notice that the Agreements were terminated, effective April 8, 2017. Any shares subject to the stock options issued under the Agreements that were not vested on the date the Agreements terminated shall be forfeited on the date of termination. Our policy is to account for forfeitures when they occur; therefore these forfeitures are recorded as a reversal to expense. Forfeiture reversals related to the termination of the Agreements was $3,629,041 in research and development expense.

Dr. Soo and Dr. Wu resigned as directors of the Company effective April 13, 2017, and Dr. Ting resigned as a member of the Company’s Scientific Advisory Board on April 13, 2017. Each of the Advisors were involved in the founding of the Company. Our licensing agreement with UCLA is independent of the Founders’ services and remains unchanged as a result of the Founders resignation.

11. Subsequent Events

The Company has evaluated subsequent events through November 10, 2017, the date which the consolidated financial statements were available to be issued. There were no additional subsequent events noted that would require adjustment to or disclosure in these consolidated financial statements.

F-19

Item 2. Management’s Discussion and Analysis.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and audited consolidated financial statements for the years ended December 31, 2016 and 2015 and the related notes included in our Annual Report on Form 10-K filed for the fiscal year ended December 31, 2016, with the SEC on March 30, 2017. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. See “Note Regarding Forward-Looking Statements” for a discussion of the uncertainties, risks and assumptions associated with these statements. Actual results and the timing of events could differ materially from those discussed in our forward-looking statements as a result of many factors.

Overview

The Company was founded by University of California professors in collaboration with an Osaka University professor and a University of Southern California surgeon in 2004 as a privately-held company with proprietary, patented technology that has been validated in sheep and non-human primate models to facilitate bone growth. Our platform technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Lead product development and clinical studies are targeted on spinal fusion surgery, one of the larger segments in the orthopedic market.

We are a development stage entity. The production and marketing of our products and ongoing research and development activities will be subject to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any combination product developed by us must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive regulatory approval process implemented by the FDA under the Food, Drug and Cosmetic Act. There can be no assurance that we will not encounter problems in clinical trials that will cause us or the FDA to delay or suspend the clinical trials.

Our success will depend in part on our ability to obtain patents and product license rights, maintain trade secrets, and operate without infringing on the proprietary rights of others, both in the United States and other countries. There can be no assurance that patents issued to or licensed by us will not be challenged, invalidated, or circumvented, or that the rights granted thereunder will provide proprietary protection or competitive advantages to us.

UCLA TDG Exclusive License Agreement

We have agreed to pay an annual maintenance fee to UCLA TDG of $10,000 as well as to pay certain royalties to UCLA TDG under the Restated License Agreement at the rate of 3.0% of net sales of licensed products. We must pay the royalties to UCLA TDG on a quarterly basis. Upon a first commercial sale, we also must pay between $50,000 and $250,000, depending on the calendar year which is after the first commercial sale. If we are required to pay any third party any royalties as a result of us making use of UCLA TDG patents, then we may reduce the royalty owed to UCLA TDG by 0.333% for every percentage point paid to a third party. If we grant sublicense rights to a third party to use the UCLA TDG patent, then we will pay to UCLA TDG10% to 20% of the sublicensing income we receive from such sublicense.

We are obligated to make the following milestone payments to UCLA TDG for each Licensed Product or Licensed Method:

	●	$100,000 upon enrollment of the first subject in a Feasibility Study;

	●	$250,000 upon enrollment of the first subject in a Pivotal Study:

	●	$500,000 upon Pre-Market Approval of a Licensed Product or Licensed Method; and

	●	$1,000,000 upon the First Commercial Sale of a Licensed Product or Licensed Method.

	●	$500,000; or

	●	2% of all proceeds in connection with a Change of Control Transaction.

Results of Operations

Since our inception, we devoted substantially all of our efforts and funding to the development of the NELL-1 protein and raising capital. We have not yet generated revenues from our planned operations.

Three Months ended September 30, 2017 compared to the Three Months ended September 30, 2016

	Three Months ended September 30, 2017			Three Months ended September 30, 2016			% Change
Operating expenses
Research and development	$	248,377		$	2,473,433			(89.96	)%
General and administrative		882,399			1,383,982			(36.24	)%

Total operating expenses		1,130,776			3,857,415			(70.69	)%

Net Loss from operations		(1,130,776	)		(3,857,415	)		(70.69	)%

Interest expense, net		(1,396,643	)		(513,846	)		171.80	%

Net Loss before provision for income taxes		(2,527,419	)		(4,372,261	)		(42.18	)%

Provision for income taxes		-			1,010			(100.00	)%

Net Loss	$	(2,527,419	)	$	(4,372,271	)		(42.19	)%

Research and Development

Our research and development expenses decreased from $2,473,433 during the three months ended September 30, 2016 to $248,377 during the three months ended September 30, 2017. The $2,225,056 decrease was primarily due to fair value of options issued in 2016 to research and development consultants. We will continue to incur significant expenses for development activities for NELL-1.

General and Administrative

Our general and administrative expenses decreased from $1,383,982 during the three months ended September 30, 2016 to $882,399 during the three months ended September 30, 2017. The $501,583 decrease was primarily due to the amortization of the fair value of management options; decreased legal expense and consulting services incurred in 2016.

Interest Expense

Our net interest expense increased from $513,846 for the three months ended September 30, 2016 to $1,396,643 during the three months ended September 30, 2017. The increase in interest of $882,797 was related to our new loans in February and August of 2017 and amortization of the fair value of the related beneficial conversion feature.

Nine Months ended September 30, 2017 compared to the Nine Months ended September 30, 2016

	Nine Months ended September 30, 2017			Nine Months ended September 30, 2016			% Change
Operating expenses
Research and development	$	(1,654,074	)	$	9,470,369			(117.47	)%
General and administrative		2,970,060			5,235,736			(43.27	)%

Total operating expenses		1,315,986			14,706,105			(91.05	)%

Loss from operations		(1,315,986	)		(14,706,105	)		(91.05	)%

Loss on disposal of assets		-			(4,862	)		(100.00	)%
Interest expense, net		(3,419,417	)		(1,436,643	)		138.01	%
Total other income/expense		(3,419,417	)		(1,441,505	)		137.21	%

Loss before provision for income taxes		(4,735,403	)		(16,147,610	)		(70.67	)%

Provision for income taxes		1,600			2,745			(41.71	)%

Net loss	$	(4,737,003	)	$	(16,150,355	)		(70.67	)%

Research and Development

Our research and development expenses decreased from $9,470,369 during the nine months ended September 30, 2016 to $(1,654,074) during the nine months ended September 30, 2017. The $11,124,443 decrease was primarily due to the fair value of options forfeited with the termination of the Professional Services Agreements with each of the Founders in April 2017. Our policy is to account for forfeitures when they occur; therefore these forfeitures are recorded as a reversal to expense. Forfeiture reversals related to the termination of the Agreements was $3,629,041 in research and development expense. We will continue to incur significant expenses for development activities for NELL-1.

General and Administrative

Our general and administrative expenses decreased from $5,235,736 during the nine months ended September 30, 2016 to $2,970,060 during the nine months ended September 30, 2017. The $2,265,676 decrease was primarily due to the 20% deferral of management salary and amortization of the fair value of management options; decreased legal expense and consulting services incurred in 2016.

Interest Expense

Our net interest expense increased from $1,436,643 for the nine months ended September 30, 2016 to $3,419,417 during the nine months ended September 30, 2017. The increase in interest of $1,982,774 was related to our new loans in February and August of 2017 and amortization of the fair value of the related beneficial conversion feature.

Liquidity and Capital Resources

	September 30, 2017			December 31, 2016
		(unaudited)
Assets

Current assets
Cash	$	1,621,979		$	620,375
Prepaid expenses		46,406			80,523
Prepaid expenses – Related Party		271,945			271,945

Total current assets		1,940,330			972,843

Property and equipment, net		170			242

Total assets	$	1,940,500		$	973,085

Liabilities and Stockholders’ Deficit

Current liabilities
Accounts payable and accrued expenses	$	740,064		$	260,149
Current notes payable, net of debt discount of $1,012,124 and $-0-, respectively		2,887,876			1,200,000
Deferred compensation		191,667			41,667
Shares to be issued		1,823,077			1,823,077

Total current liabilities		5,642,684			3,324,893

Note payable, net of debt discount of $1,797,709 and $2,717,752, respectively		7,202,291			6,282,248

Total liabilities		12,844,975			9,607,141

Commitments and Contingencies

Stockholders’ deficit
Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at September 30, 2017 and December 31, 2016		-			-
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 39,077,322 and 38,828,607 shares issued and outstanding at September 30, 2017 and December 31, 2016		39,062			38,829
Additional paid-in capital		40,737,523			38,271,173
Accumulated deficit		(51,681,060	)		(46,944,058	)

Total stockholders’ deficit		(10,904,475	)		(8,634,056	)

Total liabilities and stockholders’ deficit	$	1,940,500		$	973,085

We have no significant operating history and, from our inception to September 30, 2017, we have generated a net loss of approximately $52 million. The financial statements for the nine months ended September 30, 2017 and 2016 were prepared assuming we will continue as a going concern. Operating expenditures for the next twelve months are estimated at $6.5 million. The Company has principal payment requirements for the next 12 months of $3,900,000.

The Company will continue to incur significant expenses for development activities for our lead product NELL-1. The Company’s December 31, 2016 audited financial statements contained a notation by our auditors regarding the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements for the nine months ended September 30, 2017 and 2016, have been prepared assuming the Company will continue as a going concern. The Company closed on $1.4 million of debt and equity financing in August 2017.

The Company intends to raise additional debt and/or equity financing to fund future operations and to provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company’s needs. If cash resources are insufficient to satisfy the Company’s on-going cash requirements, the Company will be required to scale back or discontinue its product development programs, or obtain funds if available (although there can be no certainties) through strategic alliances that may require the Company to relinquish its rights to its technology, or discontinue its operations entirely.

As of September 30, 2017 and December 31, 2016, we had cash of $1,621,979 and $620,375, respectively.

Cash Flows

The following is a summary of our cash flows provided by operating, investing and financing activities for the nine months ended September 30, 2017 and 2016:

	Nine Months Ended September 30, 2017			Nine Months Ended September 30, 2016
		(unaudited)			(unaudited)
Operating activities
Net loss	$	(4,737,003	)	$	(16,150,355	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		72			660
Amortization of prepaid expenses – related party		-			39,093
Debt discount amortization		2,412,398			657,159
Debt issuance costs amortization		230,521			223,990
Stock-based compensation		1,405,396			2,938,825
Options issued to consultants		(2,338,812	)		4,512,033
Warrants issued to consultants		-			100,930
Interest expense deducted from loan proceeds		-			1,889
Loss on disposal of assets		-			4,862
Shares issued for Sygnal license		-			1,435,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		34,117			27,119
Accounts payable and accrued expenses		479,915			148,808
Deferred issuance costs		(35,000	)
Deferred compensation		150,000			-

Net cash used in operating activities		(2,398,396	)		(6,059,987	)

Financing activities
Proceeds from exercise of warrants		-			1,250,000
Proceeds from issuance of common stock		700,000			2,500,000
Proceeds from issuance of notes payable		2,700,000			1,883,111
Net cash provided by financing activities		3,400,000			5,633,111

Net increase (decrease) in cash		1,001,604			(426,876	)

Cash, beginning of period		620,375			1,115,109
Cash, end of period	$	1,621,979		$	688,233

Supplemental non-cash information
Interest paid	$	516,375		$	555,805
Taxes paid	$	1,600		$	2,745

Operating activities

During the nine months ended September 30, 2017 and 2016, cash used in operating activities was $2,398,396 and $6,059,987 respectively. Cash expenditures the nine months ended September 30, 2017 decreased primarily due to the timing of our development activities with our Contracted Manufacturing Organization (“CMO”) and management’s cash conservation efforts including a 20% deferral of wages and the Board’s 50% deferral of cash compensation.

Financing activities

During the nine months ended September 30, 2017, cash provided in financing activities of $3,400,000 resulted from the February and August 2017 convertible notes and the equity purchase of $700,000 of common stock. Cash provided during the nine months ended September 30, 2016, of $5,633,111 resulted from the $1,883,311 proceeds, net of financing fee, of the February 24, 2016 note, exercise of $1,250,000 of warrants and $2,500,000 in equity financing.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Financial Officer and Chief Executive Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act)) as of September 30, 2017. Based upon that evaluation, our Chief Financial Officer and Chief Executive Officer concluded that as of September 30, 2017, our disclosure controls and procedures were effective.

Changes in Internal Controls.

There were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

In the normal course of our business, we may periodically become subject to various lawsuits. However, there are currently no legal actions pending against us or, to our knowledge, are any such proceedings contemplated.

Item 1A. Risk Factors.

Not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None

Item 3. Defaults Upon Senior Securities.

None

Item 4. Mine Safety Disclosures.

Not Applicable

Item 5. Other Information.

None

Item 6. Exhibits.

(a) Exhibits required by Item 601 of Regulation S-K.

Exhibit		Description

10.1		Bone Biologics Corporation Convertible Note issued to Hankey Capital on August 18, 2017 (incorporated herein by reference to Exhibit 10.1 to current report on Form 8-K, File No. 000-53078, filed August 23, 2017)

10.2		Stock Purchase Agreement with Musculoskeletal Transplant Foundation, Inc. dated as of August 18, 2017 (incorporated herein by reference to Exhibit 10.2 to current report on Form 8-K, File No. 000-53078, filed August 23, 2017)

10.3		Amended and Restated Exclusive License Agreement, dated as of August 18, 2017, by and between the Company and The Regents of the University of California (incorporated herein by reference to Exhibit 10.1 to current report on Form 8-K, File No. 000-53078, filed August 23, 2017)

31.1		Certification of the Company’s Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Report on Form 10-Q for the quarter ended September 30, 2017.*

31.1		Certification of the Company’s Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Report on Form 10-Q for the quarter ended September 30, 2017.*

32.1		Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

32.1		Certification of the Company’s Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

101.INS		XBRL Instance Document*
101.SCH		XBRL Taxonomy Extension Schema Document*
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB		XBRL Taxonomy Extension Label Linkbase Document*
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document*

* Filed Herewith

SIGNATURES

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BONE BIOLOGICS CORPORATION

Dated: November 13, 2017	By:	/s/ Stephen R. LaNeve
	Name:	Stephen R. LaNeve
	Title:	Chief Executive Officer

EX-31.1 2 ex31-1.htm

Exhibit 31.1

Certification of Principal Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

and Securities and Exchange Commission Release 34-46427

I, Stephen R. LaNeve, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Bone Biologics Corporation

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. As the registrant’s Principal Financial Officer, I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and I have:

a) designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 13, 2017	/s/ Stephen R. LaNeve
	Stephen R. LaNeve
	Principal Executive Officer

EX-31.2 3 ex31-2.htm

Exhibit 31.2

Certification of Principal Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

and Securities and Exchange Commission Release 34-46427

I, Deina H. Walsh, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Bone Biologics Corporation

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 13, 2017	/s/ Deina H. Walsh
	Deina H. Walsh
	Principal Financial Officer

EX-32.1 4 ex32-1.htm

Exhibit 32.1

Certification of Principal Executive Officer

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Report of Bone Biologics Corporation (the “Company”) on Form 10-Q for the period ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stephen R. LaNeve, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	/s/ Stephen R. LaNeve
	Stephen R. LaNeve
	Principal Executive Officer

	November 13, 2017

EX-32.2 5 ex32-2.htm

Exhibit 32.2

Certification of Principal Financial Officer

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Report of Bone Biologics Corporation (the “Company”) on Form 10-Q for the period ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Deina H. Walsh, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	/s/ Deina H. Walsh
	Deina H. Walsh
	Principal Financial Officer

	November 13, 2017

EX-101.INS 6 bblg-20170930.xml XBRL INSTANCE FILE 0001419554 2017-09-30 0001419554 2017-01-01 2017-09-30 0001419554 BBLG:BoneBiologicsIncMember 2017-01-01 2017-09-30 0001419554 BBLG:BoneBiologicsIncMember 2017-09-30 0001419554 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001419554 BBLG:ConvertiblePromissoryNotesMember 2017-01-01 2017-09-30 0001419554 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001419554 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001419554 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001419554 BBLG:ConvertiblePromissoryNotesMember 2016-01-01 2016-09-30 0001419554 BBLG:LicenseAgreementMember 2017-01-01 2017-09-30 0001419554 BBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember BBLG:LicenseAgreementMember 2017-01-01 2017-09-30 0001419554 BBLG:TwoThousandNineMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:TwoThousandTenMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:AprilTwoThousandThirteenMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:TwoThousandNineMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:TwoThousandTenMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:AprilTwoThousandThirteenMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:FirstSecuredConvertibleNoteandWarrantMember BBLG:HankeyCapitalLLCMember 2014-10-24 0001419554 BBLG:FirstSecuredConvertibleNoteandWarrantMember BBLG:HankeyCapitalLLCMember 2014-10-23 2014-10-24 0001419554 BBLG:HankeyCapitalLLCMember 2014-10-24 0001419554 BBLG:HankeyCapitalLLCMember 2014-10-23 2014-10-24 0001419554 BBLG:DepositorMember 2017-09-30 0001419554 BBLG:JulyTwoThousandFourteenOneMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:JulyTwoThousandFourteenTwoMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:JulyTwoThousandFourteenThreeMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:JulyTwoThousandFourteenFourMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:JulyTwoThousandFourteenFiveMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:SeptemberTwoThousandFourteenOneMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:SeptemberTwoThousandFourteenTwoMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:SeptemberTwoThousandFourteenThreeMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:OctoberTwoThousandFourTeenMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:OctoberTwoThousandFourTeenOneMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:JulyTwoThousandFourteenTwoMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:JulyTwoThousandFourteenThreeMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:JulyTwoThousandFourteenFourMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:JulyTwoThousandFourteenFiveMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:SeptemberTwoThousandFourteenOneMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:SeptemberTwoThousandFourteenTwoMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:SeptemberTwoThousandFourteenThreeMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:OctoberTwoThousandFourTeenMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:OctoberTwoThousandFourTeenOneMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:JulyTwoThousandFourteenOneMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:SeptemberTwoThousandThirteenOneMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:SeptemberTwoThousandThirteenMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:NovemberTwoThousandThirteenMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:SeptemberTwoThousandThirteenOneMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:SeptemberTwoThousandThirteenMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:NovemberTwoThousandThirteenMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:SeptemberTwoThousandFourteenMember 2017-01-01 2017-09-30 0001419554 BBLG:SeptemberTwoThousandFourteenMember 2017-09-30 0001419554 BBLG:NovemberTwoThousandFourteenMember 2017-01-01 2017-09-30 0001419554 BBLG:NovemberTwoThousandFourteenMember 2017-09-30 0001419554 BBLG:FebruaryTwoThousandFifteenMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:FebruaryTwoThousandFifteenMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:FirstSecuredConvertibleNoteandWarrantMember BBLG:HankeyCapitalLLCMember us-gaap:PrimeRateMember 2014-10-24 0001419554 BBLG:HankeyCapitalLLCMember BBLG:SecondSecuredConvertibleNoteAndWarrantMember 2015-05-04 0001419554 BBLG:HankeyCapitalLLCMember BBLG:SecondSecuredConvertibleNoteAndWarrantMember 2015-05-03 2015-05-04 0001419554 BBLG:HankeyCapitalLLCMember BBLG:SecondSecuredConvertibleNoteAndWarrantMember us-gaap:PrimeRateMember 2015-05-04 0001419554 BBLG:HankeyCapitalLLCMember BBLG:SecondWarrantMember 2015-05-03 2015-05-04 0001419554 BBLG:HankeyCapitalLLCMember BBLG:SecondWarrantMember 2015-05-04 0001419554 BBLG:MayTwoThousandFifteenMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:MayTwoThousandFifteenMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:IssuanceOfStockOptionsMember 2016-01-01 2016-09-30 0001419554 BBLG:AugustTwoThousandFifteenMember 2017-09-30 0001419554 BBLG:AugustTwoThousandFifteenMember 2017-01-01 2017-09-30 0001419554 BBLG:SeptemberTwoThousandFifteenMember 2017-09-30 0001419554 BBLG:SeptemberTwoThousandFifteenMember 2017-01-01 2017-09-30 0001419554 BBLG:HankeyCapitalLLCMember BBLG:SecondSecuredConvertibleNoteAndWarrantMember us-gaap:MaximumMember 2015-05-03 2015-05-04 0001419554 BBLG:LicenseAgreementMember BBLG:FirstCommercialSaleMember 2017-01-01 2017-09-30 0001419554 BBLG:LicenseAgreementMember BBLG:AfterFirstCommercialSaleMember 2017-01-01 2017-09-30 0001419554 BBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember BBLG:LicenseAgreementMember us-gaap:MinimumMember 2017-01-01 2017-09-30 0001419554 BBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember BBLG:LicenseAgreementMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0001419554 BBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember BBLG:LicenseAgreementMember BBLG:FirstSubjectInFeasibilityStudyMember 2017-01-01 2017-09-30 0001419554 BBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember BBLG:LicenseAgreementMember BBLG:FirstSubjectInPivotalStudyMember 2017-01-01 2017-09-30 0001419554 BBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember BBLG:LicenseAgreementMember BBLG:PreMarketApprovalOfLicensedProductOrLicensedMethodMember 2017-01-01 2017-09-30 0001419554 BBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember BBLG:LicenseAgreementMember BBLG:FirstCommercialSaleOfLicensedProductOrLicensedMethodMember 2017-01-01 2017-09-30 0001419554 BBLG:OctoberTwoThousandFifteenMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:OctoberTwoThousandFifteenMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:TwoThousandFifteenEquityIncentivePlanMember 2015-12-31 0001419554 BBLG:NovemberTwoThousandFifteenMember 2017-09-30 0001419554 BBLG:NovemberTwoThousandFifteenMember 2017-01-01 2017-09-30 0001419554 BBLG:DecemberTwoThousandFifteenMember 2017-09-30 0001419554 BBLG:DecemberTwoThousandFifteenMember 2017-01-01 2017-09-30 0001419554 BBLG:UniversityOfCaliforniaLosAngelesTechnologyDevelopmentGroupMember BBLG:LicenseAgreementMember 2016-12-21 2016-12-22 0001419554 BBLG:FirstSecuredConvertibleNoteandWarrantMember BBLG:HankeyCapitalLLCMember us-gaap:MaximumMember 2014-10-23 2014-10-24 0001419554 BBLG:TwoThousandFifteenEquityIncentivePlanMember 2015-01-01 2015-12-31 0001419554 BBLG:EmployeesAndDirectorsMember 2016-01-01 2016-09-30 0001419554 BBLG:EmployeesAndDirectorsMember 2017-01-01 2017-09-30 0001419554 2016-12-31 0001419554 us-gaap:MinimumMember 2017-01-01 2017-09-30 0001419554 us-gaap:MaximumMember 2017-01-01 2017-09-30 0001419554 BBLG:HankeyCapitalLLCMember BBLG:ThirdConvertibleSecuredTermNoteAndWarrantMember 2016-02-24 0001419554 BBLG:HankeyCapitalLLCMember BBLG:ThirdConvertibleSecuredTermNoteAndWarrantMember 2016-02-23 2016-02-24 0001419554 BBLG:HankeyCapitalLLCMember BBLG:ThirdConvertibleSecuredTermNoteAndWarrantMember us-gaap:PrimeRateMember 2016-02-24 0001419554 BBLG:HankeyCapitalLLCMember BBLG:ThirdConvertibleSecuredTermNoteAndWarrantMember us-gaap:MaximumMember 2016-02-23 2016-02-24 0001419554 BBLG:HankeyCapitalLLCMember BBLG:ThirdWarrantMember 2016-02-24 0001419554 BBLG:HankeyCapitalLLCMember BBLG:ThirdWarrantMember 2016-02-23 2016-02-24 0001419554 BBLG:FebruaryTwoThousandSixteenMember BBLG:UnexercisedCommonStockWarrantsMember 2017-01-01 2017-09-30 0001419554 BBLG:FebruaryTwoThousandSixteenMember BBLG:UnexercisedCommonStockWarrantsMember 2017-09-30 0001419554 BBLG:JanuaryTwoThousandSixteenMember 2017-09-30 0001419554 BBLG:JanuaryTwoThousandSixteenMember 2017-01-01 2017-09-30 0001419554 BBLG:MarchTwoThousandSixteenMember 2017-09-30 0001419554 BBLG:MarchTwoThousandSixteenMember 2017-01-01 2017-09-30 0001419554 BBLG:AFHMember us-gaap:PrivatePlacementMember us-gaap:MinimumMember 2016-02-09 2016-02-10 0001419554 BBLG:AFHMember 2016-02-10 0001419554 BBLG:AFHMember us-gaap:PrivatePlacementMember us-gaap:MaximumMember 2016-02-09 2016-02-10 0001419554 BBLG:AFHMember 2016-02-09 2016-02-10 0001419554 BBLG:MtfMember 2016-02-22 0001419554 BBLG:MtfMember 2016-02-24 0001419554 BBLG:MtfMember 2015-10-02 0001419554 2016-01-08 0001419554 BBLG:FirstAnniversaryMember 2016-01-08 0001419554 BBLG:SecondAnniversaryMember 2016-01-08 0001419554 BBLG:ThirdAnniversaryMember 2016-01-08 0001419554 BBLG:FourthAnniversaryMember 2016-01-08 0001419554 BBLG:FifthAnniversaryMember 2016-01-08 0001419554 BBLG:HankeyCapitalLLCMember BBLG:ThirdWarrantMember 2017-09-30 0001419554 BBLG:HankeyCapitalLLCMember BBLG:ThirdWarrantMember BBLG:FirstTwoConvertibleSecuredNotesMember 2017-01-01 2017-09-30 0001419554 BBLG:MayTwoThousandSixteenMember 2017-09-30 0001419554 BBLG:MayTwoThousandSixteenMember 2017-01-01 2017-09-30 0001419554 BBLG:JuneTwoThousandSixteenMember 2017-01-01 2017-09-30 0001419554 BBLG:JuneTwoThousandSixteenMember 2017-09-30 0001419554 BBLG:AFHMember BBLG:OctoberTwentyEightTwoThousandFifteenInvoiceMember 2016-06-01 2016-06-02 0001419554 BBLG:AFHMember BBLG:LetterAgreementFebTenTwoThousandSixteenMember 2016-06-01 2016-06-02 0001419554 BBLG:MtfMember 2016-06-24 0001419554 BBLG:FounderMember BBLG:TenYearStockOptionMember 2016-06-01 2016-06-02 0001419554 BBLG:FounderMember BBLG:TenYearStockOptionMember 2016-06-02 0001419554 BBLG:OctoberTwoThousandSixteenAndFebruaryTwoThousandSeventeenNotePurchaseAgreementMember 2017-01-01 2017-09-30 0001419554 BBLG:OctoberTwoThousandSixteenAndFebruaryTwoThousandSeventeenNotePurchaseAgreementMember BBLG:DirectorsMember 2017-01-01 2017-09-30 0001419554 BBLG:FirstSecuredConvertibleNoteandWarrantMember BBLG:HankeyCapitalLLCMember us-gaap:MinimumMember 2014-10-24 0001419554 BBLG:HankeyCapitalLLCMember BBLG:SecondSecuredConvertibleNoteAndWarrantMember us-gaap:MinimumMember 2015-05-04 0001419554 BBLG:HankeyCapitalLLCMember BBLG:ThirdConvertibleSecuredTermNoteAndWarrantMember us-gaap:MinimumMember 2016-02-24 0001419554 BBLG:MTFandHankeyCapitalLLCMember BBLG:ConvertiblePromissoryNotesMember BBLG:NotePurchaseAgreementMember 2016-10-13 2016-10-14 0001419554 BBLG:MTFandHankeyCapitalLLCMember BBLG:ConvertiblePromissoryNotesMember BBLG:NotePurchaseAgreementMember 2016-10-14 0001419554 BBLG:ConvertiblePromissoryNotesMember BBLG:NotePurchaseAgreementMember 2016-10-14 0001419554 BBLG:MTFandHankeyCapitalLLCMember BBLG:ConvertiblePromissoryNotesMember BBLG:NotePurchaseAgreementMember us-gaap:DirectorMember 2016-10-13 2016-10-14 0001419554 BBLG:MTFandHankeyCapitalLLCMember BBLG:ConvertiblePromissoryNotesMember BBLG:NotePurchaseAgreementMember BBLG:NoncurrentStockholdersMember 2016-10-14 0001419554 BBLG:IssuanceOfStockOptionsMember 2017-01-01 2017-09-30 0001419554 BBLG:NotePurchaseAgreementMember BBLG:MtfMember 2016-10-14 0001419554 BBLG:FirstSecuredConvertibleNoteandWarrantMember BBLG:HankeyCapitalLLCMember us-gaap:MinimumMember 2014-10-23 2014-10-24 0001419554 BBLG:HankeyCapitalLLCMember BBLG:SecondSecuredConvertibleNoteAndWarrantMember us-gaap:MinimumMember 2015-05-03 2015-05-04 0001419554 BBLG:HankeyCapitalLLCMember BBLG:ThirdConvertibleSecuredTermNoteAndWarrantMember us-gaap:MinimumMember 2016-02-23 2016-02-24 0001419554 2016-01-01 2016-09-30 0001419554 2015-12-31 0001419554 2016-01-01 2016-12-31 0001419554 BBLG:SecuredConvertibleNoteMember 2017-01-01 2017-09-30 0001419554 BBLG:SecuredConvertibleNoteMember 2017-09-30 0001419554 BBLG:SecuredConvertibleNoteMember 2016-12-31 0001419554 BBLG:SecondSecuredConvertibleNoteMember 2017-01-01 2017-09-30 0001419554 BBLG:SecondSecuredConvertibleNoteMember 2017-09-30 0001419554 BBLG:SecondSecuredConvertibleNoteMember 2016-12-31 0001419554 BBLG:ThirdSecuredConvertibleNoteMember 2017-01-01 2017-09-30 0001419554 BBLG:ThirdSecuredConvertibleNoteMember 2017-09-30 0001419554 BBLG:ThirdSecuredConvertibleNoteMember 2016-12-31 0001419554 BBLG:ConvertiblePromissoryNotesMember 2017-01-01 2017-09-30 0001419554 BBLG:ConvertiblePromissoryNotesMember 2017-09-30 0001419554 BBLG:HankeyCapitalLLCMember 2017-01-01 2017-09-30 0001419554 2016-09-30 0001419554 BBLG:MTFandHankeyCapitalLLCMember BBLG:ConvertiblePromissoryNotesMember BBLG:NotePurchaseAgreementMember 2017-02-10 0001419554 BBLG:MTFandHankeyCapitalLLCMember BBLG:ConvertiblePromissoryNotesMember BBLG:NotePurchaseAgreementMember 2017-02-09 2017-02-10 0001419554 BBLG:ConvertiblePromissoryNotesMember BBLG:NotePurchaseAgreementMember 2017-02-10 0001419554 BBLG:ConvertiblePromissoryNotesMember 2016-12-31 0001419554 BBLG:ConvertiblePromissoryNotesOneMember 2017-01-01 2017-09-30 0001419554 BBLG:ConvertiblePromissoryNotesOneMember 2017-09-30 0001419554 BBLG:JanuaryTwoThousandSeventeenMember 2017-09-30 0001419554 BBLG:JanuaryTwoThousandSeventeenMember 2017-01-01 2017-09-30 0001419554 BBLG:AFHMember 2017-09-30 0001419554 BBLG:AFHMember 2017-01-01 2017-09-30 0001419554 BBLG:AFHMember 2016-01-01 2016-09-30 0001419554 BBLG:MtfMember 2016-01-01 2016-12-31 0001419554 BBLG:NotePurchaseAgreementMember BBLG:MtfMember 2017-02-10 0001419554 2016-12-30 2017-01-02 0001419554 BBLG:HankeyCapitalLLCMember BBLG:FirstTwoConvertibleSecuredNotesMember 2017-09-30 0001419554 BBLG:ConvertiblePromissoryNotesMember 2016-01-01 2016-09-30 0001419554 2017-07-01 2017-09-30 0001419554 2016-07-01 2016-09-30 0001419554 2017-11-10 0001419554 BBLG:NonaffiliatesMember 2017-04-01 2017-06-30 0001419554 BBLG:FoundersProfessionalServicesAgreementMember 2016-01-01 2016-09-30 0001419554 BBLG:FoundersProfessionalServicesAgreementMember 2017-01-01 2017-09-30 0001419554 BBLG:DirectorsMember 2017-01-01 2017-09-30 0001419554 BBLG:DirectorsMember 2016-01-01 2016-09-30 0001419554 2016-12-12 2016-12-13 0001419554 BBLG:HankeyCapitalLLCMember BBLG:ConvertiblePromissoryNotesMember BBLG:NotePurchaseAgreementMember 2017-08-18 0001419554 BBLG:HankeyCapitalLLCMember BBLG:ConvertiblePromissoryNotesMember BBLG:NotePurchaseAgreementMember 2017-08-17 2017-08-18 0001419554 BBLG:ConvertiblePromissoryNotesMember BBLG:NotePurchaseAgreementMember 2017-08-18 0001419554 BBLG:ConvertiblePromissoryNotesOneMember 2017-12-31 0001419554 BBLG:ConvertiblePromissoryNotesTwoMember 2017-09-30 0001419554 BBLG:ConvertiblePromissoryNotesTwoMember 2017-12-31 0001419554 BBLG:ConvertiblePromissoryNotesTwoMember 2017-01-01 2017-09-30 0001419554 2017-08-17 2017-08-18 0001419554 2017-08-18 0001419554 2007-10-18 2017-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

-4737003

-16150355

-2527419

-4372271

52000000

10-Q false 2017-09-30 Smaller Reporting Company --12-31 Q3

0.001

20000000

0.001

0.0001

0.001

100000000

39077322

38828607

39077322

38828607

1405396

4512033

2938825

1405396

-2338812

2938825

5648658

10000

As of September 30, 2017, the Company had outstanding unexercised Common Stock Warrants as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Date Issued</td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Expiration date</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 47%">2009</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.44</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">118,383</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">March 16, 2019</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2010</td> <td> </td> <td>$</td> <td style="text-align: right">0.44</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">254,997</td> <td> </td> <td> </td> <td style="text-align: right">February 4, 2020</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>April 2013</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td style="text-align: right">April 28, 2020</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>September 2013</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td style="text-align: right">September 4, 2020</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>September 2013</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25,000</td> <td> </td> <td> </td> <td style="text-align: right">September 20, 2020</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>November 2013</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">75,000</td> <td> </td> <td> </td> <td style="text-align: right">November 14, 2020</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>July 2014</td> <td> </td> <td>$</td> <td style="text-align: right">1.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">166,667</td> <td> </td> <td> </td> <td style="text-align: right">May 30, 2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>July 2014</td> <td> </td> <td>$</td> <td style="text-align: right">1.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">166,667</td> <td> </td> <td> </td> <td style="text-align: right">September 30, 2018</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>July 2014</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td style="text-align: right">September 30, 2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>July 2014</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">46,667</td> <td> </td> <td> </td> <td style="text-align: right">July 2, 2018</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>July 2014</td> <td> </td> <td>$</td> <td style="text-align: right">0.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">12,625</td> <td> </td> <td> </td> <td style="text-align: right">July 10, 2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>September 2014</td> <td> </td> <td>$</td> <td style="text-align: right">1.62</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">625,000</td> <td> </td> <td> </td> <td style="text-align: right">August 31, 2021</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>September 2014</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">699,671</td> <td> </td> <td> </td> <td style="text-align: right">September 18, 2021</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>September 2014</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">89,588</td> <td> </td> <td> </td> <td style="text-align: right">September 29, 2021</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>October 2014</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">126,582</td> <td> </td> <td> </td> <td style="text-align: right">October 23, 2017</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>October 2014</td> <td> </td> <td>$</td> <td style="text-align: right">1.58</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,164,558</td> <td> </td> <td> </td> <td style="text-align: right">October 23, 2019</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>February 2015</td> <td> </td> <td>$</td> <td style="text-align: right">1.58</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">699,037</td> <td> </td> <td> </td> <td style="text-align: right">February 14, 2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>May 2015</td> <td> </td> <td>$</td> <td style="text-align: right">1.58</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,898,734</td> <td> </td> <td> </td> <td style="text-align: right">May 4, 2020</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>October 2015</td> <td> </td> <td>$</td> <td style="text-align: right">1.58</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">158,229</td> <td> </td> <td> </td> <td style="text-align: right">October 27, 2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>February 2016</td> <td> </td> <td style="padding-bottom: 1.5pt">$</td> <td style="padding-bottom: 1.5pt; text-align: right">2.05</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,463,415</td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">February 23, 2021</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total warrants at September 30, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">10,390,820</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2.45 years</td></tr> </table>

A summary of stock option activity for the nine months ended September 30, 2017, is presented below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">of Shares</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Aggregate</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Subject to Exercise</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Life (Years)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Value</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 36%">Outstanding as of January 1, 2016</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">6,294,226</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">1.59</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">10.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted – 2016</td> <td> </td> <td> </td> <td style="text-align: right">6,361,841</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.66</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9.95</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Forfeited – 2016</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Exercised – 2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding as of January 1, 2017</td> <td> </td> <td> </td> <td style="text-align: right">12,656,067</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.62</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9.21</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted – 2017</td> <td> </td> <td> </td> <td style="text-align: right">80,341</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.05</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Forfeited – 2017</td> <td> </td> <td> </td> <td style="text-align: right">(4,270,639</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">1.60</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8.54</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Exercised – 2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(68,553</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2.05</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">8.25</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Outstanding as of September 30, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8,397,216</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1.64</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">7.80</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

A summary of the changes in the Company’s non-vested options during the three months ended September 30, 2017, is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Non-vested Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Fair Value at Grant Date</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Intrinsic Value</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%">Non-vested at January 1, 2016</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">5,156,710</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">1.29</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted in 2016</td> <td> </td> <td> </td> <td style="text-align: right">6,361,841</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.93</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Vested in year ended December 31, 2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1,913,491</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.31</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Non-vested at January 1, 2017</td> <td> </td> <td> </td> <td style="text-align: right">9,605,060</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.74</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Granted in 2017</td> <td> </td> <td> </td> <td style="text-align: right">80,341</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.87</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Forfeited – 2017</td> <td> </td> <td> </td> <td style="text-align: right">(4,145,391</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">1.95</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Vested in 2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,718,316</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.69</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Non-vested at September 30, 2017</td> <td> </td> <td> </td> <td style="text-align: right">2,821,694</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.49</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Exercisable at September 30, 2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,575,522</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.44</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Outstanding at September 30, 2017</td> <td> </td> <td> </td> <td style="text-align: right">8,397,216</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.46</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> </table>

2151926

3955697

1898734

1463415

1260255

731707

700000

1153846

1800364

791139

700000

100000

250000

500000

1000000

500000

1435000

503

333

261

250000

5000000

6500000

225082

226516

19897587

The Company utilized the Black-Scholes option pricing model. The assumptions used for the nine months ended September 30, 2017 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk free interest rate</td> <td> </td> <td> </td> <td style="text-align: right">1.99%-2.306</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected life (in years)</td> <td> </td> <td> </td> <td style="text-align: right">5.5-9.0</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected Volatility</td> <td> </td> <td> </td> <td style="text-align: right">135.94%-153.79 </td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 81%">Expected dividend yield</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">0</td> <td style="width: 1%">%</td></tr> </table>

0.030 0.00333 0.10 0.20 Bone Biologics Corp

-10904475

-8634056

2970060

5235736

882399

1383982

28384239

8397216

9596203

10390820

10451740

12656067

5696203

28804010

50000

250000

2. Summary of Significant Accounting Policies   We have prepared the unaudited interim condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in the annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes for the year ended December 31, 2016. The results of the three and nine month periods ended September 30, 2017 are not necessarily indicative of the results to be expected for the full year ending December 31, 2017.   Basis of Presentation   The accompanying condensed consolidated financial statements and related notes included activities of the Company and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).   Use of Estimates   The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant estimates include warrants and income tax valuation allowances. Actual results could differ from those estimates.   Fair Value of Financial Instruments   The Company’s consolidated financial instruments are accounts payable and notes payable. The recorded values of accounts payable approximate their values based on their short-term nature. Notes payable are recorded at their issue value or if warrants are attached at their issue value less the value of the warrant.   The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable:   Level 1: Quoted prices in active markets for identical assets or liabilities.   Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.   Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from embedded derivatives associated with certain warrants to purchase common stock.   Property and Equipment   Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets, ranging from three to seven years. Expenditures for additions and improvements are capitalized, while repairs and maintenance costs are expensed as incurred. The cost and related accumulated depreciation of property and equipment sold or otherwise disposed of are removed from the accounts and any gain or loss is recorded in the year of disposal.   Impairment of Long-Lived Assets   The long-lived assets held and used by the Company are reviewed for impairment no less frequently than annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. Management has determined that there was no impairment in the value of long-lived assets during the nine months ended September 30, 2017.   Research and Development Costs   Research and development costs include, but are not limited to, patents and license expenses, payroll and other personnel expenses, consultants, expenses incurred under agreements with contract research and manufacturing organizations and animal clinical investigative sites and the cost to manufacture clinical trial materials. Costs related to research, design and development of products are charged to research and development expense as incurred.   Patents and Licenses   In March 2006, the Company entered into an exclusive license agreement (“Exclusive License Agreement”), with UCLA TDG for the worldwide application of the NELL-1 protein through a technology transfer. See Note 5 for commitments related to the Exclusive License Agreement. Patent expenses include costs to acquire the license of NELL-1, which was de minimis, and costs to file patent applications related to NELL-1.   The Company expenses the costs incurred to file patent applications, all costs related to abandoned patent applications and maintenance costs, and these costs are included in research and development expenses. Costs associated with licenses acquired to be able to use products from third parties prior to receipt of regulatory approval to market the related products are also expensed. The Company’s licensed technologies may have alternative future uses in that they are enabling (or platform) technologies that can be the basis for multiple products that would each target a specific indication. Costs of acquisition of licenses are expensed.   Prepaid expenses – related party   Prepaid expenses – related party represent the fair value of warrants issued to AFH Holding & Advisory, LLC (“AFH”), a shareholder, for services pursuant to certain letter agreement dated May 4, 2014. Prepaid costs will be amortized as the required services are performed. As of September 30, 2017 and December 31, 2016 prepaid expenses – related party totaled $271,945.   Concentration of Credit Risk and Other Risks and Uncertainties   Cash balances are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. Federal insurance coverage is $250,000 per depositor at each financial institution. A substantial majority of the Company’s cash balances exceed federally insured limits.   Debt Issuance Costs   Debt issuance costs represent costs incurred in connection with the issuance of the convertible notes payable and private equity financing. Debt issuance costs related to the issuance of debt are being amortized over the term of the financing instrument using the effective interest method, while debt issuance costs from equity financings are netted against the gross proceeds received from the equity financings.   Stock Based Compensation   ASC 718, Compensation – Stock Compensation, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).   The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, Equity – based Payments to Non-Employees. Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.   Pursuant to ASU No. 2016-09 – Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, the Company accounts for forfeitures when they occur.   Income Taxes   Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due and deferred taxes resulting from timing differences in recording of transactions for tax purposes and financial reporting purposes.   The deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are received or settled. Valuation allowances are established when necessary to reduce deferred tax assets to amounts expected to be realized.   The accounting provisions related to uncertain income tax positions require the Company to determine whether any tax position in all open years meets a more likely than not threshold of being sustained upon examination by the applicable taxing authority. The Company did not have any changes to its liability for uncertain tax positions as at September 30, 2017 and December 31, 2016.   The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. No such amounts are accrued as of September 30, 2017 and December 31, 2016.   Loss per Common Share   The Company utilizes FASB ASC Topic No. 260, Earnings per Share. Basic loss per share is computed by dividing loss available to common shareholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible debentures, options and warrants were to be exercised or converted or otherwise resulted in the issuance of common stock that then shared in the earnings of the entity.   Since the effects of outstanding options, warrants, and the conversion of convertible debt are anti-dilutive in during the three months ended September 30, 2016 and the nine months periods ended September 30, 2017 and 2016, shares of common stock underlying these instruments have been excluded from the computation of loss per common share.   The following sets forth the number of shares of common stock underlying outstanding options, warrants, and convertible debt as of September 30, 2017 and 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%">Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">10,390,820</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">10,451,740</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock options</td> <td> </td> <td> </td> <td style="text-align: right">8,397,216</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">12,656,067</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Convertible promissory notes</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">9,596,203</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,696,203</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">28,384,239</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">28,804,010</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   New Accounting Standards   The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its consolidated financial statements.   In August 2016, the FASB issued authoritative guidance under ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 is intended to reduce diversity in practice in how certain cash receipts and cash payments are presented and classified in the Consolidated Statement of Cash Flows by providing guidance on eight specific cash flow issues. ASU 2016-15 is effective retrospectively on January 1, 2018, with early adoption permitted. We have not yet determined the effect of the ASU on our Consolidated Financial Statements nor have we selected a transition date.   In January 2017, the FASB issued authoritative guidance under ASU 2017-01, Business Combinations – Clarifying the Definition of a Business, which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The standard introduces a screen for determining when assets acquired are not a business and clarifies that a business must include, at a minimum, an input and a substantive process that contribute to an output to be considered a business. This standard is effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. The Company does not expect this new guidance to have a material impact on its consolidated financial statements.

3. Property and Equipment   Property and equipment consist of the following at:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31,  2016</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; text-align: justify">Furniture and equipment</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">503</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">503</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; text-align: justify">Less accumulated depreciation</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(333</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(261</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: justify"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">170</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">242</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Depreciation expense for the nine months ended September 30, 2017 and 2016 was $72 and $660, respectively. During the nine months ended September 30, 2016, we recorded a loss on disposal of assets of $4,862.

4. Accounts Payable and Accrued Expenses   Accounts payable and accrued expenses consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31,  2016</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Interest expense</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">218,757</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">22,383</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Accounts payable</td> <td> </td> <td> </td> <td style="text-align: right">225,082</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">226,516</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Accrued bonus</td> <td> </td> <td> </td> <td style="text-align: right">256,500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Deferred Directors’ fees</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">39,725</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">11,250</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">740,064</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">260,149</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

5. Commitments and Contingencies   UCLA TDG Exclusive License Agreement   Effective August 18, 2017, the Company entered into an Amended and Restated Exclusive License Agreement (the “Restated License Agreement”) with the UCLA Technology Development Group on behalf of UC Regents (“UCLA TDG”). The Restated License Agreement amends and restates the Exclusive License Agreement, effective March 15, 2006, between the Company and UCLA TDG, as amended by ten amendments. Under the terms of the Restated License Agreement, the Regents have continued to grant the Company exclusive rights to develop and commercialize NELL-1 (the “Licensed Product”) for spinal fusion applications. The Licensed Product is a recombinant human protein growth factor that is essential for normal bone development.   Following the completion of several key milestones, Bone Biologics has expanded its Field of Use definition beyond spine fusion within the NELL-1 license agreement with UCLA TDG. Consistent with that expansion, Bone Biologics has entered into an exclusive license agreement with UCLA TDG for the worldwide application of the NELL-1 protein for both osteoporosis and trauma through a technology transfer.   We have agreed to pay an annual maintenance fee to UCLA TDG of $10,000 as well as to pay certain royalties to UCLA TDG under the Restated License Agreement at the rate of 3.0% of net sales of licensed products. We must pay the royalties to UCLA TDG on a quarterly basis. Upon a first commercial sale, we also must pay between $50,000 and $250,000, depending on the calendar year that is after the first commercial sale. If we are required to pay any third party any royalties as a result of us making use of UCLA TDG patents, then we may reduce the royalty owed to UCLA TDG by 0.333% for every percentage point paid to a third party. If we grant sublicense rights to a third party to use the UCLA TDG patent, then we will pay to UCLA TDG 10% to 20% of the sublicensing income we receive from such sublicense.   We are obligated to make the following milestone payments to UCLA TDG for each Licensed Product or Licensed Method:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="text-align: justify">$100,000 upon enrollment of the first subject in a Feasibility Study;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">●</td> <td style="text-align: justify">$250,000 upon enrollment of the first subject in a Pivotal Study:</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">●</td> <td style="text-align: justify">$500,000 upon Pre-Market Approval of a Licensed Product or Licensed Method; and</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">●</td> <td style="text-align: justify">$1,000,000 upon the First Commercial Sale of a Licensed Product or Licensed Method.</td></tr> </table>    We are also obligated to pay UCLA TDG a cash milestone payment within thirty (30) days of a Liquidity Event (including a Change of Control Transaction and a payment election by UCLA TDG exercisable after December 22, 2016, such payment to equal the greater of:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">$500,000; or</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td style="text-align: justify">2% of all proceeds in connection with a Change of Control Transaction.</td></tr> </table>   We are obligated to diligently proceed with developing and commercializing licensed products under UCLA patents set forth in the Restated License Agreement. UCLA TDG has the right to either terminate the license or reduce the license to a non-exclusive license if we do not meet certain diligence milestone deadlines set forth in the Restated License Agreement.   We must reimburse or pre-pay UCLA TDG for patent prosecution and maintenance costs incurred during the term of the Restated License Agreement. We have the right to bring infringement actions against third party infringers of the Restated License Agreement, UCLA TDG may join voluntarily, at its own expense, or, at our expense, be joined involuntarily to the action. We are required to indemnify UCLA TDG against any third party claims arising out of our exercise of the rights under the Restated License Agreement or any sublicense.   Contingencies   The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company’s management does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows.   Indemnification   In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.   In accordance with its amended and restated certificate of incorporation and amended and restated bylaws, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. There have been no claims to date and the Company has a director and officer insurance policy that enables it to recover a portion of any amounts paid for future potential claims.

7. Stockholders’ Equity    Preferred Stock   The Company’s amended and restated certificate of incorporation authorizes the Company to issue a total of 20,000,000 shares of preferred stock. No shares have been issued.   Common Stock   The Company’s amended and restated certificate of incorporation authorizes the Company to issue a total of 100,000,000 shares of common stock. As of September 30, 2017 and December 31, 2016, the Company had an aggregate of 39,077,322 and 38,828,607 shares of common stock outstanding, respectively.   On August 18, 2017, the Company sold to MTF an aggregate of 233,333 shares of common stock of the Company at a price per share equal to $3.00.   On August 18, 2017, 15,382 shares of common stock of the Company were issued from the exercise of options.   In connection with the Secured Convertible Notes to Hankey Capital, the Company issued 11,392,406 common shares as collateral. (See Note 6)   Each share of common stock has the right to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared by the Board.   Common Stock Warrants   As of September 30, 2017, the Company had outstanding unexercised Common Stock Warrants as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Date Issued</td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Expiration date</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 47%">2009</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.44</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">118,383</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">March 16, 2019</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2010</td> <td> </td> <td>$</td> <td style="text-align: right">0.44</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">254,997</td> <td> </td> <td> </td> <td style="text-align: right">February 4, 2020</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>April 2013</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td style="text-align: right">April 28, 2020</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>September 2013</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td style="text-align: right">September 4, 2020</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>September 2013</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25,000</td> <td> </td> <td> </td> <td style="text-align: right">September 20, 2020</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>November 2013</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">75,000</td> <td> </td> <td> </td> <td style="text-align: right">November 14, 2020</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>July 2014</td> <td> </td> <td>$</td> <td style="text-align: right">1.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">166,667</td> <td> </td> <td> </td> <td style="text-align: right">May 30, 2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>July 2014</td> <td> </td> <td>$</td> <td style="text-align: right">1.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">166,667</td> <td> </td> <td> </td> <td style="text-align: right">September 30, 2018</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>July 2014</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td style="text-align: right">September 30, 2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>July 2014</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">46,667</td> <td> </td> <td> </td> <td style="text-align: right">July 2, 2018</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>July 2014</td> <td> </td> <td>$</td> <td style="text-align: right">0.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">12,625</td> <td> </td> <td> </td> <td style="text-align: right">July 10, 2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>September 2014</td> <td> </td> <td>$</td> <td style="text-align: right">1.62</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">625,000</td> <td> </td> <td> </td> <td style="text-align: right">August 31, 2021</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>September 2014</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">699,671</td> <td> </td> <td> </td> <td style="text-align: right">September 18, 2021</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>September 2014</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">89,588</td> <td> </td> <td> </td> <td style="text-align: right">September 29, 2021</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>October 2014</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">126,582</td> <td> </td> <td> </td> <td style="text-align: right">October 23, 2017</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>October 2014</td> <td> </td> <td>$</td> <td style="text-align: right">1.58</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,164,558</td> <td> </td> <td> </td> <td style="text-align: right">October 23, 2019</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>February 2015</td> <td> </td> <td>$</td> <td style="text-align: right">1.58</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">699,037</td> <td> </td> <td> </td> <td style="text-align: right">February 14, 2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>May 2015</td> <td> </td> <td>$</td> <td style="text-align: right">1.58</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,898,734</td> <td> </td> <td> </td> <td style="text-align: right">May 4, 2020</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>October 2015</td> <td> </td> <td>$</td> <td style="text-align: right">1.58</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">158,229</td> <td> </td> <td> </td> <td style="text-align: right">October 27, 2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>February 2016</td> <td> </td> <td style="padding-bottom: 1.5pt">$</td> <td style="padding-bottom: 1.5pt; text-align: right">2.05</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,463,415</td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">February 23, 2021</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total warrants at September 30, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">10,390,820</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2.45 years</td></tr> </table> No common stock warrants were exercised or expired during the nine months ended September 30, 2017. An aggregate of 791,139 common stock warrants were exercised during the nine months ended September 30, 2016. No common stock warrants expired during the nine months ended September 30, 2016.

10. Related Party Transactions   AFH Holding & Advisory LLC   Pursuant to a letter agreement dated February 10, 2016, the Company agreed to issue a total of 1,260,255 shares of common stock of the Company to AFH. The Letter Agreement was entered into in connection with the AFH/MTF Agreement under which AFH and its affiliated entities, individuals or assignees (“AFH Group”) were entitled to 10% of the outstanding shares of common stock of the Company (the “Share Adjustment”) after giving effect to an anticipated private placement of between $8,000,000 and $10,000,000 (the “PIPE”). In the Letter Agreement, the Company recognized that, at the time the AFH/MTF Agreement was entered into, it was not anticipated that certain events in addition to the PIPE would dilute directly or indirectly the interest of AFH Group as stockholders of the Company, including the Ninth Amendment to the UCLA License Agreement and the issuance of the Company’s Common Shares pursuant to the Professional Services Agreement with each of Dr. Chia Soo, Dr. Ben Wu, and Dr. Eric Ting discussed below. Accordingly, the Company agreed to issue the 1,260,255 shares in connection with the Share Adjustment.    On April 7, 2016, the Company entered into a consulting agreement with AFH pursuant to which the Company engaged AFH for a term of three months to provide certain consulting services to the Company effective April 5, 2016. Under the consulting agreement, AFH received an up-front retainer of $100,000 and $33,333.33 per month for three months.   On June 1, 2016, the Company agreed (i) to issue to AFH 20,186 shares of common stock of the Company as an adjustment to the October 28, 2015 invoice and (ii) to issue 23,173 shares of common stock of the Company as an adjustment to the letter agreement dated February 10, 2016. The fair value of the shares issued for services, $100,930, was recorded as general and administrative expense.   In addition to the shares and warrants issued for services, AFH received cash totaling $-0- and $325,000 for services during the nine months ended September 30, 2017 and 2016, respectively.   Amir Heshmatpour is the controlling party of AFH.   Musculoskeletal Transplant Foundation (MTF)   On February 22, 2016, the Company entered into a share purchase agreement with MTF, pursuant to which MTF purchased from the Company an aggregate of 731,707 shares of common stock of the Company at a price per share equal to $2.05.   On February 24, 2016 the Company entered into an Option Agreement for the Distribution and Supply of Sygnal™ demineralized bone matrix (“Sygnal”) with MTF pursuant to which:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">a.</td> <td style="text-align: justify">MTF grants to the Company the exclusive right and option (the “Option”) to distribute Sygnal upon the critical terms as described in the Option Agreement (the “Option Rights”). The Company will exercise the Option, if at all, by providing written notice to MTF of its intent to do so. During the term of the Option, MTF will not enter into any agreements with any third parties which include the transfer by MTF of the Option Rights.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>b.</td> <td style="text-align: justify">Upon the exercising of the Option, the Company will grant to MTF 700,000 shares of common stock in the Company.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>c.</td> <td style="text-align: justify">Within 30 days of exercising the Option, MTF will provide the Company with a written proposal of a Definitive Agreement that includes, inter alia, the Critical Terms and those other commercially reasonable terms as agreed upon by the parties. The parties will fully negotiate in good faith all of the terms of the Definitive Agreement, and any ancillary agreements thereto consistent with the Critical Terms.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>d.</td> <td style="text-align: justify">In the event the Company does not exercise the Option within the Term of the Option Agreement, MTF will be free to enter into any other agreement relating to the Option Rights as it deems appropriate without liability to the Company.</td></tr> </table>   Sygnal is a bone void filler contouring allograft bone that has the inorganic mineral removed, leaving behind the organic “collagen” matrix.   On June 24, 2016, the Company exercised this option. As provided in the Option Agreement, the Company issued 700,000 shares of its restricted common stock in connection with the exercise of the Option. Additionally, within 30 days of exercising the Option, MTF will provide the Company with a written proposal of a Definitive Agreement that includes, inter alia, certain Critical Terms described in the Agreement and those other commercially reasonable terms as agreed upon by the parties. The parties will fully negotiate in good faith all of the terms of the Definitive Agreement and any ancillary agreements thereto consistent with the Critical Terms. The Company expensed the cost of this license, $1,435,000, as research and development during the year ended December 31, 2016.   On October 14, 2016, pursuant to a Note Purchase Agreement, the Company issued to MTF a convertible promissory note in the amount of $600,000 (See Note 6).   On February 10, 2017, pursuant to a Note Purchase Agreement, the Company issued to MTF a convertible promissory note in the amount of $1,000,000 (See Note 6).   On August 18, 2017, the Company entered into a share purchase agreement with MTF, pursuant to which MTF purchased from the Company an aggregate of 233,333 shares of common stock of the Company at a price per share equal to $3.00.   Bruce Stroever, our Chairman of the Board, is the President and Chief Executive Officer of MTF.   Founders   The Company entered into a Letter Agreement effective October 2, 2015, with each of Dr. Chia Soo, Dr. Eric Kang Ting and Dr. Ben Wu (collectively, the “Founders”). The Founders were three of the original shareholders of the Company. Pursuant to the Letter Agreement, the Founders agrees to deliver to the Company all past work product and past data related to NELL-1 (the “Data”) for use by the Company in its sole discretion, within the applicable licensing rights granted under the UCLA license and in exchange the Company agreed to the future issuance of an aggregate of 1,153,846 shares of the Company’s common stock. The Shares are to be equally distributed between the Founders upon the earlier of (i) the third anniversary of the Agreement and (ii) the occurrence of a Liquidity Event (as defined in the Letter Agreement) and is currently reported as shares to be issued.   Founders Professional Services Agreement   Effective January 8, 2016, the Company entered into separate Professional Services Agreements with each of the Founders. Pursuant to each of the Agreements, each Founder has agreed to provide certain services to the Company, including providing strategic advice and strategic introductions to the Company’s management team as well as specific services set forth on an Exhibit to each Agreement. The Agreements are substantially identical. In consideration for the services to be rendered under the applicable Agreement, each Founder is granted 10-year stock options (the “Options”) to purchase 1,800,364 shares of the Company’s common stock corresponding to 4% of the Company’s outstanding common stock, on a fully diluted basis, at an exercise price of $1.59 per share. The shares subject to the Options will vest 25% on each of the first, second and third anniversary of the effective date and 12.5% on each of the fourth and fifth anniversary of the effective date. The options fully vest on a change of control of the Company, if the Company terminates the Agreement without cause or the Founder terminates the Agreement with cause. Additionally, beginning January 1, 2017, the Company will pay each Founder an annual consulting fee of $200,000 in cash or, at the option of the Company, in shares of its common stock valued as provided in the Agreement.   On June 1, 2016, the Company agreed to issue to each Founder a 10-year stock options to purchase 33,105 shares of the Company’s common stock at an exercise price of $2.05 per share as an adjustment to the Professional Services Agreements with each of the Founders dated January 8, 2016.   On December 13, 2016, the Company provided written notice to each of the Founders that it was terminating the Agreements for cause, indicating that absent cure of the material breach of the Agreements, termination of the Agreements was to be effective on January 12, 2017. Despite lengthy discussions with the Founders, and multiple extensions of the termination date to accommodate such discussions, the Company was unable to resolve the outstanding issues under the Agreements, and the Company provided notice that the Agreements were terminated, effective April 8, 2017. Any shares subject to the stock options issued under the Agreements that were not vested on the date the Agreements terminated shall be forfeited on the date of termination. Our policy is to account for forfeitures when they occur; therefore these forfeitures are recorded as a reversal to expense. Forfeiture reversals related to the termination of the Agreements was $3,629,041 in research and development expense.   Dr. Soo and Dr. Wu resigned as directors of the Company effective April 13, 2017, and Dr. Ting resigned as a member of the Company’s Scientific Advisory Board on April 13, 2017. Each of the Advisors were involved in the founding of the Company. Our licensing agreement with UCLA is independent of the Founders’ services and remains unchanged as a result of the Founders resignation.

Fair Value of Financial Instruments   The Company’s consolidated financial instruments are accounts payable and notes payable. The recorded values of accounts payable approximate their values based on their short-term nature. Notes payable are recorded at their issue value or if warrants are attached at their issue value less the value of the warrant.   The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable:   Level 1: Quoted prices in active markets for identical assets or liabilities.   Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.   Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from embedded derivatives associated with certain warrants to purchase common stock.

Property and Equipment   Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets, ranging from three to seven years. Expenditures for additions and improvements are capitalized, while repairs and maintenance costs are expensed as incurred. The cost and related accumulated depreciation of property and equipment sold or otherwise disposed of are removed from the accounts and any gain or loss is recorded in the year of disposal.

Impairment of Long-Lived Assets   The long-lived assets held and used by the Company are reviewed for impairment no less frequently than annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. Management has determined that there was no impairment in the value of long-lived assets during the nine months ended September 30, 2017.

Research and Development Costs   Research and development costs include, but are not limited to, patents and license expenses, payroll and other personnel expenses, consultants, expenses incurred under agreements with contract research and manufacturing organizations and animal clinical investigative sites and the cost to manufacture clinical trial materials. Costs related to research, design and development of products are charged to research and development expense as incurred.

Patents and Licenses   In March 2006, the Company entered into an exclusive license agreement (“Exclusive License Agreement”), with UCLA TDG for the worldwide application of the NELL-1 protein through a technology transfer. See Note 5 for commitments related to the Exclusive License Agreement. Patent expenses include costs to acquire the license of NELL-1, which was de minimis, and costs to file patent applications related to NELL-1.   The Company expenses the costs incurred to file patent applications, all costs related to abandoned patent applications and maintenance costs, and these costs are included in research and development expenses. Costs associated with licenses acquired to be able to use products from third parties prior to receipt of regulatory approval to market the related products are also expensed. The Company’s licensed technologies may have alternative future uses in that they are enabling (or platform) technologies that can be the basis for multiple products that would each target a specific indication. Costs of acquisition of licenses are expensed.

Concentration of Credit Risk and Other Risks and Uncertainties   Cash balances are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. Federal insurance coverage is $250,000 per depositor at each financial institution. A substantial majority of the Company’s cash balances exceed federally insured limits.

Stock Based Compensation   ASC 718, Compensation – Stock Compensation, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).   The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, Equity – based Payments to Non-Employees. Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.   Pursuant to ASU No. 2016-09 – Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, the Company accounts for forfeitures when they occur.

Income Taxes   Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due and deferred taxes resulting from timing differences in recording of transactions for tax purposes and financial reporting purposes.   The deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are received or settled. Valuation allowances are established when necessary to reduce deferred tax assets to amounts expected to be realized.   The accounting provisions related to uncertain income tax positions require the Company to determine whether any tax position in all open years meets a more likely than not threshold of being sustained upon examination by the applicable taxing authority. The Company did not have any changes to its liability for uncertain tax positions as at September 30, 2017 and December 31, 2016.   The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. No such amounts are accrued as of September 30, 2017 and December 31, 2016.

Loss per Common Share   The Company utilizes FASB ASC Topic No. 260, Earnings per Share. Basic loss per share is computed by dividing loss available to common shareholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible debentures, options and warrants were to be exercised or converted or otherwise resulted in the issuance of common stock that then shared in the earnings of the entity.   Since the effects of outstanding options, warrants, and the conversion of convertible debt are anti-dilutive in during the three months ended September 30, 2016 and the nine months periods ended September 30, 2017 and 2016, shares of common stock underlying these instruments have been excluded from the computation of loss per common share.   The following sets forth the number of shares of common stock underlying outstanding options, warrants, and convertible debt as of September 30, 2017 and 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%">Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">10,390,820</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">10,451,740</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock options</td> <td> </td> <td> </td> <td style="text-align: right">8,397,216</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">12,656,067</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Convertible promissory notes</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">9,596,203</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,696,203</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">28,384,239</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">28,804,010</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

New Accounting Standards   The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its consolidated financial statements.   In August 2016, the FASB issued authoritative guidance under ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 is intended to reduce diversity in practice in how certain cash receipts and cash payments are presented and classified in the Consolidated Statement of Cash Flows by providing guidance on eight specific cash flow issues. ASU 2016-15 is effective retrospectively on January 1, 2018, with early adoption permitted. We have not yet determined the effect of the ASU on our Consolidated Financial Statements nor have we selected a transition date.   In January 2017, the FASB issued authoritative guidance under ASU 2017-01, Business Combinations – Clarifying the Definition of a Business, which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The standard introduces a screen for determining when assets acquired are not a business and clarifies that a business must include, at a minimum, an input and a substantive process that contribute to an output to be considered a business. This standard is effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. The Company does not expect this new guidance to have a material impact on its consolidated financial statements.

The following sets forth the number of shares of common stock underlying outstanding options, warrants, and convertible debt as of September 30, 2017 and 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%">Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">10,390,820</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">10,451,740</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock options</td> <td> </td> <td> </td> <td style="text-align: right">8,397,216</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">12,656,067</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Convertible promissory notes</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">9,596,203</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,696,203</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">28,384,239</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">28,804,010</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Property and equipment consist of the following at:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31,  2016</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; text-align: justify">Furniture and equipment</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">503</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">503</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; text-align: justify">Less accumulated depreciation</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(333</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(261</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: justify"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">170</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">242</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Accounts payable and accrued expenses consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31,  2016</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Interest expense</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">218,757</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">22,383</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Accounts payable</td> <td> </td> <td> </td> <td style="text-align: right">225,082</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">226,516</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Accrued bonus</td> <td> </td> <td> </td> <td style="text-align: right">256,500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Deferred Directors’ fees</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">39,725</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">11,250</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">740,064</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">260,149</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

0.02

11. Subsequent Events   The Company has evaluated subsequent events through November 10, 2017, the date which the consolidated financial statements were available to be issued. There were no additional subsequent events noted that would require adjustment to or disclosure in these consolidated financial statements.

9. Income Taxes   The Company’s effective tax rate is 0% for income tax for the nine months ended September 30, 2017 and the Company expects that its effective tax rate for the full year 2017 will be 0%. Based on the weight of available evidence, including cumulative losses since inception and expected future losses, the Company has determined that it is more likely than not that the deferred tax asset amount will not be realized and therefore a valuation allowance has been provided on net deferred tax assets.   The Company files tax returns for U.S. Federal and the states of New Jersey and California. The Company is not currently subject to any income tax examinations. Since the Company’s inception, the Company had incurred losses from operations, which generally allows all tax years to remain open.   Uncertain Tax Positions   The Company recognizes the financial statement effects of a tax position when it becomes more likely than not, based upon the technical merits, that the position will be sustained upon examination.   The Company recognizes interest and/or penalties related to uncertain tax positions. To the extent accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected in the period that such determination is made. The interest and penalties are recognized as other expense and not tax expense. The Company currently has no interest and penalties related to uncertain tax positions.

2412398

657159

230521

223990

P3Y

P7Y

7202291

6282248

6. Notes Payable   Convertible Notes Payable   The convertible promissory notes are considered hybrid instruments, which consist of a debt host instrument together with a conversion feature, thus giving the holder of a convertible note an option to convert into an equity instrument providing the holder a residual interest in the Company. The holder of a convertible promissory note also has the option to present its convertible promissory note to the Company and demand payment under the terms of the note after the maturity date or upon the occurrence of certain events such as the failure of the Company to make a payment on the note when due, bankruptcy or certain other liquidation events. The Company concluded that the convertible promissory notes would be accounted for as a typical debt instrument with related interest expense recorded in the Company’s statements of operations. The Company’s Third Convertible Secured Term Note and October 2016 and February 2017 Convertible Promissory Notes contain a conversion feature is determined to be “beneficial” and the fair value of the conversion feature is recorded as financing costs Company’s statements of operations.   First Secured Convertible Note and Warrant   On October 24, 2014, the Company issued a convertible promissory note in the amount of $5,000,000 to Hankey Capital, LLC (“Hankey Capital”). The Convertible Note matures on December 31, 2019 and bears interest at an annual rate of interest of the “prime rate” plus 4.0%, with a minimum rate of 8.5% per annum until maturity, with interest payable monthly in arrears. Prior to the Maturity Date, Hankey Capital has a right, in its sole discretion, to convert the Convertible Note into shares of the Company’s Common Stock, at a conversion rate of $1.58 per share.   The Convertible Note is secured by certain collateral shares of Common Stock issued by the Company in the name of Hankey Capital, in such amount so as to maintain a loan to value ratio of no greater than 50% (the “Collateral”). 6,329,114 shares were issued upon closing the lending. The number of shares in the Collateral shall be adjusted on a yearly basis. The shares representing the Collateral contain a restrictive legend. The Company shall seek to register the Collateral shares initially delivered on the date of the Convertible Note pursuant to the Registration Rights Agreement described below. Upon the effectiveness of such Registration Statement, the Company will remove the restrictive legends from the Collateral shares so long as Hankey Capital agrees in any event not to sell any Collateral shares if Hankey Capital is notified that the Registration Statement is no longer effective. Hankey Capital may hold the Collateral in any brokerage account of its choosing, but shall not transfer, sell or otherwise dispose of any Collateral, except during the existence of an Event of Default, as defined in the Convertible Note. The Convertible Note is further secured by collateral assignments of all the Company’s license agreements. The principal amount of the loan is pre-payable in whole or in part at any time, without premium or penalty. Upon any voluntary partial prepayment of outstanding principal, Hankey Capital will return Collateral shares to the Company in the amount necessary, if any, to maintain the loan to value ratio at no less than 50%. Upon a full payment of the outstanding principal, all Collateral shares shall be returned return and cancelled. Hankey Capital will also return Collateral shares under the same terms in case of partial or full conversion of the Convertible Note. The Company paid a commitment fee in the amount of 3.0% of the original principal amount of the loan ($150,000) to Hankey Capital. On October 24, 2014, the Company also issued a warrant to Hankey Capital for 3,955,697 shares of Common Stock at an exercise price per share of $1.58. The Warrant was amended as of February 10, 2016 to extend the expiration date to October 24, 2019. The Note and Warrant contain provisions limiting the exercise/conversion thereof.   Second Secured Convertible Note and Warrant   On May 4, 2015, the Company issued a convertible promissory note in the amount of $2,000,000 to Hankey Capital. The Second Convertible Note matures on December 31, 2019 and bears interest at an annual rate of interest of the “prime rate” plus 4.0%, with a minimum rate of 8.5% per annum until maturity, with interest payable monthly in arrears. Prior to the Maturity Date, Hankey Capital has a right, in its sole discretion, to convert the Convertible Note into shares of the Company’s Common Stock, at a conversion rate of $1.58 per share. The Convertible Note is secured by certain collateral shares of Common Stock issued by the Company in the name of Hankey Capital, in such amount so as to maintain a loan to value ratio of no greater than 50%. The number of shares in the Collateral shall be adjusted on a yearly basis. The Convertible Note is further secured by collateral assignments of all the Company’s license agreements. The principal amount of the loan is pre-payable in whole or in part at any time, without premium or penalty. Upon any voluntary partial prepayment of outstanding principal, Hankey Capital shall return Collateral shares to the Company in the amount necessary, if any, to maintain the loan to value ratio at no less than 50%. Upon a full payment of the outstanding principal, all the collateral shares shall be returned return and cancelled. Hankey Capital shall also return the collateral shares under the same terms in case of partial or full conversion of the Convertible Note. In connection with the Convertible Note, on May 4, 2015 the Company issued 2,531,646 common shares as collateral. The Company paid a commitment fee in the amount of $60,000 (3% of the original principal amount of the loan) to Hankey Capital. On May 4, 2015, the Company also issued a warrant to Hankey Capital for 1,898,734 shares of Common Stock at an exercise price per share of $1.58. The Warrant was amended as of February 10, 2016 to extend the expiration date to May 4, 2020. The Note and Warrant contain provisions limiting the exercise/conversion thereof.   Third Convertible Secured Term Note and Warrant   On February 24, 2016, the Company issued a convertible promissory note in the amount of $2,000,000 to Hankey Capital. The Third Convertible Note matures on February 23, 2019 (the “Maturity Date”) and bears interest at an annual rate of interest at the “prime rate” (as quoted in the “Money Rates” section of The Wall Street Journal) plus 4.0%, with a minimum rate of 8.5% per annum until maturity, with interest payable monthly in arrears. Prior to the Maturity Date, Hankey Capital has a right, in its sole discretion, to convert the Convertible Note into shares of the Company’s common stock (the “Conversion Shares”), at a conversion rate equal to $1.58 per share. The Convertible Note is secured by certain collateral shares of Common Stock issued by the Company in the name of Hankey Capital, in such amount so as to maintain a loan to value ratio of no greater than 50%. The number of Collateral Shares will be adjusted on a yearly basis. The Convertible Note is further secured by all of the Company’s personal property, including collateral assignments of all the Company’s license agreements and the Option Agreement. The principal amount of the loan is prepayable in whole or in part at any time, without premium or penalty. Upon any voluntary partial prepayment of outstanding principal, Hankey Capital will return Collateral Shares to the Company in the amount necessary, if any, to maintain the loan to value ratio at no less than 50%. Upon a full payment of the outstanding principal, all Collateral Shares will be returned and cancelled. Hankey Capital will also return Collateral Shares under the same terms in case of partial or full conversion of the Convertible Note. In connection with the Convertible Note, on February 24, 2016 the Company issued 2,531,646 common shares as collateral, paid a commitment fee in the amount of $40,000 (2% of the original principal amount of the Loan) and a warrant to Hankey Capital for 1,463,415 shares of Common Stock at an exercise price per share of $2.05. The Warrant will expire on February 23, 2021. The Note and Warrant contain provisions limiting the exercise/conversion thereof.   In connection with the financing with Hankey Capital, Hankey Capital exercised warrants to purchase an aggregate of 791,139 shares resulting in gross proceeds to the Company of $1,250,000, and the parties agreed to extend the maturity date of the first two convertible secured notes to December 31, 2019 and fix the conversion rate to $1.58. The Company also agreed to extend the term of all outstanding warrants to five years from issuance.   Convertible Promissory Notes   On October 14, 2016, pursuant to a Note Purchase Agreement, the Company issued to each of MTF and Hankey Capital a convertible promissory note in the amount of $600,000 (each a “Convertible Note”). The Convertible Note matures on December 31, 2017 (the “Maturity Date”) and bears interest at an annual rate of interest of 8.5% per annum until maturity. Prior to the Maturity Date, each of MTF and Hankey Capital has a right, in its sole discretion, to convert their Convertible Note into shares of the Company’s common stock (the “Conversion Shares”), at a conversion rate equal to $1.00 per share. In the event of a financing resulting in gross proceeds of at least $5,000,000, the holders of the Convertible Notes will be required to convert their Convertible Notes into the same securities issued in such financing at the same price per share. In addition, if the Convertible Notes are not paid by the Maturity Date, they will be automatically converted in shares of Common Stock at a conversion price of $1.00 per share. Hankey Capital’s Convertible Note is secured by all of the Company’s assets. The Company has granted piggyback registration rights with respect to the Conversion Shares.   Pursuant to the October 2016 and February 2017 Note Purchase Agreements, the Company may only use the proceeds from the issuance of those convertible notes to focus on prioritizing operations on essential research and development activities. Also pursuant to the October 2016 Note Purchase Agreement, the Company’s management has agreed to defer 20% of earned compensation and the Board of Directors has authorized a change in director compensation to defer 50% of the directors’ cash compensation until at least $5,000,000 has been received in cumulative funding from non-current stockholders.   On January 23, 2017 the Company, MTF and Hankey Capital, executed an amendment (the “Amendment”) to the Convertible Notes. The Amendment extends the maturity date of each of the Convertible Notes to December 31, 2017 from December 31, 2016. By extending the maturity date, the date that the Convertible Notes automatically convert into shares of the Company’s Common Stock was also extended to December 31, 2017. The Amendment was effective retroactive to December 31, 2016.   On February 10, 2017 pursuant to a Note Purchase Agreement, the Company issued to each of MTF and Hankey Capital a convertible promissory note in the amount of $1,000,000 (each a “Convertible Note”). The Convertible Note matures on December 31, 2017 (the “Maturity Date”) and bears interest at an annual rate of interest of 8.5% until maturity. Prior to the Maturity Date, each of MTF and Hankey Capital has a right, in its sole discretion, to convert their Convertible Note into shares of the Company’s common stock (the “Conversion Shares”), at a conversion rate equal to $1.00 per share. In the event of a financing resulting in gross proceeds of at least $5,000,000, the holders of the Convertible Notes will be required to convert their Convertible Notes into the same securities issued in such financing at the same price per share. Also, if the Convertible Notes are not paid by the Maturity Date, they will be automatically converted in shares of Common Stock at a conversion price of $1.00 per share. Hankey Capital’s Convertible Note is secured by all of the Company’s assets. The Company has granted piggyback registration rights with respect to the Conversion Shares.   On August 18, 2017 pursuant to a Note Purchase Agreement, the Company issued to Hankey Capital a convertible promissory note in the amount of $700,000 (“Convertible Note”). The Convertible Note matures on December 31, 2017 (the “Maturity Date”) and bears interest at an annual rate of interest of 8.5% until maturity. Prior to the Maturity Date, Hankey Capital has a right, in its sole discretion, to convert their Convertible Note into shares of the Company’s common stock (the “Conversion Shares”), at a conversion rate equal to $1.00 per share. In the event of a financing resulting in gross proceeds of at least $5,000,000, the holders of the Convertible Note will be required to convert their Convertible Note into the same securities issued in such financing at the same price per share. Also, if the Convertible Note is not paid by the Maturity Date, it will be automatically converted in shares of Common Stock at a conversion price of $1.00 per share. Hankey Capital’s Convertible Note is secured by all of the Company’s assets. The Company has granted piggyback registration rights with respect to the Conversion Shares.   The total debt discount costs related to our outstanding debt for the nine months ended September 30, 2017 and 2016, was $2,412,398 and $657,159, respectively was amortized to interest expense. The unamortized debt discount at September 30, 2017 was $2,655,310. The cost is expected to be recognized over a period of 1.27 years. The unamortized debt discount at December 31, 2016 was $2,367,708.   The total debt issuance costs related to our outstanding debt for the nine months ended September 30, 2017 and 2016, was $230,521 and $223,990, respectively was amortized to interest expense. The unamortized debt issuance costs at September 30, 2017 was $154,523. The cost is expected to be recognized over a period of 1.27 years. The unamortized debt issuance costs at December 31, 2016 was $350,044.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Note Type</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Issue Date</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Maturity Date</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Interest Rate</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31,  2016</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 37%">First Secured Convertible Note</td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: center">10/24/14</td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: center">12/31/19</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">8.5</td> <td style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">5,000,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">5,000,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Second Secured Convertible Note</td> <td> </td> <td style="text-align: center">5/4/15</td> <td> </td> <td style="text-align: center">12/31/19</td> <td> </td> <td> </td> <td style="text-align: right">8.5</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">2,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,000,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Third Secured Convertible Note</td> <td> </td> <td style="text-align: center">2/24/16</td> <td> </td> <td style="text-align: center">2/23/19</td> <td> </td> <td> </td> <td style="text-align: right">8.5</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">2,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,000,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Convertible Promissory Notes</td> <td> </td> <td style="text-align: center">10/14/16</td> <td> </td> <td style="text-align: center">12/31/17</td> <td> </td> <td> </td> <td style="text-align: right">8.5</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Convertible Promissory Notes</td> <td> </td> <td style="text-align: center">2/10/17</td> <td> </td> <td style="text-align: center">12/31/17</td> <td> </td> <td> </td> <td style="text-align: right">8.5</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">2,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Convertible Promissory Notes</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center">8/18/17</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center">12/31/17</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right">8.5</td> <td style="padding-bottom: 1.5pt">%</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">700,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">12,900,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,200,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Current notes payable, net</td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,887,876</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Less: Debt discount</td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,655,310</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,367,708</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Less: Debt issuance costs</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">154,523</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">350,044</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Net Notes payable</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">7,202,291</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6,282,248</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Prepaid expenses – related party   Prepaid expenses – related party represent the fair value of warrants issued to AFH Holding & Advisory, LLC (“AFH”), a shareholder, for services pursuant to certain letter agreement dated May 4, 2014. Prepaid costs will be amortized as the required services are performed. As of September 30, 2017 and December 31, 2016 prepaid expenses – related party totaled $271,945.

Debt Issuance Costs   Debt issuance costs represent costs incurred in connection with the issuance of the convertible notes payable and private equity financing. Debt issuance costs related to the issuance of debt are being amortized over the term of the financing instrument using the effective interest method, while debt issuance costs from equity financings are netted against the gross proceeds received from the equity financings.

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Note Type</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Issue Date</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Maturity Date</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Interest Rate</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31,  2016</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 36%">First Secured Convertible Note</td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: center">10/24/14</td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: center">12/31/19</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">8.5</td> <td style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">5,000,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">5,000,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Second Secured Convertible Note</td> <td> </td> <td style="text-align: center">5/4/15</td> <td> </td> <td style="text-align: center">12/31/19</td> <td> </td> <td> </td> <td style="text-align: right">8.5</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">2,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,000,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Third Secured Convertible Note</td> <td> </td> <td style="text-align: center">2/24/16</td> <td> </td> <td style="text-align: center">2/23/19</td> <td> </td> <td> </td> <td style="text-align: right">8.5</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">2,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,000,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Convertible Promissory Notes</td> <td> </td> <td style="text-align: center">10/14/16</td> <td> </td> <td style="text-align: center">12/31/17</td> <td> </td> <td> </td> <td style="text-align: right">8.5</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Convertible Promissory Notes</td> <td> </td> <td style="text-align: center">2/10/17</td> <td> </td> <td style="text-align: center">12/31/17</td> <td> </td> <td> </td> <td style="text-align: right">8.5</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">2,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Convertible Promissory Notes</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center">8/18/17</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center">12/31/17</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right">8.5</td> <td style="padding-bottom: 1.5pt">%</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">700,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">12,900,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,200,000</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Current notes payable, net</td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,887,876</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,200,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Less: Debt discount</td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,655,310</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,367,708</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Less: Debt issuance costs</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">154,523</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">350,044</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Net Notes payable</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">7,202,291</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6,282,248</td></tr> </table>

0.20 0.50

5000000

BBLG

218757

22383

2887876

1200000

Use of Estimates   The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant estimates include warrants and income tax valuation allowances. Actual results could differ from those estimates.

2017

1. The Company   Bone Biologics Corporation (the “Company”) was incorporated under the laws of the State of Delaware on October 18, 2007 as AFH Acquisition X, Inc. Pursuant to a Merger Agreement, dated September 19, 2014, by and among the Company, its wholly-owned subsidiary, Bone Biologics Acquisition Corp., a Delaware corporation (“Merger Sub”), and Bone Biologics, Inc. Merger Sub merged with and into Bone Biologics Inc., with Bone Biologics Inc. remaining as the surviving corporation in the merger. Upon the consummation of the merger, the separate existence of Merger Sub ceased. On September 22, 2014, the Company officially changed its name to “Bone Biologics Corporation” to more accurately reflect the nature of its business and Bone Biologics, Inc. became a wholly owned subsidiary of the Company. Bone Biologics, Inc. was incorporated in California on June 9, 2004. In connection with the merger, the 5,000,000 outstanding shares of common stock of the Company, par value $0.001 per share (“Common Stock”), prior to the merger were consolidated into 3,853,600 shares of Common Stock and the remaining shares were cancelled.   Additionally, all of the issued and outstanding shares of Bone Biologics Inc.’s $0.0001 par value common stock converted into a combined 19,897,587 shares of the Company’s Common Stock (including 2,151,926 shares issuable upon the exercise of outstanding warrants and 5,648,658 shares issuable upon the conversion of debt).   We are a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX®. The NELL-1/DBX® combination product is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The protein, as part of the UCB-1 technology platform has been licensed exclusively for worldwide applications to us through a technology transfer from UCLA Technology Development Group on behalf of UC Regents (“UCLA TDG”). UCLA TDG and the Company received guidance from the FDA that NELL-1/DBX® will be classified as a combination product with a device lead.   We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, which we refer to as the JOBS Act. We would cease to be an emerging growth company upon the earliest of: (i) the last day of the first fiscal year in which our annual gross revenues are $1.07 billion or more; (ii) the end of any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700.0 million as of the end of the second quarter of that fiscal year; or (iii) the date on which we have, during the previous three-year period, issued more than $1.07 billion in non-convertible debt securities. An emerging growth company may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. We have elected to take advantage of these reduced disclosure obligations, and may elect to take advantage of other reduced reporting obligations in the future.   The JOBS Act permits an emerging growth company like us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We are choosing to irrevocably “opt out” of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted.   The Company is a development stage entity. The production and marketing of the Company’s products and its ongoing research and development activities will be subject to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any combination product developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive regulatory approval process implemented by the FDA under the Food, Drug and Cosmetic Act. There can be no assurance that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay or suspend clinical trials.   The Company’s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and operate without infringing on the proprietary rights of others, both in the United States and other countries. There can be no assurance that patents issued to or licensed by the Company will not be challenged, invalidated, or circumvented, or that the rights granted thereunder will provide proprietary protection or competitive advantages to the Company.   Going Concern and Liquidity   The Company has no significant operating history and since inception to September 30, 2017 has generated a net loss of approximately $52 million. The Company will continue to incur significant expenses for development activities for their lead product NELL-1. Operating expenditures for the next twelve months are estimated at $6.5 million. The accompanying consolidated financial statements for the nine months ended September 30, 2017 have been prepared assuming the Company will continue as a going concern. The Company intends to raise additional debt and/or equity financing to fund future operations and to provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company’s needs. If cash resources are insufficient to satisfy the Company’s on-going cash requirements, the Company will be required to scale back or discontinue its product development programs, or obtain funds if available (although there can be no certainties) through strategic alliances that may require the Company to relinquish rights to its technology, substantially reduce or discontinue its operations entirely.   Pursuant to the October 2016 and February 2017 Note Purchase Agreements (Note 6), the Company may only use the proceeds from the issuance of the convertible notes to focus on prioritizing operations on essential research and development activities. Also pursuant to the October 2016 Note Purchase Agreement, the Company’s management has agreed to defer 20% of earned compensation and the Board of Directors has authorized a change in director compensation to defer 50% of the directors’ cash compensation until at least $5,000,000 has been received in cumulative funding from non-current stockholders.   The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

0001419554

46406

80523

271945 271945

1940330

972843

170

242

1940500

973085

740064

260149

191667

41667

1823077 1823077

5642684

3324893

12844975

9607141

39062

38829

40737523

38271173

-51681060

-46944058

1940500

973085

1797709

2717752

1070000000

-1654074

9470369

248377

2473433

3629041

1315986

14706105

1130776

3857415

-1315986

-14706105

-1130776

-3857415

3419417

1436643

1396643

513846

-3419417

-1441505

-1396643

-513846

-4735403

-16147610

-2527419

-4371261

1600

2745

1010

4862

660

39093

230521

223990

-2338812 4512033 1889

-4862

-34117

-27119

479915

148808

150000

-2398396

-6059987

1250000

700000

2500000

2700000

1883111

3400000

5633111

1001604

-426876

1621979

620375

1115109

688233

1600

2745

Basis of Presentation   The accompanying condensed consolidated financial statements and related notes included activities of the Company and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

39725

11250

5000000

2000000

600000

1000000

700000

2019-12-31

2019-02-23

2017-12-31

2019-12-31

2019-02-23

2017-12-31

0.040

0.085

1.58

1.00

1.58

1.00

0.50

6329114

2531646

0.030

0.03

0.02

-150000

60000

40000

1.58

2.05

1.59

2.05

2019-10-24 2020-05-04 2021-02-23 2019-12-31 1250000 5000000 5000000 5000000

0.20

0.50

5000000

On January 23, 2017 the Company, MTF and Hankey Capital, executed an amendment (the “Amendment”) to the Convertible Notes. The Amendment extends the maturity date of each of the Convertible Notes to December 31, 2017 from December 31, 2016. By extending the maturity date, the date that the Convertible Notes automatically convert into shares of the Company’s Common Stock was also extended to December 31, 2017. The Amendment was effective retroactive to December 31, 2016.On January 23, 2017 the Company, MTF and Hankey Capital, executed an amendment (the “Amendment”) to the Convertible Notes. The Amendment extends the maturity date of each of the Convertible Notes to December 31, 2017 from December 31, 2016. By extending the maturity date, the date that the Convertible Notes automatically convert into shares of the Company’s Common Stock was also extended to December 31, 2017. The Amendment was effective retroactive to December 31, 2016.

2655310

2367708

P1Y3M8D P1Y3M8D

2014-10-24

2015-05-04

2016-02-24

2016-10-14

2017-02-10

2017-08-18

12900000

10200000

5000000

2000000

1200000

2000000

700000

154523

350044

11392406 791139 0.44 0.44 1.00 1.50 1.00 1.00 0.00 1.62 1.00 1.00 1.00 1.58 1.50 1.00 1.00 1.00 1.58 1.58 1.58 2.05

8397216

118383

254997

50000

10390820

166667

500000

46667

12625

625000

699671

89588

126582

3164558

25000

50000

75000

699037

1898734

158229

1463415

2019-03-16 2020-02-04 2020-04-28 2018-09-30 2018-09-30 2018-07-02 2018-07-10 2021-08-31 2021-09-18 2021-09-29 2017-10-23 2019-10-23 2018-05-30 2020-09-20 2020-09-04 2020-11-14 2018-02-14 2020-05-04 2018-10-27 2021-02-23 P2Y5M12D

39077322

100930

35000

1435000

1012124

256500

700000000 1070000000

14000000

0.05

4125306

20085

3650419 0

80341

6361841

647091

P0Y7M10D

8397216

12656067

6294226

-4270639

68553

15382

1.64

1.62

1.59

2.05

1.66

1.60

2.05

P9Y2M16D

P10Y

P10Y P9Y11M12D P8Y6M14D P0Y P7Y9M18D P9Y2M16D

1.59

2.05

8397216

583059

174918

3121787

200000

1224640

802716

1275786

54000

807434

99315

53561

2025-12-27

2026-01-09

2021-02-24

2026-05-26

2026-05-31

2027-01-01

0.0199

0.02306

P5Y6M

P9Y

1.3594

1.5379

0.00

2821694

9605060

5156710

-2718316

-1913491

-4145391

5575522

1.49

1.74

1.29

1.87

1.93

1.69

1.31

1.95

1.44 1.46

0.00

0.10 0.04

8000000

10000000

1260255 33105

100000

33333

20186

23173

100930

325000

600000

1000000

0.25 0.25 0.25 0.125 0.125

200000

516375

555805

-0.12

-0.43

-0.06

-0.11

38868692

37228340

38888082

38828607

233333

3.00

P8Y2M30D P0Y

8. Stock-based Compensation   2015 Equity Incentive Plan   The Company has 14,000,000 shares of Common Stock authorized and reserved for issuance under our 2015 Equity Incentive Plan for option awards. This reserve may be increased by the Board each year by up to the number of shares of stock equal to 5% of the number of shares of stock issued and outstanding on the immediately preceding December 31. Appropriate adjustments will be made in the number of authorized shares and other numerical limits in our 2015 Equity Incentive Plan and in outstanding awards to prevent dilution or enlargement of participants’ rights in the event of a stock split or other change in our capital structure. Shares subject to awards granted under our 2015 Equity Incentive Plan which expire, are repurchased or are cancelled or forfeited will again become available for issuance under our 2015 Equity Incentive Plan. The shares available will not be reduced by awards settled in cash. Shares withheld to satisfy tax withholding obligations will not again become available for grant. The gross number of shares issued upon the exercise of stock appreciation rights or options exercised by means of a net exercise or by tender of previously owned shares will be deducted from the shares available under our 2015 Equity Incentive Plan.   Awards may be granted under our 2015 Equity Incentive Plan to our employees, including officers, director or consultants, and our present or future affiliated entities. While we may grant incentive stock options only to employees, we may grant non-statutory stock options, stock appreciation rights, restricted stock purchase rights or bonuses, restricted stock units, performance shares, performance units and cash-based awards or other stock based awards to any eligible participant.   The 2015 Equity Incentive Plan will be administered by our compensation committee. Subject to the provisions of our 2015 Equity Incentive Plan, the compensation committee determines, in its discretion, the persons to whom, and the times at which, awards are granted, as well as the size, terms and conditions of each award. All awards are evidenced by a written agreement between us and the holder of the award. The compensation committee has the authority to construe and interpret the terms of our 2015 Equity Incentive Plan and awards granted under our 2015 Equity Incentive Plan.   During the nine months ended September 30, 2017 and 2016, the Company had stock-based compensation expenses of $1,405,396 and $2,938,825, respectively, related to issuances to the Company’s employees and directors, included in our reported net loss. During the nine months ended September 30, 2017 and 2016, the Company had stock-based compensation expenses of $(2,338,812) and $4,512,033, respectively, related to issuances to consultants.   A summary of stock option activity for the nine months ended September 30, 2017, is presented below:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Number</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">of Shares</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Weighted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Remaining</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Exercise</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Average</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Aggregate</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">Subject to Exercise</td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Life (Years)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Value</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 36%; line-height: 107%">Outstanding as of January 1, 2016</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">6,294,226</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">1.59</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">10.00</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted – 2016</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">6,361,841</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1.66</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">9.95</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Forfeited – 2016</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercised – 2016</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding as of January 1, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">12,656,067</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.62</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">9.21</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted – 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">80,341</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2.05</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">10.00</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Forfeited – 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(4,270,639</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1.60</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">8.54</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercised – 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(68,553</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">2.05</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">8.25</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding as of September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">8,397,216</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1.64</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">7.80</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> Date Issued</td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Exercise Price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Number of Shares</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Expiration date</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 45%; line-height: 107%">September 2014</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">1.59</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 15%; text-align: right; line-height: 107%">583,059</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 20%; text-align: right; line-height: 107%">December 27, 2025</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">November 2014</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.59</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">174,918</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">December 27, 2025</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">August 2015</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.59</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3,121,787</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">December 27, 2025</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">September 2015</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.59</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">200,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">December 27, 2025</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">November 2015</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.59</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,224,640</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">December 27, 2025</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">December 2015</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.59</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">802,716</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">December 27, 2025</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">January 2016</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.59</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,275,786</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">January 9, 2026</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">March 2016</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">2.05</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">54,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">February 24, 2021</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">May 2016</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">2.05</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">807,434</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">May 26, 2026</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">June 2016</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">2.05</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">99,315</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">May 31, 2026</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">January 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">2.05</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">53,561</td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">January 1, 2027</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total options at September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">8,397,216</td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td></tr> </table>   The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (i.e., the difference between our closing stock price on the respective date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised their options. There were 68,553 and -0- options exercised during either the nine months ended September 30, 2017 and 2016. There were 4,125,306 options cancelled in conjunction with the termination of the Founders Professional Services Agreement (Note 10). There were 20,085 options forfeited upon the resignation of one of our directors. Our policy is to account for forfeitures when they occur; therefore these forfeitures are recorded as a reversal to expense. Forfeiture reversals for the nine months ended September 30, 2017 and 2016 were $3,650,419 and $-0-, respectively.   There were 80,341 and 6,361,841 options issued during the nine months ended September 30, 2017 and 2016, respectively. Vesting of options differs based on the terms of each option. The Company has valued the options at their date of grant utilizing the Black-Scholes option pricing model. As of the issuance of these consolidated financial statements, there was not an active public market for the Company’s shares. Accordingly, the fair value of the underlying options was determined based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified method. The expected life of the options used was based on the contractual life of the option granted. Stock-based compensation is a non-cash expense because we settle these obligations by issuing shares of our common stock from our authorized shares instead of settling such obligations with cash payments.   The Company utilized the Black-Scholes option pricing model. The assumptions used for the nine months ended September 30, 2017 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Risk free interest rate</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1.99%-2.306</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected life (in years)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">5.5-9.0</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected Volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">135.94%-153.79 </td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 81%; line-height: 107%">Expected dividend yield</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 16%; text-align: right; line-height: 107%">0</td> <td style="width: 1%; line-height: 107%">%</td></tr> </table>   A summary of the changes in the Company’s non-vested options during the three months ended September 30, 2017, is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Number of Non-vested Options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted Average Fair Value at Grant Date</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Intrinsic Value</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%; line-height: 107%">Non-vested at January 1, 2016</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">5,156,710</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">1.29</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted in 2016</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">6,361,841</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.93</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Vested in year ended December 31, 2016</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(1,913,491</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1.31</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Non-vested at January 1, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">9,605,060</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.74</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Granted in 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">80,341</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.87</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Forfeited – 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(4,145,391</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.95</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Vested in 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(2,718,316</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1.69</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Non-vested at September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,821,694</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.49</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Exercisable at September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">5,575,522</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1.44</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Outstanding at September 30, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">8,397,216</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.46</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>   As of September 30, 2017, total unrecognized compensation cost related to unvested stock options was $647,091. The cost is expected to be recognized over a weighted average period of 0.61 years.

EX-101.SCH 7 bblg-20170930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - The Company link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Accounts Payable and Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - The Company (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Stockholders' Equity - Schedule of Outstanding Unexercised Common Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Stock-based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Stock-based Compensation - Schedule of Stock Option (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Stock-based Compensation - Schedule of Assumptions Using Black-Scholes Option Pricing Model (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Stock-based Compensation - Schedule of Non-Vested Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 bblg-20170930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 bblg-20170930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 bblg-20170930_lab.xml XBRL LABEL FILE Legal Entity [Axis] Bone Biologics Inc [Member] Antidilutive Securities [Axis] Stock Options [Member] Convertible Promissory Notes [Member] Warrants [Member] Type of Arrangement and Non-arrangement Transactions [Axis] License Agreement [Member] Statement Geographical [Axis] UCLA TDG [Member] Award Date [Axis] 2009 [Member] Equity Components [Axis] Unexercised Common Stock Warrants [Member] 2010 [Member] April 2013 [Member] Short-term Debt, Type [Axis] First Secured Convertible Note and Warrant [Member] Related Party [Axis] Hankey Capital, LLC [Member] Related Party Transaction [Axis] Depositor [Member] July 2014 (1) [Member] July 2014 (2) [Member] July 2014 (3) [Member] July 2014 (4) [Member] July 2014 (5) [Member] September 2014 (1) [Member] September 2014 (2) [Member] September 2014 (3) [Member] October 2014 [Member] October 2014 (1) [Member] September 2013 (1) [Member] September 2013 [Member] November 2013 [Member] September 2014 [Member] November 2014 [Member] February 2015 [Member] Variable Rate [Axis] Prime Rate [Member] Debt Instrument [Axis] Second Secured Convertible Note And Warrant [Member] Second Warrant [Member] May 2015 [Member] Award Type [Axis] Issuance of Stock Options [Member] August 2015 [Member] September 2015 [Member] Range [Axis] Maximum [Member] Scenario [Axis] First Commercial Sale [Member] After First Commercial Sale [Member] Minimum [Member] Other Commitments [Axis] First Subject In Feasibility Study [Member] First Subject In Pivotal Study [Member] Pre-Market Approval Of Licensed Product Or Licensed Method [Member] First Commercial Sale Of Licensed Product Or Licensed Method [Member] October 2015 [Member] 2015 Equity Incentive Plan [Member] November 2015 [Member] December 2015 [Member] Employees and Directors [Member] Third Convertible Secured Term Note and Warrant [Member] Third Warrant [Member] February 2016 [Member] January 2016 [Member] March 2016 [Member] AFH [Member] PIPE [Member] MTF [Member] First Anniversary [Member] Second Anniversary [Member] Third Anniversary [Member] Fourth Anniversary [Member] Fifth Anniversary [Member] First Two Convertible Secured Notes [Member] May 2016 [Member] June 2016 [Member] Transaction Type [Axis] October 28, 2015 Invoice [Member] Letter Agreement February 10, 2016 [Member] Title of Individual [Axis] Founder [Member] 10 Year Stock Options [Member] October 2016 and February 2017 Note Purchase Agreement [Member] Directors [Member] MTF and Hankey Capital, LLC [Member] Note Purchase Agreement [Member] Directors [Member] Noncurrent Stockholders[Member] First Secured Convertible Note [Member] Second Secured Convertible Note [Member] Third Secured Convertible Note [Member] Convertible Promissory Notes One [Member] January 2017 [Member] Non-affiliates [Member] Founders Professional Services Agreement [Member] Convertible Promissory Notes Two [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current assets Cash Prepaid expenses Prepaid expenses – Related Party Total current assets Property and equipment, net Total assets Liabilities and Stockholders’ Deficit Current liabilities Accounts payable and accrued expenses Current notes payable, net of debt discount of $1,012,124 and $-0-, respectively Deferred compensation Shares to be issued Total current liabilities Note payable, net of debt discount of $1,797,709 and $2,717,752, respectively Total liabilities Commitments and Contingencies Stockholders’ deficit Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at September 30, 2017 and December 31, 2016 Common stock, $0.001 par value per share; 100,000,000 shares authorized; 39,077,322 and 38,828,607 shares issued and outstanding at September 30, 2017 and December 31, 2016 Additional paid-in capital Accumulated deficit Total stockholders’ deficit Total liabilities and stockholders’ deficit Debt discount on note payable, current Debt discount on note payable, noncurrent Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Cost of revenues Gross profit Operating expenses Research and development General and administrative Total operating expenses Loss from operations Other expenses Other expense Interest expense, net Total other expenses Loss before provision for income taxes Provision for income taxes Net Loss Weighted average shares outstanding – basic and diluted Net Loss per share – basic and diluted Statement of Cash Flows [Abstract] Operating activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Amortization of prepaid expenses – related party Debt discount amortization Debt issuance costs amortization Stock-based compensation Options issued to consultants Warrants issued to consultants Interest expense deducted from loan proceeds Loss on disposal of assets Shares issued for Sygnal license Changes in operating assets and liabilities: Prepaid expenses and other current assets Accounts payable and accrued expenses Deferred issuance costs Deferred compensation Net cash used in operating activities Financing activities Proceeds from exercise of warrants Proceeds from issuance of common stock Proceeds from issuance of notes payable Net cash provided by financing activities EX-101.PRE 11 bblg-20170930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Nov. 10, 2017
Document And Entity Information
Entity Registrant Name	Bone Biologics Corp
Entity Central Index Key	0001419554
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		39,077,322
Trading Symbol	BBLG
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2017

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets
Cash	$ 1,621,979	$ 620,375
Prepaid expenses	46,406	80,523
Prepaid expenses – Related Party	271,945	271,945
Total current assets	1,940,330	972,843
Property and equipment, net	170	242
Total assets	1,940,500	973,085
Current liabilities
Accounts payable and accrued expenses	740,064	260,149
Current notes payable, net of debt discount of $1,012,124 and $-0-, respectively	2,887,876	1,200,000
Deferred compensation	191,667	41,667
Shares to be issued	1,823,077	1,823,077
Total current liabilities	5,642,684	3,324,893
Note payable, net of debt discount of $1,797,709 and $2,717,752, respectively	7,202,291	6,282,248
Total liabilities	12,844,975	9,607,141
Commitments and Contingencies
Stockholders’ deficit
Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at September 30, 2017 and December 31, 2016
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 39,077,322 and 38,828,607 shares issued and outstanding at September 30, 2017 and December 31, 2016	39,062	38,829
Additional paid-in capital	40,737,523	38,271,173
Accumulated deficit	(51,681,060)	(46,944,058)
Total stockholders’ deficit	(10,904,475)	(8,634,056)
Total liabilities and stockholders’ deficit	$ 1,940,500	$ 973,085

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Debt discount on note payable, current	$ 1,012,124	$ 0
Debt discount on note payable, noncurrent	$ 1,797,709	$ 2,717,752
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	39,077,322	38,828,607
Common stock, shares outstanding	39,077,322	38,828,607

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Revenues
Cost of revenues
Gross profit
Operating expenses
Research and development	248,377	2,473,433	(1,654,074)	9,470,369
General and administrative	882,399	1,383,982	2,970,060	5,235,736
Total operating expenses	1,130,776	3,857,415	1,315,986	14,706,105
Loss from operations	(1,130,776)	(3,857,415)	(1,315,986)	(14,706,105)
Other expenses
Other expense				(4,862)
Interest expense, net	(1,396,643)	(513,846)	(3,419,417)	(1,436,643)
Total other expenses	(1,396,643)	(513,846)	(3,419,417)	(1,441,505)
Loss before provision for income taxes	(2,527,419)	(4,371,261)	(4,735,403)	(16,147,610)
Provision for income taxes		1,010	1,600	2,745
Net Loss	$ (2,527,419)	$ (4,372,271)	$ (4,737,003)	$ (16,150,355)
Weighted average shares outstanding – basic and diluted	38,888,082	38,828,607	38,868,692	37,228,340
Net Loss per share – basic and diluted	$ (0.06)	$ (0.11)	$ (0.12)	$ (0.43)

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Operating activities
Net loss	$ (4,737,003)	$ (16,150,355)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	72	660
Amortization of prepaid expenses – related party		39,093
Debt discount amortization	2,412,398	657,159
Debt issuance costs amortization	230,521	223,990
Stock-based compensation	1,405,396	2,938,825
Options issued to consultants	(2,338,812)	4,512,033
Warrants issued to consultants		100,930
Interest expense deducted from loan proceeds		1,889
Loss on disposal of assets		4,862
Shares issued for Sygnal license		1,435,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	34,117	27,119
Accounts payable and accrued expenses	479,915	148,808
Deferred issuance costs	(35,000)
Deferred compensation	150,000
Net cash used in operating activities	(2,398,396)	(6,059,987)
Financing activities
Proceeds from exercise of warrants		1,250,000
Proceeds from issuance of common stock	700,000	2,500,000
Proceeds from issuance of notes payable	2,700,000	1,883,111
Net cash provided by financing activities	3,400,000	5,633,111
Net increase (decrease) in cash	1,001,604	(426,876)
Cash, beginning of period	620,375	1,115,109
Cash, end of period	1,621,979	688,233
Supplemental non-cash information
Interest paid	516,375	555,805
Taxes paid	$ 1,600	$ 2,745

XML 17 R6.htm IDEA: XBRL DOCUMENT

The Company

9 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The Company

1. The Company

Going Concern and Liquidity

XML 18 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

Use of Estimates

Fair Value of Financial Instruments

Level 1: Quoted prices in active markets for identical assets or liabilities.

Property and Equipment

Impairment of Long-Lived Assets

Research and Development Costs

Patents and Licenses

Prepaid expenses – related party

Concentration of Credit Risk and Other Risks and Uncertainties

Debt Issuance Costs

Stock Based Compensation

Pursuant to ASU No. 2016-09 – Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, the Company accounts for forfeitures when they occur.

Income Taxes

The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. No such amounts are accrued as of September 30, 2017 and December 31, 2016.

Loss per Common Share

The following sets forth the number of shares of common stock underlying outstanding options, warrants, and convertible debt as of September 30, 2017 and 2016:

	September 30,
		2017	2016
Warrants		10,390,820	10,451,740
Stock options		8,397,216	12,656,067
Convertible promissory notes		9,596,203	5,696,203
		28,384,239	28,804,010

New Accounting Standards

XML 19 R8.htm IDEA: XBRL DOCUMENT

Property and Equipment

9 Months Ended

Sep. 30, 2017

Property, Plant and Equipment [Abstract]

Property and Equipment

3. Property and Equipment

Property and equipment consist of the following at:

	September 30, 2017			December 31, 2016
Furniture and equipment	$	503		$	503
Less accumulated depreciation		(333	)		(261	)
	$	170		$	242

XML 20 R9.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses

9 Months Ended

Sep. 30, 2017

Payables and Accruals [Abstract]

Accounts Payable and Accrued Expenses

4. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following:

	September 30, 2017		December 31, 2016
Interest expense	$	218,757	$	22,383
Accounts payable		225,082		226,516
Accrued bonus		256,500		-
Deferred Directors’ fees		39,725		11,250
	$	740,064	$	260,149

XML 21 R10.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

5. Commitments and Contingencies

UCLA TDG Exclusive License Agreement

We are obligated to make the following milestone payments to UCLA TDG for each Licensed Product or Licensed Method:

	●	$100,000 upon enrollment of the first subject in a Feasibility Study;

	●	$250,000 upon enrollment of the first subject in a Pivotal Study:

	●	$500,000 upon Pre-Market Approval of a Licensed Product or Licensed Method; and

	●	$1,000,000 upon the First Commercial Sale of a Licensed Product or Licensed Method.

	●	$500,000; or

	●	2% of all proceeds in connection with a Change of Control Transaction.

Contingencies

Indemnification

XML 22 R11.htm IDEA: XBRL DOCUMENT

Notes Payable

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Notes Payable

6. Notes Payable

Convertible Notes Payable

First Secured Convertible Note and Warrant

Second Secured Convertible Note and Warrant

Third Convertible Secured Term Note and Warrant

Convertible Promissory Notes

Note Type	Issue Date	Maturity Date	Interest Rate			September 30, 2017		December 31, 2016

First Secured Convertible Note	10/24/14	12/31/19		8.5	%		5,000,000		5,000,000

Second Secured Convertible Note	5/4/15	12/31/19		8.5	%		2,000,000		2,000,000

Third Secured Convertible Note	2/24/16	2/23/19		8.5	%		2,000,000		2,000,000

Convertible Promissory Notes	10/14/16	12/31/17		8.5	%		1,200,000		1,200,000

Convertible Promissory Notes	2/10/17	12/31/17		8.5	%		2,000,000		-

Convertible Promissory Notes	8/18/17	12/31/17		8.5	%		700,000		-
							12,900,000		10,200,000
Less: Current notes payable, net							2,887,876		1,200,000
Less: Debt discount							2,655,310		2,367,708
Less: Debt issuance costs							154,523		350,044
Net Notes payable						$	7,202,291	$	6,282,248

XML 23 R12.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2017

Equity [Abstract]

Stockholders' Equity

7. Stockholders’ Equity

Preferred Stock

The Company’s amended and restated certificate of incorporation authorizes the Company to issue a total of 20,000,000 shares of preferred stock. No shares have been issued.

Common Stock

On August 18, 2017, the Company sold to MTF an aggregate of 233,333 shares of common stock of the Company at a price per share equal to $3.00.

On August 18, 2017, 15,382 shares of common stock of the Company were issued from the exercise of options.

In connection with the Secured Convertible Notes to Hankey Capital, the Company issued 11,392,406 common shares as collateral. (See Note 6)

Common Stock Warrants

As of September 30, 2017, the Company had outstanding unexercised Common Stock Warrants as follows:

Date Issued	Exercise Price		Number of Shares		Expiration date
2009	$	0.44		118,383	March 16, 2019
2010	$	0.44		254,997	February 4, 2020
April 2013	$	1.00		50,000	April 28, 2020
September 2013	$	1.00		50,000	September 4, 2020
September 2013	$	1.00		25,000	September 20, 2020
November 2013	$	1.00		75,000	November 14, 2020
July 2014	$	1.50		166,667	May 30, 2018
July 2014	$	1.50		166,667	September 30, 2018
July 2014	$	1.00		500,000	September 30, 2018
July 2014	$	1.00		46,667	July 2, 2018
July 2014	$	0.00		12,625	July 10, 2018
September 2014	$	1.62		625,000	August 31, 2021
September 2014	$	1.00		699,671	September 18, 2021
September 2014	$	1.00		89,588	September 29, 2021
October 2014	$	1.00		126,582	October 23, 2017
October 2014	$	1.58		3,164,558	October 23, 2019
February 2015	$	1.58		699,037	February 14, 2018
May 2015	$	1.58		1,898,734	May 4, 2020
October 2015	$	1.58		158,229	October 27, 2018
February 2016	$	2.05		1,463,415	February 23, 2021

Total warrants at September 30, 2017				10,390,820	2.45 years

XML 24 R13.htm IDEA: XBRL DOCUMENT

Stock-based Compensation

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-based Compensation

8. Stock-based Compensation

2015 Equity Incentive Plan

A summary of stock option activity for the nine months ended September 30, 2017, is presented below:

	Number			Weighted
	of Shares			Average		Weighted
	Remaining			Exercise		Average		Aggregate
Subject to Exercise	Options			Price		Life (Years)		Value
Outstanding as of January 1, 2016		6,294,226		$	1.59		10.00		-
Granted – 2016		6,361,841			1.66		9.95		-
Forfeited – 2016		-			-		-		-
Exercised – 2016		-			-		-		-
Outstanding as of January 1, 2017		12,656,067		$	1.62		9.21		-
Granted – 2017		80,341			2.05		10.00		-
Forfeited – 2017		(4,270,639	)		1.60		8.54		-
Exercised – 2017		(68,553	)		2.05		8.25		-
Outstanding as of September 30, 2017		8,397,216		$	1.64		7.80		-

Date Issued	Exercise Price		Number of Shares		Expiration date
September 2014	$	1.59		583,059	December 27, 2025
November 2014	$	1.59		174,918	December 27, 2025
August 2015	$	1.59		3,121,787	December 27, 2025
September 2015	$	1.59		200,000	December 27, 2025
November 2015	$	1.59		1,224,640	December 27, 2025
December 2015	$	1.59		802,716	December 27, 2025
January 2016	$	1.59		1,275,786	January 9, 2026
March 2016	$	2.05		54,000	February 24, 2021
May 2016	$	2.05		807,434	May 26, 2026
June 2016	$	2.05		99,315	May 31, 2026
January 2017	$	2.05		53,561	January 1, 2027

Total options at September 30, 2017				8,397,216

The Company utilized the Black-Scholes option pricing model. The assumptions used for the nine months ended September 30, 2017 are as follows:

	September 30, 2017
Risk free interest rate		1.99%-2.306	%
Expected life (in years)		5.5-9.0
Expected Volatility		135.94%-153.79	%
Expected dividend yield		0	%

A summary of the changes in the Company’s non-vested options during the three months ended September 30, 2017, is as follows:

	Number of Non-vested Options			Weighted Average Fair Value at Grant Date		Intrinsic Value
Non-vested at January 1, 2016		5,156,710		$	1.29		-
Granted in 2016		6,361,841		$	1.93		-
Vested in year ended December 31, 2016		(1,913,491	)	$	1.31		-
Non-vested at January 1, 2017		9,605,060		$	1.74		-
Granted in 2017		80,341		$	1.87		-
Forfeited – 2017		(4,145,391	)	$	1.95		-
Vested in 2017		(2,718,316	)	$	1.69		-
Non-vested at September 30, 2017		2,821,694		$	1.49		-
Exercisable at September 30, 2017		5,575,522		$	1.44		-
Outstanding at September 30, 2017		8,397,216		$	1.46		-

As of September 30, 2017, total unrecognized compensation cost related to unvested stock options was $647,091. The cost is expected to be recognized over a weighted average period of 0.61 years.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2017

Income Tax Disclosure [Abstract]

Income Taxes

9. Income Taxes

Uncertain Tax Positions

The Company recognizes the financial statement effects of a tax position when it becomes more likely than not, based upon the technical merits, that the position will be sustained upon examination.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Sep. 30, 2017

Related Party Transactions

10. Related Party Transactions

AFH Holding & Advisory LLC

In addition to the shares and warrants issued for services, AFH received cash totaling $-0- and $325,000 for services during the nine months ended September 30, 2017 and 2016, respectively.

Amir Heshmatpour is the controlling party of AFH.

Musculoskeletal Transplant Foundation (MTF)

On February 24, 2016 the Company entered into an Option Agreement for the Distribution and Supply of Sygnal™ demineralized bone matrix (“Sygnal”) with MTF pursuant to which:

	a.	MTF grants to the Company the exclusive right and option (the “Option”) to distribute Sygnal upon the critical terms as described in the Option Agreement (the “Option Rights”). The Company will exercise the Option, if at all, by providing written notice to MTF of its intent to do so. During the term of the Option, MTF will not enter into any agreements with any third parties which include the transfer by MTF of the Option Rights.

	b.	Upon the exercising of the Option, the Company will grant to MTF 700,000 shares of common stock in the Company.

	c.	Within 30 days of exercising the Option, MTF will provide the Company with a written proposal of a Definitive Agreement that includes, inter alia, the Critical Terms and those other commercially reasonable terms as agreed upon by the parties. The parties will fully negotiate in good faith all of the terms of the Definitive Agreement, and any ancillary agreements thereto consistent with the Critical Terms.

	d.	In the event the Company does not exercise the Option within the Term of the Option Agreement, MTF will be free to enter into any other agreement relating to the Option Rights as it deems appropriate without liability to the Company.

Sygnal is a bone void filler contouring allograft bone that has the inorganic mineral removed, leaving behind the organic “collagen” matrix.

On October 14, 2016, pursuant to a Note Purchase Agreement, the Company issued to MTF a convertible promissory note in the amount of $600,000 (See Note 6).

On February 10, 2017, pursuant to a Note Purchase Agreement, the Company issued to MTF a convertible promissory note in the amount of $1,000,000 (See Note 6).

Bruce Stroever, our Chairman of the Board, is the President and Chief Executive Officer of MTF.

Founders

Founders Professional Services Agreement

XML 27 R16.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2017

Subsequent Events [Abstract]

Subsequent Events

11. Subsequent Events

XML 28 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Use of Estimates

Use of Estimates

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Level 1: Quoted prices in active markets for identical assets or liabilities.

Property and Equipment

Property and Equipment

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

Research and Development Costs

Research and Development Costs

Patents and Licenses

Patents and Licenses

Prepaid Expenses - Related Party

Prepaid expenses – related party

Concentration of Credit Risk and Other Risks and Uncertainties

Concentration of Credit Risk and Other Risks and Uncertainties

Debt Issuance Costs

Debt Issuance Costs

Stock Based Compensation

Stock Based Compensation

Pursuant to ASU No. 2016-09 – Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, the Company accounts for forfeitures when they occur.

Income Taxes

Income Taxes

The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. No such amounts are accrued as of September 30, 2017 and December 31, 2016.

Loss Per Common Share

Loss per Common Share

The following sets forth the number of shares of common stock underlying outstanding options, warrants, and convertible debt as of September 30, 2017 and 2016:

	September 30,
		2017	2016
Warrants		10,390,820	10,451,740
Stock options		8,397,216	12,656,067
Convertible promissory notes		9,596,203	5,696,203
		28,384,239	28,804,010

New Accounting Standards

New Accounting Standards

XML 29 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following sets forth the number of shares of common stock underlying outstanding options, warrants, and convertible debt as of September 30, 2017 and 2016:

	September 30,
		2017	2016
Warrants		10,390,820	10,451,740
Stock options		8,397,216	12,656,067
Convertible promissory notes		9,596,203	5,696,203
		28,384,239	28,804,010

XML 30 R19.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

9 Months Ended

Sep. 30, 2017

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment consist of the following at:

	September 30, 2017			December 31, 2016
Furniture and equipment	$	503		$	503
Less accumulated depreciation		(333	)		(261	)
	$	170		$	242

XML 31 R20.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2017

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following:

	September 30, 2017		December 31, 2016
Interest expense	$	218,757	$	22,383
Accounts payable		225,082		226,516
Accrued bonus		256,500		-
Deferred Directors’ fees		39,725		11,250
	$	740,064	$	260,149

XML 32 R21.htm IDEA: XBRL DOCUMENT

Notes Payable (Tables)

9 Months Ended

Sep. 30, 2017

Debt Disclosure [Abstract]

Schedule of Notes Payable

Note Type	Issue Date	Maturity Date	Interest Rate			September 30, 2017		December 31, 2016

First Secured Convertible Note	10/24/14	12/31/19		8.5	%		5,000,000		5,000,000

Second Secured Convertible Note	5/4/15	12/31/19		8.5	%		2,000,000		2,000,000

Third Secured Convertible Note	2/24/16	2/23/19		8.5	%		2,000,000		2,000,000

Convertible Promissory Notes	10/14/16	12/31/17		8.5	%		1,200,000		1,200,000

Convertible Promissory Notes	2/10/17	12/31/17		8.5	%		2,000,000		-

Convertible Promissory Notes	8/18/17	12/31/17		8.5	%		700,000		-
							12,900,000		10,200,000
Less: Current notes payable, net							2,887,876		1,200,000
Less: Debt discount							2,655,310		2,367,708
Less: Debt issuance costs							154,523		350,044
Net Notes payable						$	7,202,291	$	6,282,248

XML 33 R22.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2017

Equity [Abstract]

Schedule of Outstanding Unexercised Common Stock Warrants

As of September 30, 2017, the Company had outstanding unexercised Common Stock Warrants as follows:

Date Issued	Exercise Price		Number of Shares		Expiration date
2009	$	0.44		118,383	March 16, 2019
2010	$	0.44		254,997	February 4, 2020
April 2013	$	1.00		50,000	April 28, 2020
September 2013	$	1.00		50,000	September 4, 2020
September 2013	$	1.00		25,000	September 20, 2020
November 2013	$	1.00		75,000	November 14, 2020
July 2014	$	1.50		166,667	May 30, 2018
July 2014	$	1.50		166,667	September 30, 2018
July 2014	$	1.00		500,000	September 30, 2018
July 2014	$	1.00		46,667	July 2, 2018
July 2014	$	0.00		12,625	July 10, 2018
September 2014	$	1.62		625,000	August 31, 2021
September 2014	$	1.00		699,671	September 18, 2021
September 2014	$	1.00		89,588	September 29, 2021
October 2014	$	1.00		126,582	October 23, 2017
October 2014	$	1.58		3,164,558	October 23, 2019
February 2015	$	1.58		699,037	February 14, 2018
May 2015	$	1.58		1,898,734	May 4, 2020
October 2015	$	1.58		158,229	October 27, 2018
February 2016	$	2.05		1,463,415	February 23, 2021

Total warrants at September 30, 2017				10,390,820	2.45 years

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 34 R23.htm IDEA: XBRL DOCUMENT

Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock Option Activity

A summary of stock option activity for the nine months ended September 30, 2017, is presented below:

	Number			Weighted
	of Shares			Average		Weighted
	Remaining			Exercise		Average		Aggregate
Subject to Exercise	Options			Price		Life (Years)		Value
Outstanding as of January 1, 2016		6,294,226		$	1.59		10.00		-
Granted – 2016		6,361,841			1.66		9.95		-
Forfeited – 2016		-			-		-		-
Exercised – 2016		-			-		-		-
Outstanding as of January 1, 2017		12,656,067		$	1.62		9.21		-
Granted – 2017		80,341			2.05		10.00		-
Forfeited – 2017		(4,270,639	)		1.60		8.54		-
Exercised – 2017		(68,553	)		2.05		8.25		-
Outstanding as of September 30, 2017		8,397,216		$	1.64		7.80		-

Schedule of Stock Option

Date Issued	Exercise Price		Number of Shares		Expiration date
September 2014	$	1.59		583,059	December 27, 2025
November 2014	$	1.59		174,918	December 27, 2025
August 2015	$	1.59		3,121,787	December 27, 2025
September 2015	$	1.59		200,000	December 27, 2025
November 2015	$	1.59		1,224,640	December 27, 2025
December 2015	$	1.59		802,716	December 27, 2025
January 2016	$	1.59		1,275,786	January 9, 2026
March 2016	$	2.05		54,000	February 24, 2021
May 2016	$	2.05		807,434	May 26, 2026
June 2016	$	2.05		99,315	May 31, 2026
January 2017	$	2.05		53,561	January 1, 2027

Total options at September 30, 2017				8,397,216

Schedule of Assumptions Using Black-Scholes Option Pricing Model

The Company utilized the Black-Scholes option pricing model. The assumptions used for the nine months ended September 30, 2017 are as follows:

	September 30, 2017
Risk free interest rate		1.99%-2.306	%
Expected life (in years)		5.5-9.0
Expected Volatility		135.94%-153.79	%
Expected dividend yield		0	%

Schedule of Non-Vested Options

A summary of the changes in the Company’s non-vested options during the three months ended September 30, 2017, is as follows:

	Number of Non-vested Options			Weighted Average Fair Value at Grant Date		Intrinsic Value
Non-vested at January 1, 2016		5,156,710		$	1.29		-
Granted in 2016		6,361,841		$	1.93		-
Vested in year ended December 31, 2016		(1,913,491	)	$	1.31		-
Non-vested at January 1, 2017		9,605,060		$	1.74		-
Granted in 2017		80,341		$	1.87		-
Forfeited – 2017		(4,145,391	)	$	1.95		-
Vested in 2017		(2,718,316	)	$	1.69		-
Non-vested at September 30, 2017		2,821,694		$	1.49		-
Exercisable at September 30, 2017		5,575,522		$	1.44		-
Outstanding at September 30, 2017		8,397,216		$	1.46		-

XML 35 R24.htm IDEA: XBRL DOCUMENT

The Company (Details Narrative) - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended	119 Months Ended
The Company (Details Narrative) - USD ($)	Sep. 30, 2017	Jun. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Sep. 30, 2017	Jan. 08, 2016
Common stock outstanding shares	5,000,000			5,000,000			5,000,000
Common stock issued and outstanding per share	$ 0.001			$ 0.001		$ 0.001	$ 0.001
Common stock remaining shares were cancelled	3,853,600			3,853,600			3,853,600
Number of outstanding warrants issuable shares								1,800,364
Gross revenue						$ 1,070,000,000
Non-convertible debt securities	1,070,000,000			1,070,000,000			$ 1,070,000,000
Net income loss	(2,527,419)		$ (4,372,271)	(4,737,003)	$ (16,150,355)		52,000,000
Estimated operating expenditure for next twelve months	$ 6,500,000			$ 6,500,000			$ 6,500,000
Non-affiliates [Member]
Market value of common stock		$ 700,000,000
October 2016 and February 2017 Note Purchase Agreement [Member]
Percentage of defer earned compensation				20.00%
October 2016 and February 2017 Note Purchase Agreement [Member] \| Directors [Member]
Percentage of defer earned compensation				50.00%
Cash compensation received				$ 5,000,000
Bone Biologics Inc [Member]
Common stock issued and outstanding per share	$ 0.0001			$ 0.0001			$ 0.0001
Common stock converted combined number of shares				19,897,587
Number of outstanding warrants issuable shares	2,151,926			2,151,926			2,151,926
Number of shares issuable upon the conversion of debt				5,648,658

XML 36 R25.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Prepaid expenses - related party	$ 271,945	$ 271,945
Uncertain tax positions
Interest and/or penalties related to income tax
Depositor [Member]
Federal insurance coverage cost	$ 250,000
Minimum [Member]
Estimated useful lives of property and equipment	3 years
Maximum [Member]
Estimated useful lives of property and equipment	7 years

XML 37 R26.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Anti-dilutive securities outstanding excluded from computation of diluted net loss per share	28,384,239	28,804,010
Warrants [Member]
Anti-dilutive securities outstanding excluded from computation of diluted net loss per share	10,390,820	10,451,740
Stock Options [Member]
Anti-dilutive securities outstanding excluded from computation of diluted net loss per share	8,397,216	12,656,067
Convertible Promissory Notes [Member]
Anti-dilutive securities outstanding excluded from computation of diluted net loss per share	9,596,203	5,696,203

XML 38 R27.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details Narrative) - USD ($)	9 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Sep. 30, 2017	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 72	$ 660
Loss on disposal of assets		$ 4,862

XML 39 R28.htm IDEA: XBRL DOCUMENT

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Furniture and equipment	$ 503	$ 503
Less accumulated depreciation	(333)	(261)
Furniture and equipment, Net	$ 170	$ 242

XML 40 R29.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Interest expense	$ 218,757	$ 22,383
Accounts payable	225,082	226,516
Accrued bonus	256,500
Deferred Directors' fees	39,725	11,250
Total Accounts Payable and Accrued Expenses	$ 740,064	$ 260,149

XML 41 R30.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) - USD ($)		9 Months Ended
	Dec. 22, 2016	Sep. 30, 2017
License commitment fee
License Agreement [Member]
Payment of UCLA TDG annual maintenance fee		$ 10,000
Percentage of commercial sale of the licensed product equal to net sales		3.00%
License Agreement [Member] \| UCLA TDG [Member]
Percentage of commercial sale of the licensed product equal to net sales		0.333%
License commitment fee	$ 500,000
Percentage of amount raised in private placement	2.00%
License Agreement [Member] \| UCLA TDG [Member] \| First Subject In Feasibility Study [Member]
License commitment fee		$ 100,000
License Agreement [Member] \| UCLA TDG [Member] \| First Subject In Pivotal Study [Member]
License commitment fee		250,000
License Agreement [Member] \| UCLA TDG [Member] \| Pre-Market Approval Of Licensed Product Or Licensed Method [Member]
License commitment fee		500,000
License Agreement [Member] \| UCLA TDG [Member] \| First Commercial Sale Of Licensed Product Or Licensed Method [Member]
License commitment fee		1,000,000
License Agreement [Member] \| First Commercial Sale [Member]
Annual minimum royalty for life of the patent rights		50,000
License Agreement [Member] \| After First Commercial Sale [Member]
Annual minimum royalty for life of the patent rights		$ 250,000
Minimum [Member] \| License Agreement [Member] \| UCLA TDG [Member]
Percentage of commercial sale of the licensed product equal to net sales		10.00%
Maximum [Member] \| License Agreement [Member] \| UCLA TDG [Member]
Percentage of commercial sale of the licensed product equal to net sales		20.00%

XML 42 R31.htm IDEA: XBRL DOCUMENT

Notes Payable (Details Narrative) - USD ($)							9 Months Ended
Notes Payable (Details Narrative) - USD ($)	Aug. 18, 2017	Feb. 10, 2017	Oct. 14, 2016	Feb. 24, 2016	May 04, 2015	Oct. 24, 2014	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Jan. 08, 2016
Warrant to purchase shares of common stock										1,800,364
Warrant exercise price										$ 1.59
Debt discount amortization							$ 2,412,398	$ 657,159
Unamortized debt discount							$ 2,655,310		$ 2,367,708
Amortization over period							1 year 3 months 8 days
Unamortized debt issuance cost							$ 154,523		$ 350,044
Convertible Promissory Notes [Member]
Debt maturity date							Dec. 31, 2017
Debt instrument interest rate							8.50%
Debt discount amortization							$ 230,521	$ 223,990
Amortization over period							1 year 3 months 8 days
Convertible Promissory Notes [Member] \| Note Purchase Agreement [Member]
Debt instrument conversion price per share	$ 1.00	$ 1.00	$ 1.00
Hankey Capital, LLC [Member]
Warrant to purchase shares of common stock						3,955,697
Warrant exercise price						$ 1.58
Warrant expiration date						Oct. 24, 2019
Hankey Capital, LLC [Member] \| Second Warrant [Member]
Warrant to purchase shares of common stock					1,898,734
Warrant exercise price					$ 1.58
Warrant expiration date					May 04, 2020
Hankey Capital, LLC [Member] \| Third Warrant [Member]
Warrant to purchase shares of common stock				1,463,415			791,139
Warrant exercise price				$ 2.05
Warrant expiration date				Feb. 23, 2021
Hankey Capital, LLC [Member] \| Second Secured Convertible Note And Warrant [Member]
Convertible promissory note amount					$ 2,000,000
Debt maturity date					Dec. 31, 2019
Number of common stock shares issued for lending					2,531,646
Percentage of commitment fee paid					3.00%
Loan commitment fee amount					$ 60,000
Hankey Capital, LLC [Member] \| Third Convertible Secured Term Note and Warrant [Member]
Convertible promissory note amount				$ 2,000,000
Debt maturity date				Feb. 23, 2019
Number of common stock shares issued for lending				2,531,646
Percentage of commitment fee paid				2.00%
Loan commitment fee amount				$ 40,000
Hankey Capital, LLC [Member] \| First Two Convertible Secured Notes [Member]
Debt instrument conversion price per share							$ 1.58
Hankey Capital, LLC [Member] \| First Two Convertible Secured Notes [Member] \| Third Warrant [Member]
Warrant expiration date							Dec. 31, 2019
Gross proceeds from warrant issued							$ 1,250,000
Hankey Capital, LLC [Member] \| Convertible Promissory Notes [Member] \| Note Purchase Agreement [Member]
Convertible promissory note amount	$ 700,000
Debt maturity date	Dec. 31, 2017
Debt instrument interest rate	8.50%
Debt instrument conversion price per share	$ 1.00
Gross proceeds from convertible notes	$ 5,000,000
Hankey Capital, LLC [Member] \| Minimum [Member] \| Second Secured Convertible Note And Warrant [Member]
Debt instrument interest rate					8.50%
Loan for collateral value ratio percentage					50.00%
Hankey Capital, LLC [Member] \| Minimum [Member] \| Third Convertible Secured Term Note and Warrant [Member]
Debt instrument interest rate				8.50%
Loan for collateral value ratio percentage				50.00%
Hankey Capital, LLC [Member] \| Maximum [Member] \| Second Secured Convertible Note And Warrant [Member]
Loan for collateral value ratio percentage					50.00%
Hankey Capital, LLC [Member] \| Maximum [Member] \| Third Convertible Secured Term Note and Warrant [Member]
Loan for collateral value ratio percentage				50.00%
Hankey Capital, LLC [Member] \| Prime Rate [Member] \| Second Secured Convertible Note And Warrant [Member]
Debt instrument interest rate					4.00%
Debt instrument conversion price per share					$ 1.58
Hankey Capital, LLC [Member] \| Prime Rate [Member] \| Third Convertible Secured Term Note and Warrant [Member]
Debt instrument interest rate				4.00%
Debt instrument conversion price per share				$ 1.58
MTF and Hankey Capital, LLC [Member] \| Convertible Promissory Notes [Member] \| Note Purchase Agreement [Member]
Convertible promissory note amount		$ 1,000,000	$ 600,000
Debt maturity date		Dec. 31, 2017	Dec. 31, 2017
Debt instrument interest rate		8.50%	8.50%
Debt instrument conversion price per share		$ 1.00	$ 1.00
Gross proceeds from convertible notes		$ 5,000,000	$ 5,000,000
Deferred compensation, percentage			20.00%
Debt instrument, maturity date, description			On January 23, 2017 the Company, MTF and Hankey Capital, executed an amendment (the “Amendment”) to the Convertible Notes. The Amendment extends the maturity date of each of the Convertible Notes to December 31, 2017 from December 31, 2016. By extending the maturity date, the date that the Convertible Notes automatically convert into shares of the Company’s Common Stock was also extended to December 31, 2017. The Amendment was effective retroactive to December 31, 2016.On January 23, 2017 the Company, MTF and Hankey Capital, executed an amendment (the “Amendment”) to the Convertible Notes. The Amendment extends the maturity date of each of the Convertible Notes to December 31, 2017 from December 31, 2016. By extending the maturity date, the date that the Convertible Notes automatically convert into shares of the Company’s Common Stock was also extended to December 31, 2017. The Amendment was effective retroactive to December 31, 2016.
MTF and Hankey Capital, LLC [Member] \| Convertible Promissory Notes [Member] \| Note Purchase Agreement [Member] \| Directors [Member]
Deferred compensation, percentage			50.00%
MTF and Hankey Capital, LLC [Member] \| Convertible Promissory Notes [Member] \| Note Purchase Agreement [Member] \| Noncurrent Stockholders[Member]
Compensation, amount			$ 5,000,000
First Secured Convertible Note and Warrant [Member] \| Hankey Capital, LLC [Member]
Convertible promissory note amount						$ 5,000,000
Debt maturity date						Dec. 31, 2019
Number of common stock shares issued for lending						6,329,114
Percentage of commitment fee paid						3.00%
Loan commitment fee amount						$ (150,000)
First Secured Convertible Note and Warrant [Member] \| Hankey Capital, LLC [Member] \| Minimum [Member]
Debt instrument interest rate						8.50%
Loan for collateral value ratio percentage						50.00%
First Secured Convertible Note and Warrant [Member] \| Hankey Capital, LLC [Member] \| Maximum [Member]
Loan for collateral value ratio percentage						50.00%
First Secured Convertible Note and Warrant [Member] \| Hankey Capital, LLC [Member] \| Prime Rate [Member]
Debt instrument interest rate						4.00%
Debt instrument conversion price per share						$ 1.58

XML 43 R32.htm IDEA: XBRL DOCUMENT

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Secured Convertible Note	$ 12,900,000		$ 10,200,000
Less: Current notes payable, net	2,887,876		1,200,000
Less: Debt discount	2,655,310		2,367,708
Less: Debt issuance costs	154,523		350,044
Net Notes payable	$ 7,202,291		6,282,248
First Secured Convertible Note [Member]
Issue Date	Oct. 24, 2014
Maturity Date	Dec. 31, 2019
Interest Rate	8.50%
Secured Convertible Note	$ 5,000,000		5,000,000
Second Secured Convertible Note [Member]
Issue Date	May 04, 2015
Maturity Date	Dec. 31, 2019
Interest Rate	8.50%
Secured Convertible Note	$ 2,000,000		2,000,000
Third Secured Convertible Note [Member]
Issue Date	Feb. 24, 2016
Maturity Date	Feb. 23, 2019
Interest Rate	8.50%
Secured Convertible Note	$ 2,000,000		2,000,000
Convertible Promissory Notes [Member]
Issue Date	Oct. 14, 2016
Maturity Date	Dec. 31, 2017
Interest Rate	8.50%
Secured Convertible Note	$ 1,200,000		$ 1,200,000
Convertible Promissory Notes One [Member]
Issue Date	Feb. 10, 2017
Maturity Date	Dec. 31, 2017
Interest Rate	8.50%
Secured Convertible Note	$ 2,000,000
Convertible Promissory Notes Two [Member]
Issue Date	Aug. 18, 2017
Maturity Date	Dec. 31, 2017
Interest Rate	8.50%
Secured Convertible Note	$ 700,000

XML 44 R33.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Narrative) - $ / shares		9 Months Ended		12 Months Ended
Stockholders' Equity (Details Narrative) - $ / shares	Aug. 18, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Preferred stock, shares authorized		20,000,000		20,000,000
Preferred stock, shares issued
Common stock, shares authorized		100,000,000		100,000,000
Common stock, shares outstanding		39,077,322		38,828,607
Sale of common stock, shares	233,333
Sale of common stock, price per share	$ 3.00
Common stock issued for exercise options	15,382	68,553	0
Common stock warrants exercised			791,139
Common stock warrants expired
Hankey Capital, LLC [Member]
Common shares issued for collateral on loan, shares		11,392,406

XML 45 R34.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Outstanding Unexercised Common Stock Warrants (Details) - $ / shares	9 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Number of Shares	8,397,216
Unexercised Common Stock Warrants [Member]
Number of Shares	10,390,820
Warrant expiration term	2 years 5 months 12 days
2009 [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 0.44
Number of Shares	118,383
Warrants expiration date	Mar. 16, 2019
2010 [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 0.44
Number of Shares	254,997
Warrants expiration date	Feb. 04, 2020
April 2013 [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 1.00
Number of Shares	50,000
Warrants expiration date	Apr. 28, 2020
September 2013 [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 1.00
Number of Shares	50,000
Warrants expiration date	Sep. 04, 2020
September 2013 (1) [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 1.00
Number of Shares	25,000
Warrants expiration date	Sep. 20, 2020
November 2013 [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 1.00
Number of Shares	75,000
Warrants expiration date	Nov. 14, 2020
July 2014 (1) [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 1.50
Number of Shares	166,667
Warrants expiration date	May 30, 2018
July 2014 (2) [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 1.50
Number of Shares	166,667
Warrants expiration date	Sep. 30, 2018
July 2014 (3) [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 1.00
Number of Shares	500,000
Warrants expiration date	Sep. 30, 2018
July 2014 (4) [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 1.00
Number of Shares	46,667
Warrants expiration date	Jul. 02, 2018
July 2014 (5) [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 0.00
Number of Shares	12,625
Warrants expiration date	Jul. 10, 2018
September 2014 (1) [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 1.62
Number of Shares	625,000
Warrants expiration date	Aug. 31, 2021
September 2014 (2) [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 1.00
Number of Shares	699,671
Warrants expiration date	Sep. 18, 2021
September 2014 (3) [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 1.00
Number of Shares	89,588
Warrants expiration date	Sep. 29, 2021
October 2014 [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 1.00
Number of Shares	126,582
Warrants expiration date	Oct. 23, 2017
October 2014 (1) [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 1.58
Number of Shares	3,164,558
Warrants expiration date	Oct. 23, 2019
February 2015 [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 1.58
Number of Shares	699,037
Warrants expiration date	Feb. 14, 2018
May 2015 [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 1.58
Number of Shares	1,898,734
Warrants expiration date	May 04, 2020
October 2015 [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 1.58
Number of Shares	158,229
Warrants expiration date	Oct. 27, 2018
February 2016 [Member] \| Unexercised Common Stock Warrants [Member]
Exercise price	$ 2.05
Number of Shares	1,463,415
Warrants expiration date	Feb. 23, 2021

XML 46 R35.htm IDEA: XBRL DOCUMENT

Stock-based Compensation (Details Narrative) - USD ($)		9 Months Ended		12 Months Ended
Stock-based Compensation (Details Narrative) - USD ($)	Aug. 18, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Stock-based compensation expense		$ 1,405,396	$ 2,938,825
Options exercised	15,382	68,553	0
Forfeiture credits		$ 3,650,419	$ 0
Number options, granted		80,341	6,361,841	6,361,841
Unrecognized compensation cost related to unvested stock options		$ 647,091
Compensation, expected to be recognized over a weighted average period		7 months 10 days
Directors [Member]
Options cancelled		20,085	20,085
Founders Professional Services Agreement [Member]
Options cancelled		4,125,306	4,125,306
Employees and Directors [Member]
Stock-based compensation expense		$ 1,405,396	$ 2,938,825
2015 Equity Incentive Plan [Member]
Shares authorized and reserved for issuance					14,000,000
Percentage of stock issued and outstanding					5.00%
Issuance of Stock Options [Member]
Stock-based compensation expense		$ (2,338,812)	$ 4,512,033

XML 47 R36.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Schedule of Stock Option Activity (Details) - USD ($)		9 Months Ended		12 Months Ended
	Aug. 18, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Shares Remaining Options Outstanding, Beginning balance		12,656,067	6,294,226	6,294,226
Number of Shares Remaining Options, Granted		80,341	6,361,841	6,361,841
Number of Shares Remaining Options, Forfeited		(4,270,639)
Number of Shares Remaining Options, Exercised	(15,382)	(68,553)	0
Number of Shares Remaining Options Outstanding, Ending balance		8,397,216		12,656,067
Weighted Average Exercise Price, Outstanding, Beginning		$ 1.62	$ 1.59	$ 1.59
Weighted Average Exercise Price, Granted		2.05		1.66
Weighted Average Exercise Price, Forfeited		1.60
Weighted Average Exercise Price, Exercised		2.05
Weighted Average Exercise Price, Outstanding, Ending		$ 1.64		$ 1.62
Weighted Average Life (Years), Outstanding, Beginning		9 years 2 months 16 days		10 years
Weighted Average Life (Years), Granted		10 years		9 years 11 months 12 days
Weighted Average Life (Years), Forfeited		8 years 6 months 14 days		0 years
Weighted Average Life (Years), Exercised		8 years 2 months 30 days		0 years
Weighted Average Life (Years), Outstanding. Ending		7 years 9 months 18 days		9 years 2 months 16 days
Intrinsic Value, Outstanding Beginning
Intrinsic Value, Outstanding Ending

XML 48 R37.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Schedule of Stock Option (Details)	9 Months Ended
	Sep. 30, 2017 $ / shares shares
Stock option	8,397,216
September 2014 [Member]
Exercise price \| $ / shares	$ 1.59
Stock option	583,059
Expiration date	Dec. 27, 2025
November 2014 [Member]
Exercise price \| $ / shares	$ 1.59
Stock option	174,918
Expiration date	Dec. 27, 2025
August 2015 [Member]
Exercise price \| $ / shares	$ 1.59
Stock option	3,121,787
Expiration date	Dec. 27, 2025
September 2015 [Member]
Exercise price \| $ / shares	$ 1.59
Stock option	200,000
Expiration date	Dec. 27, 2025
November 2015 [Member]
Exercise price \| $ / shares	$ 1.59
Stock option	1,224,640
Expiration date	Dec. 27, 2025
December 2015 [Member]
Exercise price \| $ / shares	$ 1.59
Stock option	802,716
Expiration date	Dec. 27, 2025
January 2016 [Member]
Exercise price \| $ / shares	$ 1.59
Stock option	1,275,786
Expiration date	Jan. 09, 2026
March 2016 [Member]
Exercise price \| $ / shares	$ 2.05
Stock option	54,000
Expiration date	Feb. 24, 2021
May 2016 [Member]
Exercise price \| $ / shares	$ 2.05
Stock option	807,434
Expiration date	May 26, 2026
June 2016 [Member]
Exercise price \| $ / shares	$ 2.05
Stock option	99,315
Expiration date	May 31, 2026
January 2017 [Member]
Exercise price \| $ / shares	$ 2.05
Stock option	53,561
Expiration date	Jan. 01, 2027

XML 49 R38.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Schedule of Assumptions Using Black-Scholes Option Pricing Model (Details)	9 Months Ended
	Sep. 30, 2017
Risk free interest rate, minimum	1.99%
Risk free interest rate, maximum	2.306%
Expected Volatility, minimum	135.94%
Expected Volatility, maximum	153.79%
Expected dividend yield	0.00%
Minimum [Member]
Expected life (in years)	5 years 6 months
Maximum [Member]
Expected life (in years)	9 years

XML 50 R39.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Schedule of Non-Vested Options (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Non-vested Options, Beginning Balance	9,605,060	5,156,710	5,156,710
Number of Non-vested Options, Granted	80,341	6,361,841	6,361,841
Number of Non-vested Options, Vested	(2,718,316)		(1,913,491)
Number of Non-vested Options, Forfeited	(4,145,391)
Number of Non-vested Options, Ending Balance	2,821,694		9,605,060
Number of Non-vested Options, Exercisable	5,575,522
Number of Non-vested Options, Outstanding	8,397,216
Weighted Average Fair Value at Grant Date, Beginning Balance	$ 1.74	$ 1.29	$ 1.29
Weighted Average Fair Value at Grant Date, Granted	1.87		1.93
Weighted Average Fair Value at Grant Date, Vested	1.69		1.31
Weighted Average Fair Value at Grant Date, Forfeited	1.95
Weighted Average Fair Value at Grant Date, Ending Balance	1.49		1.74
Weighted Average Fair Value at Grant Date, Exercisable	1.44
Weighted Average Fair Value at Grant Date, Outstanding	$ 1.46
Intrinsic Value, Outstanding, Beginning Balance
Intrinsic Value, Outstanding, Ending Balance

XML 51 R40.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative)	9 Months Ended
Income Taxes (Details Narrative)	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Effective tax rate	0.00%

XML 52 R41.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)						3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 18, 2017	Jan. 02, 2017	Dec. 13, 2016	Jun. 02, 2016	Feb. 10, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Feb. 10, 2017	Oct. 14, 2016	Jun. 24, 2016	Feb. 24, 2016	Feb. 22, 2016	Jan. 08, 2016	Oct. 02, 2015
Warrant to purchase shares of common stock																1,800,364
Maximum percentage of warrants purchase of fully diluted shares of common stock outstanding																4.00%
Number of shares issued for services, value								$ 100,930
Warrant exercise price per share																$ 1.59
Cost of license
Sale of common stock, shares	233,333
Sale of common stock, price per share	$ 3.00
Consulting fees for related party		$ 200,000
Research and development expense			$ 3,629,041			$ 248,377	$ 2,473,433	(1,654,074)	$ 9,470,369
Founder [Member] \| 10 Year Stock Options [Member]
Warrant exercise price per share				$ 2.05
First Anniversary [Member]
Percentage of option vest																25.00%
Second Anniversary [Member]
Percentage of option vest																25.00%
Third Anniversary [Member]
Percentage of option vest																25.00%
Fourth Anniversary [Member]
Percentage of option vest																12.50%
Fifth Anniversary [Member]
Percentage of option vest																12.50%
Note Purchase Agreement [Member] \| MTF [Member]
Convertible promissory note											$ 1,000,000	$ 600,000
10 Year Stock Options [Member] \| Founder [Member]
Number of shares issued in connection with adjustment				33,105
AFH [Member]
Warrant to purchase shares of common stock					1,260,255
Maximum percentage of warrants purchase of fully diluted shares of common stock outstanding					10.00%
Number of shares issued in connection with adjustment					1,260,255
Up-front retainer received						100,000		100,000
Up-front retainer receivable per month						$ 33,333		33,333
Number of shares issued for services, value								$ 0	$ 325,000
AFH [Member] \| October 28, 2015 Invoice [Member]
Number of shares issued for services				20,186
AFH [Member] \| Letter Agreement February 10, 2016 [Member]
Number of shares issued for services				23,173
AFH [Member] \| PIPE [Member] \| Minimum [Member]
Fair value of warrants value					$ 8,000,000
AFH [Member] \| PIPE [Member] \| Maximum [Member]
Fair value of warrants value					$ 10,000,000
MTF [Member]
Warrant to purchase shares of common stock													700,000	700,000	731,707		1,153,846
Warrant exercise price per share															$ 2.05
Cost of license										$ 1,435,000

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 54 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 196 218 1 false 86 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://bonebiologics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://bonebiologics.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://bonebiologics.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://bonebiologics.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://bonebiologics.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - The Company Sheet http://bonebiologics.com/role/Company The Company Notes 6 false false R7.htm 00000007 - Disclosure - Summary of Significant Accounting Policies Sheet http://bonebiologics.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Property and Equipment Sheet http://bonebiologics.com/role/PropertyAndEquipment Property and Equipment Notes 8 false false R9.htm 00000009 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://bonebiologics.com/role/AccountsPayableAndAccruedExpenses Accounts Payable and Accrued Expenses Notes 9 false false R10.htm 00000010 - Disclosure - Commitments and Contingencies Sheet http://bonebiologics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 10 false false R11.htm 00000011 - Disclosure - Notes Payable Notes http://bonebiologics.com/role/NotesPayable Notes Payable Notes 11 false false R12.htm 00000012 - Disclosure - Stockholders' Equity Sheet http://bonebiologics.com/role/StockholdersEquity Stockholders' Equity Notes 12 false false R13.htm 00000013 - Disclosure - Stock-based Compensation Sheet http://bonebiologics.com/role/Stock-basedCompensation Stock-based Compensation Notes 13 false false R14.htm 00000014 - Disclosure - Income Taxes Sheet http://bonebiologics.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 00000015 - Disclosure - Related Party Transactions Sheet http://bonebiologics.com/role/RelatedPartyTransactions Related Party Transactions Notes 15 false false R16.htm 00000016 - Disclosure - Subsequent Events Sheet http://bonebiologics.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 00000017 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://bonebiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://bonebiologics.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://bonebiologics.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://bonebiologics.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Property and Equipment (Tables) Sheet http://bonebiologics.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://bonebiologics.com/role/PropertyAndEquipment 19 false false R20.htm 00000020 - Disclosure - Accounts Payable and Accrued Expenses (Tables) Sheet http://bonebiologics.com/role/AccountsPayableAndAccruedExpensesTables Accounts Payable and Accrued Expenses (Tables) Tables http://bonebiologics.com/role/AccountsPayableAndAccruedExpenses 20 false false R21.htm 00000021 - Disclosure - Notes Payable (Tables) Notes http://bonebiologics.com/role/NotesPayableTables Notes Payable (Tables) Tables http://bonebiologics.com/role/NotesPayable 21 false false R22.htm 00000022 - Disclosure - Stockholders' Equity (Tables) Sheet http://bonebiologics.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://bonebiologics.com/role/StockholdersEquity 22 false false R23.htm 00000023 - Disclosure - Stock-based Compensation (Tables) Sheet http://bonebiologics.com/role/Stock-basedCompensationTables Stock-based Compensation (Tables) Tables http://bonebiologics.com/role/Stock-basedCompensation 23 false false R24.htm 00000024 - Disclosure - The Company (Details Narrative) Sheet http://bonebiologics.com/role/CompanyDetailsNarrative The Company (Details Narrative) Details http://bonebiologics.com/role/Company 24 false false R25.htm 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://bonebiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://bonebiologics.com/role/SummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 00000026 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://bonebiologics.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 26 false false R27.htm 00000027 - Disclosure - Property and Equipment (Details Narrative) Sheet http://bonebiologics.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://bonebiologics.com/role/PropertyAndEquipmentTables 27 false false R28.htm 00000028 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) Sheet http://bonebiologics.com/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails Property and Equipment - Schedule of Property and Equipment (Details) Details 28 false false R29.htm 00000029 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) Sheet http://bonebiologics.com/role/AccountsPayableAndAccruedExpenses-ScheduleOfAccountsPayableAndAccruedExpensesDetails Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) Details 29 false false R30.htm 00000030 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://bonebiologics.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://bonebiologics.com/role/CommitmentsAndContingencies 30 false false R31.htm 00000031 - Disclosure - Notes Payable (Details Narrative) Notes http://bonebiologics.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://bonebiologics.com/role/NotesPayableTables 31 false false R32.htm 00000032 - Disclosure - Notes Payable - Schedule of Notes Payable (Details) Notes http://bonebiologics.com/role/NotesPayable-ScheduleOfNotesPayableDetails Notes Payable - Schedule of Notes Payable (Details) Details 32 false false R33.htm 00000033 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://bonebiologics.com/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://bonebiologics.com/role/StockholdersEquityTables 33 false false R34.htm 00000034 - Disclosure - Stockholders' Equity - Schedule of Outstanding Unexercised Common Stock Warrants (Details) Sheet http://bonebiologics.com/role/StockholdersEquity-ScheduleOfOutstandingUnexercisedCommonStockWarrantsDetails Stockholders' Equity - Schedule of Outstanding Unexercised Common Stock Warrants (Details) Details 34 false false R35.htm 00000035 - Disclosure - Stock-based Compensation (Details Narrative) Sheet http://bonebiologics.com/role/Stock-basedCompensationDetailsNarrative Stock-based Compensation (Details Narrative) Details http://bonebiologics.com/role/Stock-basedCompensationTables 35 false false R36.htm 00000036 - Disclosure - Stock-based Compensation - Schedule of Stock Option Activity (Details) Sheet http://bonebiologics.com/role/Stock-basedCompensation-ScheduleOfStockOptionActivityDetails Stock-based Compensation - Schedule of Stock Option Activity (Details) Details 36 false false R37.htm 00000037 - Disclosure - Stock-based Compensation - Schedule of Stock Option (Details) Sheet http://bonebiologics.com/role/Stock-basedCompensation-ScheduleOfStockOptionDetails Stock-based Compensation - Schedule of Stock Option (Details) Details 37 false false R38.htm 00000038 - Disclosure - Stock-based Compensation - Schedule of Assumptions Using Black-Scholes Option Pricing Model (Details) Sheet http://bonebiologics.com/role/Stock-basedCompensation-ScheduleOfAssumptionsUsingBlack-scholesOptionPricingModelDetails Stock-based Compensation - Schedule of Assumptions Using Black-Scholes Option Pricing Model (Details) Details 38 false false R39.htm 00000039 - Disclosure - Stock-based Compensation - Schedule of Non-Vested Options (Details) Sheet http://bonebiologics.com/role/Stock-basedCompensation-ScheduleOfNon-vestedOptionsDetails Stock-based Compensation - Schedule of Non-Vested Options (Details) Details 39 false false R40.htm 00000040 - Disclosure - Income Taxes (Details Narrative) Sheet http://bonebiologics.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://bonebiologics.com/role/IncomeTaxes 40 false false R41.htm 00000041 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://bonebiologics.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://bonebiologics.com/role/RelatedPartyTransactions 41 false false All Reports Book All Reports bblg-20170930.xml bblg-20170930.xsd bblg-20170930_cal.xml bblg-20170930_def.xml bblg-20170930_lab.xml bblg-20170930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 59 0001493152-17-013098-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-17-013098-xbrl.zip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